

**CUMULATIVE  
SUPPLEMENT 12  
DEC'99**

# **APPROVED DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**19<sup>TH</sup> EDITION**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**


**PUBLIC HEALTH SERVICE**

**FOOD AND DRUG ADMINISTRATION**

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**OFFICE OF INFORMATION TECHNOLOGY**

**DIVISION OF DATA MANAGEMENT AND SERVICES**



RM  
301.45  
.A66  
1999  
Dec  
Suppl

RM301.45 .A66 1999 Dec Suppl

Approved drug products with  
therapeutic equivalence

C:355661 M:174736 O:12937927

Prepared By  
Division of Data Management and Services  
Office of Information Technology  
Center for Drug Evaluation and Research  
Food and Drug Administration

LIBRARY  
ST. LOUIS COLLEGE OF PHARMACY  
4588 PARKVIEW PL.  
ST. LOUIS, 63110

*Prescription  
Subscriptions*

# ***SUBSCRIBE NOW!***

Available in March 2000

## ***New 20th Edition***



### **APPROVED DRUG PRODUCTS**

WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS

20<sup>TH</sup> EDITION  
2000

**Library Use Only**

#### **CONTENTS**

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

*See Subscription Form Inside Back Cover*

APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Cumulative Supplement 12

DECEMBER 1999

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION .....	iii
1.1 How to Use the Cumulative Supplement .....	iii
1.2 Applicant Name Changes .....	iv
1.3 Diclofenac Sodium Ophthalmic Solution.....	v
1.4 Availability of the Edition .....	vi
1.5 Report of Counts for the Prescription Drug Product List.....	vii
2.0 DRUG PRODUCT LISTS.....	
2.1 Prescription Drug Product List.....	1
2.2 OTC Drug Product List .....	66
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	69
2.4 Orphan Product Designations and Approvals List .....	70
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	87
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Terms .....	88
B. Patent and Exclusivity Lists.....	92

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**19TH EDITION**

**CUMULATIVE SUPPLEMENT 12  
DECEMBER 1999**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (\*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >DLT> (DELETE) to the left of the line. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 19th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 20th Edition.

## 1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

ASTRA PHARMACEUTICALS LP  
(ASTRA PHARMS)

ASTRA ZENECA LP  
(ASTRA ZENECA)

PENEDERM INC  
(PENEDERM)

BERTEK PHARMACEUTICALS  
(BERTEK PHARMS)

SANOFI PHARMACEUTICALS INC  
(SANOFI)

SANOFI SYNTHELABO INC  
(SANOFI SYNTHELABO)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

#### 1.4 AVAILABILITY OF THE EDITION

The 19th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents  
Government Printing Office  
P.O. Box 371954  
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is \$90.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the hard copy monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 19th annual edition of the 1998 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/19bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1998) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1998</u>	<u>JUN 1999</u>	<u>SEP 1999</u>	<u>DEC 1999</u>
DRUG PRODUCTS LISTED	9923	10009	9939	10045
SINGLE SOURCE	2504 (25.2%)	2523 (25.2%)	2557 (25.7%)	2599 (25.9%)
MULTISOURCE	7308 (73.6%)	7375 (73.7%)	7271 (73.2%)	7335 (73.0%)
THERAPEUTICALLY EQUIVALENT	6934 (69.9%)	7012 (70.1%)	6923 (69.7%)	6986 (69.5%)
NOT THERAPEUTICALLY EQUIVALENT	374 (3.8%)	363 (3.6%)	348 (3.5%)	349 (3.5%)
EXCEPTIONS <sup>1</sup>	111 (1.1%)	111 (1.1%)	111 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	10	5	13	0
NUMBER OF APPLICANTS	563	568	572	576

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

PRESCRIPTION DRUG PRODUCT LIST  
19TH EDITION

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'99 - DEC'99

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL  
ACEBUTOLOL HCL  
PAR PHARM

AB EQ 200MG BASE  
AB EQ 400MG BASE

N75047 001  
DEC 30, 1999  
N75047 002  
DEC 30, 1999

N89907 001  
JAN 13, 1989  
N89956 001  
JUL 19, 1985

AA ZENITH GOLDLINE 500MG;5MG  
AA MALLINCKRODT 500MG;5MG

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL  
ALLAY

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL  
BUTALBITAL, ACETAMINOPHEN, CAFFEINE  
GRAHAM DM

AB 325MG; 50MG; 40MG  
MALLINCKRODT  
AB FENCET 325MG; 50MG; 40MG  
MALLINCKRODT  
TRIAD 325MG; 50MG; 40MG  
MALLINCKRODT

N88758 001  
MAR 27, 1985  
N88758 001  
MAR 27, 1985  
N89102 001  
JUN 19, 1985  
N89102 001  
JUN 19, 1985

N40289 001  
MAR 16, 1999  
N40303 001  
DEC 30, 1999

AA DURAMED 500MG;5MG  
AA ENDO PHARMS 500MG;5MG

TABLET; ORAL

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE  
OXYCODONE AND ACETAMINOPHEN

AB 325MG; 50MG; 40MG  
WEST WARD  
AB 500MG; 50MG; 40MG

N89023 001  
JUN 19, 1985  
N89023 001  
JUN 19, 1985  
N40336 001  
AUG 18, 1999

N40203 001  
MAR 15, 1999

TABLET; ORAL  
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE  
WEST WARD

AB 500MG; 50MG; 40MG

N40336 001  
AUG 18, 1999

AA AMIDE PHARM 325MG;5MG  
PERCOCET ENDO PHARMS 325MG;2.5MG

N40330 001  
JUN 25, 1999  
N40330 002  
JUN 25, 1999  
N40330 001  
JUN 25, 1999  
N40341 001  
JUL 26, 1999  
N40341 002  
JUL 26, 1999

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL  
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE  
+ MIKART

N40316 001  
APR 28, 1999

AA ACETAMINOPHEN, PROPOXYPHENE NAPSYLATE

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL  
ALLAY  
NORTON HN

AA 500MG;5MG

N89907 001  
JAN 13, 1989

TABLET; ORAL  
PROFACET 100  
TEVA

AB 650MG;100MG  
650MG;100MG

N70107 001  
JUN 12, 1985  
N70107 001  
JUN 12, 1985

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN '99 - DEC '99

ACITRETIN

CAPSULE; ORAL  
SORIATANE  
HLR

10MG

25MG

10MG

25MG

N19821 001  
OCT 28, 1996  
N19821 002  
OCT 28, 1996  
N19821 001  
OCT 28, 1996  
N19821 002  
OCT 28, 1996

AB

AEROSOL, METERED; INHALATION

ALBUTEROL  
MEDEVA PHARMS MA 0.09MG/INH

N72273 001  
AUG 14, 1996

ROCHE

\*

ACYCLOVIR

CAPSULE; ORAL  
ACYCLOVIR  
STASON

200MG

N75090 001  
JAN 26, 1999

AB

TABLET; ORAL

ACYCLOVIR  
CARLSBAD

400MG

800MG

N75382 001  
APR 30, 1999  
N75382 002  
APR 30, 1999

AA

SYRUP; ORAL

ALBUTEROL SULFATE  
UDL

EQ 2MG BASE/5ML

N75262 001  
MAR 30, 1999

VENTOLIN

\* GLAXO WELLCOME

EQ 2MG BASE/5ML

N19621 001  
JUN 10, 1987  
N19621 001  
JUN 10, 1987

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR  
ABBOTT

EQ 50MG BASE/ML

N75114 001  
JUL 26, 1999

AP

ACYCLOVIR SODIUM

EQ 50MG BASE/ML

N74930 001  
MAY 13, 1998

EQ 50MG BASE/ML

N74930 001  
MAY 13, 1998  
N75065 001  
FEB 25, 1999

AP

EQ 50MG BASE/ML

N75065 001  
FEB 25, 1999

AP

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA  
+ AKORN

EQ 0.5MG BASE/ML

N19353 001

DEC 29, 1986

N19353 001

DEC 29, 1986

ALFENTANIL

ABBOTT

EQ 0.5MG BASE/ML

N75221 001

OCT 28, 1999

0.09MG/INH

N72273 001  
AUG 14, 1996

AB

AEROSOL, METERED; INHALATION

ALBUTEROL  
MEDEVA

EQ 0.5MG BASE/ML

N75221 001

OCT 28, 1999

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5% IN WATER  
5ML/100ML; 5GM/100ML

5ML/100ML; 5GM/100ML

N83256 001  
N83256 001

AP

BAXTER HITHCARE

\*

5ML/100ML; 5GM/100ML

N83256 001  
N83256 001

ALITRETINOLIN

GEL; TOPICAL  
PANRETIN  
+ LIGAND

EQ 0.1% BASE

N20886 001  
FEB 02, 1999

1MG/ML

N74312 001  
OCT 31, 1993

ALLOPURINOL

TABLET; ORAL

ZYLOPRIM  
FARO PHARMS

100MG  
300MG  
100MG  
300MG

N16084 001  
N16084 002  
N16084 001  
N16084 002

0.5MG/5ML  
0.5MG/5ML

N74314 001  
OCT 31, 1993  
N74314 001  
OCT 31, 1993

+ GIAXO WELLCOME

AB  
AB  
AB  
AB

2MG

N74046 004  
MAY 07, 1997

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM  
+ CATALYTICA PHARMS

EQ 500MG BASE/VIAL

N20298 001  
MAY 17, 1996

0.5MG/ML

N75196 001  
APR 30, 1999

ZYLOPRIM  
\* CATALYTICA PHARMS

EQ 500MG BASE/VIAL

N20298 001  
MAY 17, 1996

AMCINONIDE

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL;  
CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID;  
PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION  
CERNEVIT-12  
+ BAXTER HLTHCARE

11.2 IU/VIAL; 125MG/VIAL; 60 UGM/VIAL;  
200 IU/VIAL; 5.5MG/VIAL; 414 UGM/VIAL;  
46MG/VIAL; 17.25MG/VIAL; 4.53MG/VIAL;  
4.14MG/VIAL; 3.51MG/VIAL;  
3,500 IU/VIAL

N20924 001  
APR 06, 1999

0.025%  
0.1%  
0.025%  
0.1%

N18116 001  
N18116 002  
N18116 001  
N18116 002

LOTION; TOPICAL  
CYCLOCORT

0.1%

N19729 001  
JUN 13, 1988  
N19729 001  
JUN 13, 1988

\* LEEDERLE

ALPRAZOLAM

CONCENTRATE; ORAL  
ALPRAZOLAM  
ROXANE

1MG/ML

N74312 001  
OCT 31, 1993

OINTMENT; TOPICAL  
CYCLOCORT

0.1%  
0.1%

N18498 001  
N18498 001

+ FUJISAWA HLTHCARE  
\* WYETH AYERST

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'99 - DEC'99

AMIFOSTINE

INJECTABLE; INJECTION  
ETHYOL  
US BIOSCIENCE

375MG/VIAL

N20221 002  
SEP 10, 1999

> ADD > AMINOLEVULINIC ACID HYDROCHLORIDE  
> ADD > SOLUTION; TOPICAL  
> ADD > LEVULAN  
> ADD > + DUSA  
> ADD > 20%

N20965 001  
DEC 03, 1999

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE  
FRESENIUS KABI

5.2%

N18901 001  
APR 06, 1984

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE  
SMITH AND NEPHEW

25MG/ML

N88749 001  
MAY 30, 1985  
N88749 001  
MAY 30, 1985

NEOPHAM 6.4%

® FRESENIUS KABI

6.4%

N18792 001  
JAN 17, 1984

®

25MG/ML

® PHARMACIA AND UPJOHN 6.4%

N17957 003  
AUG 09, 1982

AMIODARONE HYDROCHLORIDE

NOVAMINE 11.4%

FRESENIUS KABI

11.4%

N17957 004  
NOV 28, 1986

TABLET; ORAL

AMIODARONE HCL  
ALPHAPHARM

200MG

N75188 001  
FEB 24, 1999  
N74895 001  
APR 16, 1999

NOVAMINE 15%

FRESENIUS KABI

15%

N17957 003  
AUG 09, 1982

® NOVOPHARM

200MG

® PHARMACIA AND UPJOHN 15%

N17957 004  
NOV 28, 1986

AMITRIPTYLINE HYDROCHLORIDE

NOVAMINE 8.5%

® FRESENIUS KABI

8.5%

N17957 002  
AUG 09, 1982

INJECTABLE; INJECTION

AMITRIPTYLINE HCL

10MG/ML  
10MG/ML

N85594 001  
N85594 001

® PHARMACIA AND UPJOHN 8.5%

N17957 002  
AUG 09, 1982

® ELAVIL  
\* ZENECA

10MG/ML  
10MG/ML

N12704 001  
N12704 001

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

® FRESENIUS KABI

8%; 61MG/100ML; 211MG/100ML;

56MG/100ML; 388MG/100ML

8%; 61MG/100ML; 211MG/100ML;

56MG/100ML; 388MG/100ML

N17957 001

TABLET; ORAL

AMITRIPTYLINE HCL

COPELEY PHARM

10MG

25MG

50MG

75MG

N88421 001  
APR 30, 1984  
N88422 001  
APR 30, 1984  
N88423 001  
APR 30, 1984  
N88424 001  
APR 30, 1984

AMITRIPTYLINE HYDROCHLORIDE

TABLET, ORAL  
AMITRIPTYLINE HCL  
COPELEY PHARM

BP 100MG  
BP 150MG

@ 10MG  
@ 25MG  
@ 50MG  
@ 75MG  
@ 100MG  
@ 150MG

N88425 001  
APR 30, 1984  
N88426 001  
APR 30, 1984  
N88421 001  
APR 30, 1984  
N88422 001  
APR 30, 1984  
N88423 001  
APR 30, 1984  
N88424 001  
APR 30, 1984  
N88425 001  
APR 30, 1984  
N88426 001  
APR 30, 1984

AB  
AB  
AB  
AB  
AB  
AB

10MG  
25MG  
50MG  
75MG  
100MG  
10MG  
25MG  
50MG  
75MG  
100MG

N83639 001  
N83639 002  
N83639 003  
N83639 004  
N83639 005  
N83639 001  
N83639 002  
N83639 003  
N83639 004  
N83639 005

AMOXICILLIN

CAPSULE, ORAL  
AMOXICILLIN  
RANBAXY

AB 250MG  
AB 500MG

> DLT >  
> ADD >  
AB  
AB

N65016 001  
APR 08, 1999  
N65016 002  
APR 08, 1999  
N62216 001  
N62216 001

AMOXIL  
\* SMITHKLINE BEECHAM

POWDER FOR RECONSTITUTION; ORAL  
AMOXIL  
SMITHKLINE BEECHAM

200MG/5ML

N50760 001  
APR 15, 1999

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL  
AMOXIL

+ SMITHKLINE BEECHAM 400MG/5ML

TABLET; ORAL

AMOXIL  
\* SMITHKLINE BEECHAM 500MG  
500MG

N50754 002  
JUL 10, 1998  
N50754 002  
JUL 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN  
RANBAXY  
> ADD >  
> ADD >  
> ADD >  
> ADD >  
AB  
AB  
125MG  
250MG

N65021 001  
DEC 23, 1999  
N65021 002  
DEC 23, 1999

AMOXIL

SMITHKLINE BEECHAM 200MG  
+ 400MG

N50761 001  
APR 15, 1999  
N50761 002  
APR 15, 1999

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION  
AMPHOTEC  
+ ALZA

N50729 001  
NOV 22, 1996  
N50729 002  
NOV 22, 1996  
N50729 001  
NOV 22, 1996  
N50729 002  
NOV 22, 1996

50MG/VIAL  
100MG/VIAL  
\* SEQUS 50MG/VIAL  
\* 100MG/VIAL

AMPRENAVIR

CAPSULE; ORAL  
AGENERASE  
GLAXO WELLCOME

50MG  
150MG

N21007 001  
APR 15, 1999  
N21007 002  
APR 15, 1999

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN '99 - DEC '99

AMPRENAVIR

SOLUTION; ORAL  
AGENERASE  
+ GLAXO WELLCOME

15MG/ML

N21039 001  
APR 15, 1999

ASPIRIN, DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL  
AGGRENOLX  
+ BOEHRINGER INGELHEIM 25MG;200MG

N20884 001  
NOV 22, 1999

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION  
KABIVITE PED F + W KIT  
+ FRESENIUS KABI

N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001MG/VIAL; 400 IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 1.7MG/VIAL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ 2,300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A  
N20176 001  
DEC 29, 1993

\* PHARMACIA AND UPJOHN  
N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001MG/VIAL; 400 IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 1.7MG/VIAL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ 2,300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A  
N20176 001  
DEC 29, 1993

ASPIRIN, BUTALBITAL, CAFFEINE, CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE  
ENDO PHARMS 325MG; 50MG; 40MG; 30MG N75351 001  
MAR 05, 1999

ASPIRIN, CAFFEINE, ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE  
STEVENS J 385MG; 30MG; 25MG N74988 001  
APR 30, 1999

770MG; 60MG; 50MG  
N74988 002  
APR 30, 1999

ASTEMIZOLE

TABLET; ORAL  
HISMANAL  
\* JANSSEN

10MG

N19402 001  
DEC 29, 1988

ATENOLOL

TABLET; ORAL  
ATENOLOL  
APOTHECON

50MG

N73317 001

MAR 20, 1992

N73318 001

MAR 20, 1992

N73317 001

MAR 20, 1992

N73318 001

MAR 20, 1992

N73457 002

APR 26, 1999

MYLAN

100MG

50MG

100MG

25MG

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

TRACRIUM  
AP + ABBOTT

10MG/ML

N18831 002

JUN 20, 1985

N18831 002

JUN 20, 1985

10MG/ML

TRACRIUM PRESERVATIVE FREE  
AP + ABBOTT

10MG/ML

N18831 001

NOV 23, 1983

N18831 001

NOV 23, 1983

GLAXO WELLCOME  
AP \* GLAXO WELLCOME

10MG/ML

N18831 001

NOV 23, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

AA PHARMERAI 0.025MG;2.5MG N85035 001  
 R AND S PHARMA 0.025MG;2.5MG N85035 001  
 AA DIPHENOXYLATE HCL W/ ATROPINE SULFATE  
 AA ZENITH GOLDLINE 0.025MG;2.5MG N86727 001  
 0.025MG;2.5MG N86727 001

AZATHIOPRINE

TABLET; ORAL

AZATHIOPRINE

AB APPLIED ANAL 50MG N75252 001  
 GENPHARM 50MG JUN 07, 1999  
 N75568 001  
 DEC 13, 1999

> ADD >

> ADD >

AB + FARO PHARMS 50MG N16324 001  
 25MG N16324 002  
 AB \* GLAXO WELLCOME 50MG N16324 001  
 25MG N16324 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AP IMURAN EQ 100MG BASE/VIAL N17391 001  
 AP + FARO PHARMS EQ 100MG BASE/VIAL N17391 001  
 AP \* GLAXO WELLCOME

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

POWDER FOR RECONSTITUTION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK  
 \* PFIZER EQ 1GM BASE, N/A;N/A,  
 EQ 100MG BASE  
 @ EQ 1GM BASE, N/A;N/A,  
 EQ 100MG BASE

N50762 001  
 DEC 18, 1998

N50762 001  
 DEC 18, 1998

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

AT \* ALTANA BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE  
 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; N60731 002  
 10,000 UNITS/GM N60731 002  
 @ 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; N60731 002  
 10,000 UNITS/GM N60731 002  
 AT PHARMADERM 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; N62166 002  
 10,000 UNITS/GM N62166 002  
 + 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; N62166 002  
 10,000 UNITS/GM N62166 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE 5MG;40MG N18647 001  
 APOTHECON 5MG;80MG N18647 002  
 + BRISTOL MYERS SQUIBB 5MG;40MG N18647 001  
 5MG;80MG N18647 002  
 \* MAY 25, 1983  
 N18647 002  
 MAY 25, 1983

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN 60 UMOLAR N50114 001  
 \* BAYER 60 UMOLAR N50114 001  
 + HOLLISTER STIER LABS 60 UMOLAR

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL

AB BETAMETHASONE DIPROPIONATE N75373 001  
 ALTANA EQ 0.05% BASE JUN 22, 1999



BUSULFAN

INJECTABLE; INJECTION  
BUSULFEX  
+ ORPHAN MEDCL

6MG/ML

N20954 001  
FEB 04, 1999

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION  
ENDOSOL EXTRA

0.154MG/ML; 0.92MG/ML; 0.184MG/ML;  
0.2MG/ML; 0.38MG/ML; 2.1MG/ML;  
7.14MG/ML; 0.42MG/ML N20079 001  
NOV 27, 1991

AT

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT  
+ SYNTEX

2%

N19215 001  
NOV 25, 1985  
N19215 001  
NOV 25, 1985

AT ALLERGAN

0.154MG/ML; 0.92MG/ML; 0.184MG/ML;  
0.2MG/ML; 0.38MG/ML; 2.1MG/ML;  
7.14MG/ML; 0.42MG/ML N20079 001  
NOV 27, 1991

@

FEMSTAT ONE  
+ KV PHARM

2%

N19881 001  
FEB 07, 1997  
N19881 001  
FEB 07, 1997

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

\* SYNTEX

2%

N19881 001  
FEB 07, 1997  
N19881 001  
FEB 07, 1997

INJECTABLE; INJECTION  
ISOLYTE R w/ DEXTROSE 5% IN PLASTIC CONTAINER  
E. BRAUN

37MG/100ML; 5GM/100ML; 31MG/100ML;  
120MG/100ML; 330MG/100ML;  
88MG/100ML N18271 001  
NOV 27, 1991

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION  
BUTORPHANOL TARTRATE  
MERIDIAN MEDCL TECHN

1MG/ML

N75342 001  
NOV 04, 1999  
N75342 002  
NOV 04, 1999

AP

2MG/ML

N75342 001  
NOV 04, 1999  
N75342 002  
NOV 04, 1999

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL  
CAFICIT

+ OPR DEVELOP LP EQ 10MG BASE/ML

N20793 001  
SEP 21, 1999

INJECTABLE; INJECTION  
ISOLYTE E w/ DEXTROSE 5% IN PLASTIC CONTAINER  
E. BRAUN

35MG/100ML; 5GM/100ML; 30MG/100ML;  
74MG/100ML; 640MG/100ML; 500MG/100ML;  
74MG/100ML N18269 002  
JAN 17, 1983

@

35MG/100ML; 5GM/100ML; 30MG/100ML;  
74MG/100ML; 640MG/100ML; 500MG/100ML;  
74MG/100ML N18269 002  
JAN 17, 1983

CALFACTANT

INJECTABLE; INJECTION  
INFASURF PRESERVATIVE FREE  
\* ONY 35MG/ML

N20521 001  
JUL 01, 1998

CALEFACTANT

SUSPENSION; INTRATRACHEAL  
INFASURF PRESERVATIVE FREE  
+ ONY 35MG/ML

N20521 001  
JUL 01, 1998

EQ 1GM BASE/VIAL N50306 001  
EQ 2GM BASE/VIAL N50306 004  
EQ 5GM BASE/VIAL N50306 002  
EQ 10GM BASE/VIAL N50306 002  
EQ 30GM BASE/VIAL N50306 006  
EQ 1GM BASE/VIAL N50306 001  
EQ 2GM BASE/VIAL N50306 004  
EQ 5GM BASE/VIAL N50306 002  
EQ 10GM BASE/VIAL N50306 006  
EQ 30GM BASE/VIAL N50306 007

CAPECITABINE

TABLET; ORAL  
XELODA  
HLR

150MG  
150MG

N20896 001  
APR 30, 1998  
N20896 001  
APR 30, 1998

CAPTOPRIL

TABLET; ORAL  
CAPTOPRIL  
BAKER-NORTON

12.5MG  
25MG  
50MG  
100MG  
12.5MG  
25MG  
50MG  
100MG

N74590 004  
AUG 30, 1996  
N74590 002  
AUG 30, 1996  
N74590 001  
AUG 30, 1996  
N74590 003  
AUG 30, 1996  
N74590 004  
AUG 30, 1996  
N74590 002  
AUG 30, 1996  
N74590 001  
AUG 30, 1996  
N74590 003  
AUG 30, 1996

ZENITH GOLDLINE

> ADD >  
> ADD >  
> ADD >

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL  
CARBATROL  
+ SHIRE LABS 100MG

N20712 003  
DEC 22, 1999

> ADD >  
> ADD >

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION  
GEOPEN

+ ROERIG

EQ 1GM BASE/VIAL N50306 001  
EQ 2GM BASE/VIAL N50306 004  
EQ 5GM BASE/VIAL N50306 002  
EQ 10GM BASE/VIAL N50306 002  
EQ 30GM BASE/VIAL N50306 006  
EQ 1GM BASE/VIAL N50306 001  
EQ 2GM BASE/VIAL N50306 004  
EQ 5GM BASE/VIAL N50306 002  
EQ 10GM BASE/VIAL N50306 006  
EQ 30GM BASE/VIAL N50306 007

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL  
CARBIDOPA AND LEVODOPA

50MG; 200MG  
50MG; 200MG  
50MG; 200MG

N75091 001  
SEP 30, 1999  
N19856 001  
MAY 30, 1991  
N19856 001  
MAY 30, 1991

CARBINOXAMINE MALEATE

ELIXIR; ORAL  
CLISTIN  
@ MCNEIL

4MG/5ML

N08955 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
OCUPRESS  
+ CIBA

1%

\* OTSUKA

N19972 001  
MAY 23, 1990  
N19972 001  
MAY 23, 1990

CEFACTOR

CAPSULE; ORAL

AB CEFACTOR  
LEDEBELE

EQ 250MG BASE

N64107 001

APR 27, 1995

EQ 500MG BASE

N64107 002

APR 27, 1995

EQ 250MG BASE

N64107 001

APR 27, 1995

EQ 500MG BASE

N64107 002

APR 27, 1995

EQ 250MG BASE

N64081 001

SEP 16, 1996

EQ 500MG BASE

N64081 002

SEP 16, 1996

EQ 250MG BASE

N64081 001

SEP 16, 1996

EQ 500MG BASE

N64081 002

SEP 16, 1996

POWDER FOR RECONSTITUTION; ORAL

AB CEFACTOR  
LEDEBELE

EQ 125MG BASE/5ML

N64114 001

APR 28, 1995

EQ 187MG BASE/5ML

N64115 001

APR 28, 1995

EQ 250MG BASE/5ML

N64116 001

APR 28, 1995

EQ 375MG BASE/5ML

N64110 001

APR 28, 1995

EQ 125MG BASE/5ML

N64114 001

APR 28, 1995

EQ 187MG BASE/5ML

N64115 001

APR 28, 1995

EQ 250MG BASE/5ML

N64116 001

APR 28, 1995

EQ 375MG BASE/5ML

N64110 001

APR 28, 1995

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

AB CEFADROXIL  
BARR

EQ 500MG BASE

N65015 001

JUN 22, 1999

POWDER FOR RECONSTITUTION; ORAL

AB CEFADROXIL  
APOTHECON

EQ 125MG BASE/5ML

N62334 001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

AB CEFADROXIL  
APOTHECON

EQ 250MG BASE/5ML

N62334 002

N62334 003

EQ 125MG BASE/5ML

N62334 001

EQ 250MG BASE/5ML

N62334 002

EQ 500MG BASE/5ML

N62334 003

AB DURICEF

EQ 125MG BASE/5ML

N50527 002

EQ 250MG BASE/5ML

N50527 003

EQ 500MG BASE/5ML

N50527 001

EQ 125MG BASE/5ML

N50527 002

EQ 250MG BASE/5ML

N50527 003

EQ 500MG BASE/5ML

N50527 001

TABLET; ORAL

AB CEFADROXIL  
RANBAXY

EQ 1GM BASE

N65018 001

APR 23, 1999

AB ULTRACEF  
APOTHECON

EQ 1GM BASE

N62390 001

JUN 10, 1982

EQ 1GM BASE

N62390 001

JUN 10, 1982

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

AP CEPTAZ

1GM/VIAL

N50646 002

SEP 27, 1990

2GM/VIAL

N50646 003

SEP 27, 1990

10GM/VIAL

N50646 004

SEP 27, 1990

1GM/VIAL

N50646 002

SEP 27, 1990

2GM/VIAL

N50646 003

SEP 27, 1990

10GM/VIAL

N50646 004

SEP 27, 1990

AB PENTACEF

1GM/VIAL

N63322 001

NOV 07, 1995

1GM/VIAL

N64006 001

MAR 31, 1992

CEFTAZIDIME (ARGININE FORMULATION)

<u>AP</u>	INJECTABLE; INJECTION <u>PENTACEF</u> SMITHKLINE BEECHAM	<u>2GM/VIAL</u>	N63322 002 NOV 07, 1995	<u>AB</u>	<u>CEPHALEXIN</u> CAPSULE; ORAL <u>CEPHALEXIN</u> RANBAXY	<u>EQ 500MG BASE</u>	N65007 002 SEP 16, 1999
<u>AP</u>		<u>2GM/VIAL</u>	N64006 002 MAR 31, 1992				
<u>AP</u>		<u>10GM/VIAL</u>	N64008 002 MAR 31, 1992				
		<u>6GM/VIAL</u>	N64008 001 MAR 31, 1992				
<u>©</u>		<u>1GM/VIAL</u>	N63322 001 NOV 07, 1995				
<u>©</u>		<u>1GM/VIAL</u>	N64006 001 MAR 31, 1992				
<u>©</u>		<u>2GM/VIAL</u>	N63322 002 NOV 07, 1995				
<u>©</u>		<u>2GM/VIAL</u>	N64006 002 MAR 31, 1992				
<u>©</u>		<u>6GM/VIAL</u>	N64008 001 MAR 31, 1992				
<u>©</u>		<u>10GM/VIAL</u>	N64008 002 MAR 31, 1992				

CEFUROXIME SODIUM

<u>AB</u>	INJECTABLE; INJECTION <u>CEFUROXIME</u> ASTRA PHARMS	<u>EQ 750MG BASE/VIAL</u>	N64192 002 APR 16, 1998	<u>AB</u>	<u>CEPHALEXIN</u> CAPSULE; ORAL <u>CEPHALEXIN</u> RANBAXY	<u>EQ 1GM BASE/VIAL</u>	N62547 001 SEP 11, 1985
<u>AP</u>		<u>EQ 1.5GM BASE/VIAL</u>	N64192 001 APR 16, 1998			<u>EQ 2GM BASE/VIAL</u>	N62547 002 SEP 11, 1985
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	N64191 001 APR 16, 1998			<u>EQ 1GM BASE/VIAL</u>	N62547 001 SEP 11, 1985
<u>AB</u>	TEVA	<u>EQ 750MG BASE/VIAL</u>	N64192 002 APR 16, 1998			<u>EQ 2GM BASE/VIAL</u>	N62547 002 SEP 11, 1985
<u>AP</u>		<u>EQ 1.5GM BASE/VIAL</u>	N64192 001 APR 16, 1998				
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	N64191 001 APR 16, 1998				

CEPHALEXIN

<u>AB</u>	CAPSULE; ORAL <u>CEPHALEXIN</u> RANBAXY	<u>EQ 250MG BASE</u>	N65007 001 SEP 16, 1999	<u>AT</u>	<u>CHLORAMPHENICOL</u> SOLUTION/DROPS; OPHTHALMIC <u>CHLORAMPHENICOL</u> ALCON	<u>0.5%</u>	N62628 001 SEP 25, 1985
				<u>AT</u>	<u>STERIS</u>	<u>0.5%</u>	N62628 001 SEP 25, 1985
							N62628 001 SEP 25, 1985

CHLORDIAZEPOXIDE HYDROCHLORIDE

<u>AB</u>	CAPSULE; ORAL <u>A-POXIDE</u> <u>© ABBOTT</u>	<u>5MG</u>		<u>AT</u>	<u>CHLORAMPHENICOL</u> SOLUTION/DROPS; OPHTHALMIC <u>CHLORAMPHENICOL</u> ALCON	<u>0.3MG</u>	N20740 004 JUN 26, 1997
						<u>0.3MG</u>	N20740 004 JUN 26, 1997
						<u>0.4MG</u>	N20740 005 MAY 24, 1999

CERIVASTATIN SODIUM

--	--	--	--	--	--	--	--

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A. FOXIDE

@ ABBOTT

CHLORDIAZEPOXIDE HCL

@ M&ST. MN

AA

N85517 001  
N86217 001  
N86217 001

AB  
AB

TABLET; ORAL

CHLORTHALIDONE

DANBURY PHARMA

50MG  
50MG  
25MG  
25MG  
50MG  
50MG  
50MG  
50MG  
50MG  
25MG  
50MG  
25MG  
50MG  
50MG  
25MG  
50MG  
50MG  
25MG  
50MG

N87521 001  
N87689 001  
N87296 001  
N87706 001  
N87521 001  
N87689 001  
N87118 001  
N87118 001  
N87311 001  
N87312 001  
N87311 001  
N87312 001  
N87451 001  
N87450 001  
N87451 001  
N87450 001

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

MD PHARM

@ WEST WARD

AA

AA

EQ 150MG BASE  
EQ 150MG BASE  
EQ 300MG BASE

N87228 001  
N87228 001  
N83082 002  
SEP 17, 1999

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

@ BANNER PHARMACEPS

AA

AA

12MG  
12MG  
12MG  
12MG

N84652 001  
N84652 001  
N08102 004  
N08102 004

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

BAKER MORTON

AB

AB

EQ 4GM RESIN/PACKET

EQ 4GM RESIN/SCOOPFUL

N74771 001  
JUL 09, 1997  
N74771 002  
JUL 09, 1997  
N74771 001  
JUL 09, 1997  
N74771 002  
JUL 09, 1997

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HCL

PHARM ASSOC

AA

AA

30MG/ML  
100MG/ML

N40231 001  
DEC 30, 1999  
N40224 001  
JAN 26, 1999

EQ 4GM RESIN/SCOOPFUL

EQ 4GM RESIN/SCOOPFUL

N74555 002  
SEP 30, 1998

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ ABBOTT

AB

AB

AB

25MG  
25MG  
25MG  
25MG

N87364 001  
N87364 001  
N87296 001  
N87706 001

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

CATARASE

\* CIBA

300 UNITS/VIAL

N16938 001

> ADD >  
> ADD >  
> ADD >  
> ADD >

EQ 800MG RESIN

N73403 002  
DEC 27, 1999

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC  
 CATARASE  
 @ CIBA  
 ZOLYSE  
 ALCON  
 +

300 UNITS/VIAL  
 750 UNITS/VIAL  
 750 UNITS/VIAL

N16938 001  
 N11903 001  
 N11903 001

N74735 001  
 JUL 16, 1999  
 N18057 004  
 NOV 08, 1988  
 N18057 004  
 NOV 08, 1988

CICLOPIROX

SOLUTION; TOPICAL  
 PENLAC  
 + AVENTIS PHARM

N21022 001  
 DEC 17, 1999

CITALOPRAM HYDROBROMIDE  
 SOLUTION; ORAL  
 CELEXA  
 + FOREST LABS  
 EQ 10MG BASE/5ML

N21046 001  
 DEC 22, 1999

CILOSTAZOL

TABLET; ORAL  
 PLETAL  
 OTSUKA  
 +

50MG  
 100MG

N20863 001  
 JAN 15, 1999  
 N20863 002  
 JAN 15, 1999

CLARITHROMYCIN  
 GRANULE, FOR RECONSTITUTION; ORAL  
 BIAXIN  
 ABBOTT  
 187MG/5ML

N50698 003  
 SEP 30, 1998

CISATRAURIUM BESYLATE

INJECTABLE; INJECTION  
 NIMBEX  
 + ABBOTT  
 \* GLAXO WELLCOME

EQ 2MG BASE/ML  
 EQ 2MG BASE/ML

N20551 001  
 DEC 15, 1995  
 N20551 001  
 DEC 15, 1995

TABLET; ORAL  
 BIAXIN  
 \* ABBOTT  
 250MG  
 250MG

N50662 001  
 OCT 31, 1991  
 N50662 001  
 OCT 31, 1991

NIMBEX PRESERVATIVE FREE  
 + ABBOTT

EQ 2MG BASE/ML  
 EQ 10MG BASE/ML

N20551 003  
 DEC 15, 1995  
 N20551 002  
 DEC 15, 1995

CLINDAMYCIN HYDROCHLORIDE  
 CAPSULE; ORAL  
 CLEOCIN HCL  
 \* PHARMACIA AND UPJOHN  
 EQ 75MG BASE  
 EQ 75MG BASE  
 EQ 150MG BASE  
 EQ 150MG BASE  
 EQ 300MG BASE  
 EQ 300MG BASE

N50162 001  
 N50162 001  
 N50162 002  
 N50162 002  
 N50162 003  
 APR 14, 1988  
 N50162 003  
 APR 14, 1988

AB  
 AB  
 AB  
 AB

+  
 EQ 300MG BASE

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

SOLOPAK

AP EQ 150MG BASE/ML N62819 001  
 MAR 15, 1988  
 AP EQ 150MG BASE/ML N62852 001  
 MAR 17, 1988  
 EQ 150MG BASE/ML N62819 001  
 MAR 15, 1988  
 EQ 150MG BASE/ML N62852 001  
 MAR 17, 1988  
 AP STERIS EQ 150MG BASE/ML N62900 001  
 JUN 08, 1988  
 AP EQ 150MG BASE/ML N63079 001  
 MAR 05, 1990  
 EQ 150MG BASE/ML N62900 001  
 JUN 08, 1988  
 EQ 150MG BASE/ML N63079 001  
 MAR 05, 1990

SUPPOSITORY; VAGINAL

CLEOCIN

+ PHARMACIA AND UPJOHN 100MG

N50767 001  
 AUG 13, 1999

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMIPHENE CITRATE

PAR PHARM

N75528 001  
 AUG 30, 1999

50MG

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXAPEN

SMITHKLINE BEECHAM

N62233 001  
 N62233 002  
 N62233 001  
 N62233 002

EQ 250MG BASE  
 EQ 500MG BASE  
 EQ 250MG BASE  
 EQ 500MG BASE

POWDER FOR RECONSTITUTION; ORAL

CLOXACILLIN SODIUM

TEVA

N62268 001  
 N62268 001

EQ 125MG BASE/5ML  
 EQ 125MG BASE/5ML

+ TEGOFEN

APOTHECON

N61453 001  
 N61453 001

EQ 125MG BASE/5ML  
 EQ 125MG BASE/5ML

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

ALPHARMA US PHARM

0.05%

N74139 001  
 AUG 03, 1994  
 N74139 001  
 AUG 03, 1994

0.05%

NMC

CLOBETASOL PROPIONATE (EMOLLIENT)

ALTANA

0.05%

N75430 001  
 MAY 26, 1999  
 N75430 001  
 MAY 26, 1999

0.05%

GEL; TOPICAL

CLOBETASOL PROPIONATE

TARO

0.05%

N75279 001  
 MAY 28, 1999

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

ALTANA

0.05%

N75391 001  
 FEB 08, 1999

CLOZAPINE

TABLET; ORAL

CLOZAPINE

CREIGHTON

N74546 001  
 AUG 30, 1996

25MG

N74546 002  
 AUG 30, 1996

100MG

N74546 001  
 AUG 30, 1996

25MG

N74546 002  
 AUG 30, 1996

100MG

N75417 001  
 MAY 27, 1999

25MG

N75417 002  
 MAY 27, 1999

100MG

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

PHARMA TEK

N64216 001  
 FEB 26, 1999

EQ 150MG BASE/VIAL

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLY-MYCIN M

+ PARKEDALE

EQ 150MG BASE/VIAL  
EQ 150MG BASE/VIAL

N50108 002  
N50108 002

AT KING PHARMS

4%

N75088 001  
APR 27, 1999

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE  
COPPER T MODEL TCU 380A

+ JOHNSON RW

309MG/COPPER

N18680 001  
NOV 15, 1984

\* POPULATION COUNCIL

309MG/COPPER

N38680 001  
NOV 15, 1984

AT GAIJERMA  
AT SUMMERS

10%  
10%

N87204 001  
N87204 001

CORTICOTROPIN

INJECTABLE; INJECTION

CORTICOTROPIN

+ STERIS

40 UNITS/VIAL

N88772 001  
NOV 21, 1984

40 UNITS/VIAL

N88772 001  
NOV 21, 1984

AP RUVITE  
SAVAGE LABS

1MG/ML  
1MG/ML

N80570 002  
N80570 002

CROMOLYN SODIUM

CAPSULE; ORAL

GASTROCROM

+ MEDEVA

100MG

N19188 001  
DEC 22, 1989

100MG

N19188 001  
DEC 22, 1989

AB ROXANE

25MG

N40032 001  
AUG 17, 1999

CYCLOPHOSPHAMIDE

ROXANE

25MG

N40032 002  
AUG 17, 1999

CYTOXAN

BRISTOL MYERS SQUIBB

25MG

N12141 002

50MG

N12141 001

25MG

N12141 002

50MG

N12141 001

50MG

N12141 001

50MG

N12141 001

SOLUTION; INHALATION

CROMOLYN SODIUM

ALPHARMA

10MG/ML

N75067 001  
JUL 19, 1999

AN MORTON GROVE

10MG/ML

N75346 001  
OCT 25, 1999

AN ROXANE

10MG/ML

N75175 001  
SEP 30, 1999

INJECTABLE; INJECTION

CYCLOSPORINE

BEDFORD

50MG/ML

N65004 001  
OCT 29, 1999

SANDIMMUNE

+ NOVARTIS

50MG/ML

N50573 001  
NOV 14, 1983

CROMOLYN SODIUM

ALCON

4%

N75282 001  
JUN 16, 1999

> ADD >  
> ADD >  
> DLT >  
> DLT >

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN '99 - DEC '99

Drug Name	Strength	Manufacturer	Approval Date	Approval Code
<u>CYCLOSPORINE</u>				
INJECTABLE; INJECTION				
SANDIMMUNE	50MG/ML		N50573 001	
* NOVARTIS			NOV 14, 1983	
<u>CYPROHEPTADINE HYDROCHLORIDE</u>				
TABLET; ORAL				
CYPROHEPTADINE HCL	4MG		N87566 001	
ND PHARM			NOV 10, 1982	
@	4MG		N87566 001	
			NOV 10, 1982	
<u>CYSTEINE HYDROCHLORIDE</u>				
INJECTABLE; INJECTION				
CYSTEINE HCL	7.25%		N19523 001	
@ FRESENIUS KABI			OCT 22, 1986	
@ PHARMACIA AND UPJOHN	7.25%		N19523 001	
			OCT 22, 1986	
<u>CYTARABINE</u>				
INJECTABLE; INJECTION				
CYTARABINE	2GM/VIAL		N75383 001	
FAULDING			NOV 22, 1999	
INJECTABLE, LIPOSOMAL; INJECTION				
DEPOCYT	10MG/ML		N21041 001	
* DEPOTECH			APR 01, 1999	
+ SKYEPHARMA	10MG/ML		N21041 001	
			APR 01, 1999	
<u>DACARBAZINE</u>				
INJECTABLE; INJECTION				
DACARBAZINE	100MG/VIAL		N75371 001	
AM PHARM PARTNERS			AUG 27, 1999	
<u>DACARBAZINE</u>				
INJECTABLE; INJECTION				
DACARBAZINE	200MG/VIAL		N75371 002	
AM PHARM PARTNERS			AUG 27, 1999	
<u>DACARBAZINE</u>				
INJECTABLE; INJECTION				
DACARBAZINE	100MG/VIAL		N17575 001	
AM PHARM PARTNERS			N17575 001	
			N17575 001	
			N17575 001	
			N17575 001	
<u>DALFOPRISTIN; QUINUPRISTIN</u>				
INJECTABLE; INJECTION				
SYNERCID	350MG/VIAL;		N50747 001	
RHONE-POULENC RORER	EQ 150MG BASE/VIAL		SEP 21, 1999	
	350MG/VIAL;		N50748 001	
	EQ 150MG BASE/VIAL		SEP 21, 1999	
<u>DAUNORUBICIN HYDROCHLORIDE</u>				
INJECTABLE; INJECTION				
CERUBIDINE	EQ 20MG BASE/VIAL		N64103 001	
AP + BEDFORD			FEB 03, 1995	
*	EQ 20MG BASE/VIAL		N64103 001	
			FEB 03, 1995	
<u>DAUNORUBICIN HCL</u>				
+ BEDFORD	EQ 5MG BASE/ML		N50731 001	
			JAN 30, 1998	
AP	EQ 20MG BASE/VIAL		N65000 001	
			MAY 25, 1999	
AP	EQ 20MG BASE/VIAL		N64212 001	
			JUN 23, 1998	
<u>DAUNORUBICIN HCL PRESERVATIVE FREE</u>				
+ BEDFORD	EQ 20MG BASE/VIAL		N50731 001	
			JAN 30, 1998	
AP	EQ 20MG BASE/VIAL		N64212 001	
			JUN 23, 1998	
<u>GENSIA SICOR PHARMS</u>				
+ BEDFORD	EQ 20MG BASE/VIAL		N50731 001	
			JAN 30, 1998	
AP	EQ 20MG BASE/VIAL		N64212 001	
			JUN 23, 1998	
<u>GENSIA SICOR PHARMS</u>				
+ BEDFORD	EQ 20MG BASE/VIAL		N50731 001	
			JAN 30, 1998	
AP	EQ 20MG BASE/VIAL		N64212 001	
			JUN 23, 1998	

DELAVIDINE MESYLATE

TABLET; ORAL  
 RESCRIPTOR  
 + AGOURON 100MG  
 \* PHARMACIA AND UPJOHN 100MG

N20705 001  
 APR 04, 1997  
 N20765 001  
 APR 04, 1997

DESONIDE

CREAM; TOPICAL  
 TRIDESILON

AB \* BAYER 0.05%  
 AB + CLAY PARK 0.05%

N17010 001  
 N17010 001

OINTMENT; TOPICAL

AB \* BAYER 0.05%  
 AB + CLAY PARK 0.05%

N17426 001  
 N17426 001

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

AB + DDAVP 0.01MG/SPRAY  
 AB + RHONE POULENC RORER 0.01MG/SPRAY  
 \* 0.01MG/SPRAY  
 \* 0.01MG/SPRAY  
 DDAVP (NEEDS NO REFRIGERATION)  
 AB + RHONE POULENC RORER 0.01MG/SPRAY  
 AB DESMOPRESSIN ACETATE  
 AB BAUSCH AND LOMB 0.01MG/SPRAY

N17922 002  
 FEB 06, 1989  
 N17922 003  
 AUG 07, 1996  
 N17922 002  
 FEB 06, 1989  
 N17922 003  
 AUG 07, 1996  
 N74830 001  
 JAN 25, 1999

DEXAMETHASONE  
 SUSPENSION/DROPS; OPHTHALMIC

AT DEXAMETHASONE 0.1%  
 STERIS 0.1%

N89170 001  
 MAY 09, 1989  
 N89170 001  
 MAY 09, 1989

AT MAXIDEX 0.1%  
 ALCON 0.1%

N13422 001  
 N13422 001

DESOGESTREL, ETHINYL ESTRADIOL  
 TABLET; ORAL-21

AB DESOGESTREL AND ETHINYL ESTRADIOL  
 DURAMED 0.15MG;0.03MG  
 ORTHO-CEPT  
 AB + JOHNSON RW 0.15MG;0.03MG  
 \* 0.15MG;0.03MG

N75256 001  
 AUG 12, 1999  
 N20301 001  
 DEC 14, 1992  
 N20301 001  
 DEC 14, 1992

BP DEXONE 0.5  
 SOLVAY 0.5MG  
 0.5MG  
 \* DEXONE 0.75  
 SOLVAY 0.75MG  
 0.75MG  
 \* DEXONE 4  
 SOLVAY 4MG  
 4MG

N84991 001  
 N84991 001  
 N84993 001  
 N84993 001  
 N84992 001  
 N84992 001

TABLET; ORAL-28

AB DESOGESTREL AND ETHINYL ESTRADIOL  
 DURAMED 0.15MG;0.03MG

N75256 002  
 AUG 12, 1999

OINTMENT; OPHTHALMIC

AT MAXITROL 0.1%;EQ 3.5MG BASE/GM;  
 ALCON 10,000 UNITS/GM  
 AT + FALCON PHARMS 0.1%;EQ 3.5MG BASE/GM;  
 10,000 UNITS/GM

N50065 002  
 N50065 002  
 N50065 002

SUSPENSION/DROPS; OPHTHALMIC

AT MAXITROL 0.1%;EQ 3.5MG BASE/ML;  
 ALCON 10,000 UNITS/ML

N50023 002

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN '99 - DEC '99

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE  
 SUSPENSION/DROPS; OPHTHALMIC  
 MAXITROL  
 AT + FALCON PHARMS 0.1%; EQ 3.5MG BASE/ML; N50023 002  
 10,000 UNITS/ML

DEXTROAMPHETAMINE SULFATE  
 TABLET; ORAL  
 DEXTROAMPHETAMINE SULFATE 5MG  
 AA ENDO PHARMS N40299 001  
 MAY 13, 1999

DEXAMETHASONE; TOBRAMYCIN  
 SUSPENSION; OPHTHALMIC  
 TOBRADEX  
 \* ALCON 0.1%; 0.3% N50592 001  
 AUG 18, 1988

DEXTROSE  
 INJECTABLE; INJECTION  
 DEXTROSE 25% 250MG/ML N19445 002  
 ABBOTT NOV 23, 1998

SUSPENSION/DROPS; OPHTHALMIC  
 TOBRADEX  
 AB + ALCON 0.1%; 0.3% N50592 001  
 AUG 18, 1988

TOBRAMYCIN AND DEXAMETHASONE  
 BAUSCH AND LOMB 0.1%; 0.3% N64134 001  
 OCT 27, 1999

DEXTROSE; SODIUM CHLORIDE  
 INJECTABLE; INJECTION  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 AP B. BRAUN 2.5GM/100ML; 450MG/100ML N18030 001  
 2.5GM/100ML; 450MG/100ML N18030 001  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER  
 B. BRAUN 5GM/100ML; 110MG/100ML N18030 005  
 5GM/100ML; 110MG/100ML N18030 005  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER  
 B. BRAUN 5GM/100ML; 200MG/100ML N18030 004  
 5GM/100ML; 200MG/100ML N18030 004  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER  
 B. BRAUN 5GM/100ML; 330MG/100ML N18030 003  
 5GM/100ML; 330MG/100ML N18030 003  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 B. BRAUN 5GM/100ML; 450MG/100ML N18030 002  
 5GM/100ML; 450MG/100ML N18030 002

DEXAMETHASONE SODIUM PHOSPHATE  
 INJECTABLE; INJECTION  
 DECADRON  
 AP + MERCK EQ 24MG PHOSPHATE/ML N12071 004  
 EQ 24MG PHOSPHATE/ML N12071 004  
 DEXAMETHASONE SODIUM PHOSPHATE  
 STERIS EQ 4MG PHOSPHATE/ML N83702 001  
 EQ 24MG PHOSPHATE/ML N85606 001  
 EQ 4MG PHOSPHATE/ML N83702 001  
 EQ 24MG PHOSPHATE/ML N85606 001

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM  
 INJECTABLE; INJECTION  
 MD-76 66%; 10% N87073 001  
 MALLINCKRODT 66%; 10% N87073 001  
 AP

EQ 100 UGM BASE/ML N21038 001  
 DEC 17, 1999

DEXMEDETOMIDINE  
 INJECTABLE; INJECTION  
 PRECEDEX  
 + ABBOTT N21038 001  
 DEC 17, 1999

> ADD >  
 > ADD >  
 > ADD >  
 > ADD >

DIAZEPAM

GEL; RECTAL  
DIASSTAT  
+ ATHENA

2.5MG/0.5ML  
5MG/ML  
10MG/2ML  
15MG/3ML  
20MG/4ML  
2.5MG/0.5ML  
5MG/ML  
10MG/2ML  
15MG/3ML  
20MG/4ML

N20648 001  
JUL 29, 1997  
N20648 002  
JUL 29, 1997  
N20648 003  
JUL 29, 1997  
N20648 004  
JUL 29, 1997  
N20648 005  
JUL 29, 1997  
N20648 001  
JUL 29, 1997  
N20648 002  
JUL 29, 1997  
N20648 003  
JUL 29, 1997  
N20648 004  
JUL 29, 1997  
N20648 005  
JUL 29, 1997

AB  
AB

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

ALCON  
FALCON PHARMS

0.1%  
0.1% +

N20809 001  
MAY 04, 1998  
N20809 001  
MAY 04, 1998

+

+ ELAN PHARMS

TABLET, DELAYED RELEASE; ORAL  
DICLOFENAC SODIUM

MARTEC

50MG

N74986 001  
FEB 26, 1999  
N74986 002  
FEB 26, 1999  
N74723 001  
MAR 30, 1999  
N74432 002  
JUL 29, 1999  
N74432 003  
JUL 29, 1999

75MG  
50MG  
50MG  
75MG

NOVOPHARM  
SIDMAK LABS NJ

50MG  
75MG

+

INJECTABLE; INJECTION

AP  
DIAZEPAM  
STERIS

5MG/ML  
5MG/ML  
5MG/ML  
5MG/ML

N70911 001  
AUG 28, 1986  
N70930 001  
DEC 01, 1986  
N70911 001  
AUG 28, 1986  
N70930 001  
DEC 01, 1986

AB

CAPSULE; ORAL

DICYCLOMINE HCL

MYLAN

10MG

N40319 001  
SEP 07, 1999

@

TABLET; ORAL

DICYCLOMINE HCL

LANNETT

20MG

N40230 001  
FEB 26, 1999  
N40317 001  
SEP 07, 1999

@

TABLET; ORAL

MYLAN

20MG

DICLOFENAC POTASSIUM

AB  
TABLET; ORAL  
DICLOFENAC POTASSIUM

MYLAN

50MG

N75463 001  
JUL 26, 1999

TABLET, CHEWABLE; ORAL

VIDEX

25MG

BRISTOL MYERS SQUIBB

+

150MG

N20154 002  
OCT 09, 1991  
N20154 005  
OCT 09, 1991  
N20154 002  
OCT 09, 1991

+

25MG

+ SEE SECTION 1.3 OF INTRODUCTION

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'99 - DEC'99

DIDANOSINE

TABLET, CHEWABLE; ORAL  
VIDEX  
BRISTOL MYERS SQUIBB

150MG

200MG

DIFLORASONE DIACETATE

CREAM; TOPICAL  
DIFLORASONE DIACETATE  
TARO

0.05%

DIFLORASONE DIACETATE

ALTANA

0.05%

DIFLUNISAL

TABLET, ORAL  
DIFLUNISAL  
EUREPAC PHARM

250MG

500MG

DIGOXIN

TABLET, ORAL  
DIGOXIN  
AMIDE PHARM

0.125MG

DIGOXIN

TABLET, ORAL  
DIGOXIN  
AMIDE PHARM

0.25MG

0.125MG

0.25MG

0.125MG

0.25MG

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
CARDIZEM CD

120MG

180MG

240MG

300MG

120MG

180MG

240MG

300MG

CARTIA XT  
ANDRX PHARMS

120MG

180MG

240MG

300MG

120MG

> ADD >  
> ADD >  
> ADD >  
N20154 005  
OCT 09, 1991  
N20154 006  
OCT 28, 1999

> ADD >  
> ADD >  
> ADD >  
> DLT >  
> DLT >  
> DLT >  
> DLT >  
N75331 001  
MAY 14, 1999

> ADD >  
> ADD >  
> ADD >  
N75374 001  
APR 27, 1999  
N75331 001  
MAY 14, 1999

> ADD >  
> ADD >  
> ADD >  
N19260 001  
AUG 28, 1985  
N19260 001  
AUG 28, 1985

> ADD >  
> ADD >  
> ADD >  
N74285 001  
MAY 07, 1996  
N74285 002  
MAY 07, 1996  
N74285 001  
MAY 07, 1996  
N74285 002  
MAY 07, 1996

> ADD >  
> ADD >  
> ADD >  
N40282 001  
DEC 23, 1999

N40282 002  
DEC 23, 1999  
N20405 002  
SEP 30, 1997  
N20405 004  
SEP 30, 1997  
N20405 002  
SEP 30, 1997  
N20405 004  
SEP 30, 1997

N20062 001  
AUG 10, 1992  
N20062 002  
DEC 27, 1991  
N20062 003  
DEC 27, 1991  
N20062 004  
DEC 27, 1991  
N20062 001  
AUG 10, 1992  
N20062 002  
DEC 27, 1991  
N20062 003  
DEC 27, 1991  
N20062 004  
DEC 27, 1991

N74752 002  
JUL 09, 1998  
N74752 001  
JUL 09, 1998  
N74752 003  
JUL 09, 1998  
N74752 004  
JUL 09, 1998  
N74752 002  
JUL 09, 1998  
N74752 002  
JUL 09, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARTIA XT  
@ ANDRX PHARMS

180MG  
240MG  
300MG

N74752 001  
JUL 09, 1998  
N74752 003  
JUL 09, 1998  
N74752 004  
JUL 09, 1998

N85150 001

DILTIAZEM HCL  
BIOVAIL

60MG

N74845 001  
SEP 15, 1999

90MG

N74845 002  
SEP 15, 1999

120MG

N74845 003  
SEP 15, 1999

120MG

N75116 001  
DEC 23, 1999

180MG

N75116 002  
DEC 23, 1999

240MG

N75116 003  
DEC 23, 1999

300MG

N75116 004  
DEC 23, 1999

PUREPAC PHARM

120MG

N74984 001  
DEC 20, 1999

180MG

N74984 002  
DEC 20, 1999

240MG

N74984 003  
DEC 20, 1999

300MG

N74984 004  
DEC 20, 1999

INJECTABLE; INJECTION

DILTIAZEM HCL  
APOTEX

5MG/ML

N75375 001  
SEP 30, 1999

AP MERIDIAN MEDCL TECHN

N75106 001  
APR 29, 1999

> ADD >  
> ADD >

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL  
@ PUREPAC PHARM

50MG

N85150 001

ELIXIR; ORAL

HYDRAMINE  
ALPHARMA

12.5MG/5ML  
12.5MG/5ML

N80763 002  
N80763 002

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HCL  
ALCON

0.1%

N73636 001  
JUN 30, 1994

FALCON PHARMS

0.1%

N73636 001  
JUN 30, 1994

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE  
PUREPAC PHARM

25MG

N89425 001  
JUL 12, 1990

PUREPAC PHARM

50MG

N89425 001  
JUL 12, 1990

PUREPAC PHARM

25MG

N89425 001  
JUL 12, 1990

PUREPAC PHARM

50MG

N89425 001  
JUL 12, 1990

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC  
LILLY

250MG

N50678 001  
JUN 19, 1995

LILLY RES LABS

250MG

N50678 001  
JUN 19, 1995

CAPSULE; ORAL

DIPHENHYDRAMINE HCL  
PUREPAC PHARM

25MG  
50MG

N85156 001  
N85150 001  
N85156 001

AA  
AA

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'99 - DEC'99

DIVALPROEX SODIUM  
 TABLET, DELAYED RELEASE; ORAL  
 DEPAKOTE  
 ABBOTT  
 EQ 125MG VALPROIC ACID N18723 003 OCT 26, 1984  
 EQ 250MG VALPROIC ACID N18723 001 MAR 10, 1983  
 EQ 125MG VALPROIC ACID N18723 003 OCT 26, 1984  
 EQ 250MG VALPROIC ACID N18723 001 MAR 10, 1983

> DLT >  
 > DLT >  
 > DLT >  
 > DLT >  
 > ADD >  
 > ADD >  
 > ADD >  
 > ADD >

DOXERCALCIFEROL  
 CAPSULE; ORAL  
 HECTOROL  
 + BONE CARE 2.5 UGM  
 N20862 001  
 JUN 09, 1999

DOXORUBICIN HYDROCHLORIDE  
 INJECTABLE, LIPOSOMAL; INJECTION  
 DOXIL  
 + ALZA 2MG/ML  
 N50718 001  
 NOV 17, 1995  
 N50718 001  
 NOV 17, 1995

\* SEQUUS 2MG/ML

DOFETILIDE  
 CAPSULE; ORAL  
 TIKOSYN  
 PFIZER  
 0.125MG N20931 001 OCT 01, 1999  
 0.25MG N20931 002 OCT 01, 1999  
 0.5MG N20931 003 OCT 01, 1999

> DLT >  
 > DLT >  
 > DLT >  
 > ADD >  
 > ADD >  
 > ADD >

DOPAMINE HYDROCHLORIDE  
 INJECTABLE; INJECTION  
 DOPAMINE HCL  
 SMITH AND NEPHEW  
 40MG/ML N70046 001 AUG 29, 1985  
 80MG/ML N70047 001 AUG 29, 1985  
 40MG/ML N70046 001 AUG 29, 1985  
 80MG/ML N70047 001 AUG 29, 1985

> DLT >  
 > DLT >  
 > DLT >  
 > ADD >  
 > ADD >  
 > ADD >

DOXACURIUM CHLORIDE  
 INJECTABLE; INJECTION  
 NUROMAX  
 + ABBOTT  
 EQ 1MG BASE/ML N19946 001 MAR 07, 1991  
 EQ 1MG BASE/ML N19946 001 MAR 07, 1991

\* GRAXO WELLCOME

DOXYCYCLINE HYCLATE  
 CAPSULE; ORAL  
 DOXYCHEL HYCLATE  
 RACHELLE  
 DOXYCYCLINE HYCLATE  
 HOUBA  
 @ PUREPAC PHARM  
 @  
 @ RANBAXY  
 @  
 TABLET; ORAL  
 DOXY-TABS  
 RACHELLE  
 @  
 DOXYCYCLINE HYCLATE  
 HOUBA  
 DOXYCYCLINE HYLATE  
 @ HOUBA

EQ 50MG BASE N61717 001  
 EQ 100MG BASE N61717 002  
 EQ 50MG BASE N62479 001  
 EQ 100MG BASE N62479 002  
 EQ 50MG BASE N62479 001  
 EQ 100MG BASE N62479 002  
 EQ 50MG BASE N62479 002  
 EQ 100MG BASE N62479 002

> DLT >  
 > DLT >  
 > DLT >  
 > ADD >  
 > ADD >  
 > ADD >

EQ 100MG BASE N62269 001  
 EQ 100MG BASE N62269 002  
 EQ 50MG BASE N62269 003  
 EQ 100MG BASE N62269 001  
 EQ 100MG BASE N62269 002  
 EQ 50MG BASE N62269 003

DOXYLAMINE SUCCINATE, PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
 BENDECTIN  
 @ HOECHST MARION RSSL 10MG;10MG

N10598 002

N20668 002  
 OCT 28, 1998

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL  
 LEXXEL  
 + ASTRAZENECA 5MG;2.5MG

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL  
SOLOPARK

2.5MG/ML

N71754 001

AP  
 + AKORN MFG

SEP 06, 1988

2.5MG/ML

N71755 001

AP  
 @ JANSSEN

SEP 06, 1988

2.5MG/ML

N71754 001

2.5MG/ML

SEP 06, 1988

AP  
 + AKORN MFG

2.5MG/ML

SEP 06, 1988

AP  
 + AKORN MFG

2.5MG/ML

NOV 27, 1991

INAPSINE  
 + AKORN MFG

2.5MG/ML

N16796 001

AP  
 + AKORN MFG

2.5MG/ML

N16796 001

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

INNOVAR

2.5MG/ML;

N16049 001

@ AKORN MFG

EQ 0.05MG BASE/ML

N16049 001

@ JANSSEN

2.5MG/ML;

N16049 001

EQ 0.05MG BASE/ML

N16049 001

> ADD >  
 > DLT >

> ADD >  
 > ADD >  
 > DLT >  
 > DLT >

ENTACAPONE

TABLET; ORAL

COMTAN  
 + ORION

200MG

N20796 001  
 OCT 19, 1999

EPINEPHRINE

INJECTABLE; INJECTION

SUS-PHRINE  
 \* FOREST LABS

5MG/ML

N07942 001

SUS-PHRINE SULFITE-FREE  
 FOREST LABS

1.5MG/AMP

N07942 003  
 FEB 05, 1999

+  
 5MG/ML

N07942 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLENCE

+ PHARMACIA AND UPJOHN 2MG/ML

N50778 001  
 SEP 15, 1999

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN  
 SMITHKLINE BEECHAM

EQ 300MG BASE

N20738 004  
 DEC 22, 1997

EQ 400MG BASE

N20738 005  
 DEC 22, 1997

EQ 600MG BASE

N20738 006  
 MAY 27, 1999

+  
 UNIMED PHARMS

EQ 300MG BASE

N20738 004  
 DEC 22, 1997

EQ 400MG BASE

N20738 005  
 DEC 22, 1997

EQ 400MG BASE

N20738 005  
 DEC 22, 1997

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN '99 - DEC '99

<u>EPROSARTAN MESYLATE</u>					
TABLET; ORAL					
TEVETEN					
+ UNIMED PHARMS	EQ 600MG BASE		N20738 006		
			MAY 27, 1999		
<u>ERGOTAMINE TARTRATE</u>					
AEROSOL, METERED; INHALATION					
MEDIHALER ERGOTAMINE					
* 3M	0.36MG/INH		N12102 001		
@	0.36MG/INH		N12102 001		
<u>ERYTHROMYCIN</u>					
CAPSULE, DELAYED REL PELLETS; ORAL					
ERYC					
@ PARKE DAVIS	250MG		N62338 001		
@ WARNER CHILCOTT	250MG		N62338 001		
SOLUTION; TOPICAL					
C-SOLVE-2					
BIOGLAN PHAR	2%		N62468 001		
			JUL 03, 1985		
ZENITH GOLDLINE	2%		N62468 001		
			JUL 03, 1985		
<u>ESTRADIOL</u>					
FILM, EXTENDED RELEASE; TRANSDERMAL					
ALORA					
PROCTER AND GAMBLE	0.05MG/24HR		N20655 001		
			DEC 20, 1996		
	0.075MG/24HR		N20655 002		
			DEC 20, 1996		
	0.1MG/24HR		N20655 003		
			DEC 20, 1996		
	0.05MG/24HR		N20655 001		
			DEC 20, 1996		
	0.075MG/24HR		N20655 002		
			DEC 20, 1996		
	0.1MG/24HR		N20655 003		
			DEC 20, 1996		
CLIMARA					
+ BERLEX LABS	0.025MG/24HR		N20375 004		
			MAR 05, 1999		
<u>ESTRADIOL</u>					
FILM, EXTENDED RELEASE; TRANSDERMAL					
ESCLIM					
FOURNIER	0.025MG/24HR		N20738 006		
			MAY 27, 1999		
	0.0375MG/24HR		N20738 006		
			MAY 27, 1999		
	0.05MG/24HR		N20847 003		
			AUG 04, 1998		
	0.075MG/24HR		N20847 004		
			AUG 04, 1998		
	0.1MG/24HR		N20847 005		
			AUG 04, 1998		
	WOMEN FIRST HLTHCARE		N20847 001		
	0.025MG/24HR		AUG 04, 1998		
	0.0375MG/24HR		N20847 002		
			AUG 04, 1998		
	0.05MG/24HR		N20847 003		
			AUG 04, 1998		
	0.075MG/24HR		N20847 004		
			AUG 04, 1998		
	0.1MG/24HR		N20847 005		
			AUG 04, 1998		
<u>ESTRADIOL</u>					
CYGNUS CA					
	0.05MG/24HR		N21048 001		
			SEP 20, 1999		
	0.075MG/24HR		N21048 002		
			SEP 20, 1999		
	0.1MG/24HR		N21048 003		
			SEP 20, 1999		
	0.0375MG/24HR		N20538 001		
			JUL 31, 1996		
	0.05MG/24HR		N20538 003		
			JUL 31, 1996		
	0.075MG/24HR		N20538 002		
			JUL 31, 1996		
	0.1MG/24HR		N20538 004		
			JUL 31, 1996		
	0.05MG/24HR		N21048 001		
			SEP 20, 1999		
	0.075MG/24HR		N21048 002		
			SEP 20, 1999		
	0.1MG/24HR		N21048 003		
			SEP 20, 1999		
	0.0375MG/24HR		N20538 001		
			JUL 31, 1996		
<u>ESTRADIOL</u>					
MENOREST					
	0.0375MG/24HR		N21048 001		
			SEP 20, 1999		
	0.05MG/24HR		N20538 003		
			JUL 31, 1996		
	0.075MG/24HR		N20538 002		
			JUL 31, 1996		
	0.1MG/24HR		N20538 004		
			JUL 31, 1996		
	0.05MG/24HR		N21048 001		
			SEP 20, 1999		
	0.075MG/24HR		N21048 002		
			SEP 20, 1999		
	0.1MG/24HR		N21048 003		
			SEP 20, 1999		
	0.0375MG/24HR		N20538 001		
			JUL 31, 1996		
<u>ESTRADIOL</u>					
WYETH AYERST					
	0.05MG/24HR		N21048 001		
			SEP 20, 1999		
	0.075MG/24HR		N21048 002		
			SEP 20, 1999		
	0.1MG/24HR		N21048 003		
			SEP 20, 1999		
	0.0375MG/24HR		N20538 001		
			JUL 31, 1996		
<u>VIVELLE-DOT</u>					
NOVARTIS					
	0.0375MG/24HR		N20538 001		
			JUL 31, 1996		

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

VIVELLE-DOT  
NOVARTIS

<u>AB</u>	<u>0.05MG/24HR</u>	N20538 003	
		JUL 31, 1996	
<u>AB</u>	<u>0.075MG/24HR</u>	N20538 002	
		JUL 31, 1996	
<u>AB</u>	<u>0.1MG/24HR</u>	N20538 004	
		JUL 31, 1996	

TABLET; ORAL

ESTRADIOL  
MYLAN

<u>AB</u>	<u>0.5MG</u>	N40326 001	
		APR 21, 1999	
<u>AB</u>	<u>1MG</u>	N40326 002	
		APR 21, 1999	
<u>AB</u>	<u>2MG</u>	N40326 003	
		APR 21, 1999	

INNOFEM

NOVO NORDISK

<u>AB</u>	<u>0.5MG</u>	N40312 001	
		NOV 19, 1999	
<u>AB</u>	<u>1MG</u>	N40312 002	
		NOV 19, 1999	
<u>AB</u>	<u>2MG</u>	N40312 003	
		NOV 19, 1999	

TABLET; VAGINAL

VAGIFEM  
+ NOVO NORDISK

	<u>25 UGM</u>	N20908 001	
		MAR 26, 1999	

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ORTHO-PREFEST  
+ JOHNSON RW

	<u>1MG, 1MG; 0.09MG, N/A</u>	N21040 001	
		OCT 22, 1999	

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN  
DURAMED

	<u>0.9MG</u>	N20992 003	
		MAR 24, 1999	
	<u>0.625MG</u>	N20992 002	
		MAR 24, 1999	

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN  
+ DURAMED

	<u>0.9MG</u>	N20992 003	
		MAR 24, 1999	

ESTRONE

INJECTABLE; INJECTION  
NATURAL ESTROGENIC SUBSTANCE-ESTRONE  
\* STERIS

	<u>2MG/ML</u>	N85237 001	
		NOV 23, 1982	
	<u>2MG/ML</u>	N85237 001	
		NOV 23, 1982	

ESTROPIRATE

CREAM; VAGINAL

OGEN

\* ABBOTT  
+ PHARMACIA AND UPJOHN

	<u>1.5MG/GM</u>	N84710 001	
	<u>1.5MG/GM</u>	N84710 001	

TABLET; ORAL

ESTROPIRATE  
DURAMED

<u>AB</u>	<u>0.75MG</u>	N40296 001	
		NOV 01, 1999	
<u>AB</u>	<u>1.5MG</u>	N40296 002	
		NOV 01, 1999	
<u>AB</u>	<u>3MG</u>	N40296 003	
		NOV 01, 1999	
<u>AB</u>	<u>0.75MG</u>	N40359 001	
		AUG 26, 1999	
<u>AB</u>	<u>1.5MG</u>	N40359 002	
		AUG 26, 1999	
<u>AB</u>	<u>3MG</u>	N40359 003	
		AUG 26, 1999	

OGEN .625

ABBOTT  
PHARMACIA AND UPJOHN

<u>AB</u>	<u>0.75MG</u>	N83220 001	
<u>AB</u>	<u>0.75MG</u>	N83220 001	

OGEN 1.25

ABBOTT  
PHARMACIA AND UPJOHN

<u>AB</u>	<u>1.5MG</u>	N83220 002	
<u>AB</u>	<u>1.5MG</u>	N83220 002	

OGEN 2.5

ABBOTT  
PHARMACIA AND UPJOHN

<u>AB</u>	<u>3MG</u>	N83220 003	
<u>AB</u>	<u>3MG</u>	N83220 003	

OGEN 5

ABBOTT  
PHARMACIA AND UPJOHN

<u>AB</u>	<u>6MG</u>	N83220 004	
-----------	------------	------------	--

ESTROPIPATE

TABLET; ORAL  
 OGEN 5  
 PHARMACIA AND UPJOHN 6MG

N83220 004

N20860 001  
 JUL 13, 1998

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL  
 ETHAMBUTOL HCL  
 WEST WARD

100MG

400MG

100MG  
 400MG  
 100MG  
 400MG

N75095 001  
 NOV 30, 1999  
 N75095 002  
 NOV 30, 1999  
 N16320 001  
 N16320 003  
 N16320 001  
 N16320 003

MYAMBUTOL  
 LEDERLE

AB +

AB \*

ETHCHLORVYNOL

CAPSULE; ORAL  
 ETHCHLORVYNOL  
 BANNER PHARMACAPS

200MG  
 500MG  
 750MG  
 100MG  
 100MG  
 200MG  
 500MG  
 750MG

N84463 002  
 N84463 003  
 N84463 004  
 N84463 001  
 N84463 001  
 N84463 002  
 N84463 003  
 N84463 004

PLACIDYL  
 ABBOTT

200MG  
 500MG  
 750MG  
 200MG  
 500MG  
 750MG

N10021 007  
 N10021 002  
 N10021 010  
 N10021 007  
 N10021 002  
 N10021 010

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21  
 LEVLITE  
 BERLEX LABS

0.02MG;0.1MG

N20860 001  
 JUL 13, 1998

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21  
 LEVLITE  
 + BERLEX LABS

0.02MG;0.1MG

N20860 001  
 JUL 13, 1998

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21  
 BREVICON 21-DAY  
 SEARLE  
 WATSON LABS

0.035MG;0.5MG  
 0.035MG;0.5MG

N17566 001  
 N17566 001

NORINYL 1+35 21-DAY  
 SEARLE  
 WATSON LABS

0.035MG;1MG  
 0.035MG;1MG

N17565 001  
 N17565 001

TRI-NORINYL 21-DAY  
 SEARLE

0.035MG,0.035MG;0.5MG,1MG N18977 001  
 APR 13, 1984  
 0.035MG,0.035MG;0.5MG,1MG N18977 001  
 APR 13, 1984

TABLET; ORAL-28  
 BREVICON 28-DAY  
 SEARLE  
 WATSON LABS

0.035MG;0.5MG  
 0.035MG;0.5MG

N17743 001  
 N17743 001

NORINYL 1+35 28-DAY  
 SEARLE  
 WATSON LABS

0.035MG;1MG  
 0.035MG;1MG

N17565 002  
 N17565 002

TRI-NORINYL 28-DAY  
 SEARLE

0.035MG,0.035MG;0.5MG,1MG N18977 002  
 APR 13, 1984  
 0.035MG,0.035MG;0.5MG,1MG N18977 002  
 APR 13, 1984

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL  
 FEMHRT  
 + PARKE DAVIS

0.005MG;1MG

N21065 002  
 OCT 15, 1999

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21  
 LO/OVRAL  
 + WYETH AYERST

0.03MG;0.3MG

N17612 001

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

\* WYETH AYERST

LOW-OGESTREL-21

SCS

WATSON LABS

OGESTREL 0.5/50-21

SCS

OVRAL

\* WYETH AYERST

TABLET; ORAL-28

LO/OVRAL-28

WYETH AYERST

LOW-OGESTREL-28

SCS

WATSON LABS

OGESTREL 0.5/50-28

SCS

OVRAL-28

WYETH AYERST

0.03MG; 0.3MG

0.03MG; 0.3MG

0.03MG; 0.3MG

0.05MG; 0.5MG

0.05MG; 0.5MG

0.05MG; 0.5MG

0.03MG; 0.3MG

0.03MG; 0.3MG

0.03MG; 0.3MG

0.05MG; 0.5MG

0.05MG; 0.5MG

0.05MG; 0.5MG

200MG

300MG

500MG

400MG

N17612 001

N75288 001

JUL 28, 1989

N75288 001

JUL 28, 1999

N75406 001

DEC 15, 1999

N16572 001

N16572 001

N17802 001

N17802 001

N75288 002

JUL 28, 1999

N75288 002

JUL 28, 1999

N75406 002

DEC 15, 1999

N16806 001

N16806 001

N75126 001

SEP 16, 1999

N75126 002

SEP 16, 1999

N74903 002

APR 19, 1999

N74847 001

APR 23, 1999

ETODOLAC

TABLET; ORAL

ETODOLAC

AB NOVOPHARM

500MG

N74847 002

APR 23, 1999

N75009 002

DEC 28, 1999

> ADD >

> ADD >

AB TEVA

500MG

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AM PHARM PARTNERS

20MG/ML

N74983 001

SEP 30, 1998

20MG/ML

N74983 001

SEP 30, 1998

20MG/ML

N74238 001

OCT 15, 1996

20MG/ML

N74228 001

OCT 15, 1996

20MG/ML

N18768 001

NOV 10, 1983

20MG/ML

N18768 001

NOV 10, 1983

ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE

10MG

N19369 001

SEP 30, 1986

25MG

N19369 002

SEP 30, 1986

10MG

N19369 001

SEP 30, 1986

25MG

N19369 002

SEP 30, 1986

EXEMESTANE

TABLET; ORAL

AROMASIN

+ PHARMACIA AND UPJOHN 25MG

N74903 002

APR 19, 1999

N74847 001

APR 23, 1999

N20753 001

OCT 21, 1999

FENOFIBRATE

capsule; oral  
TRICOR (MICRONIZED)  
\* ABBOTT

67MG N19304 002  
FEB 09, 1998  
67MG N19304 002  
FEB 09, 1998  
134MG N19304 003  
JUN 30, 1999  
200MG N19304 004  
JUN 30, 1999

EQ 20MG BASE N18936 001  
DEC 29, 1987  
EQ 20MG BASE N18936 001  
DEC 29, 1987  
EQ 40MG BASE N18936 003  
JUN 15, 1999  
EQ 60MG BASE N18936 004  
JUN 15, 1999

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION  
FERRLECIT  
+ R AND D LABS

62.5MG/5ML N20955 001  
FEB 18, 1999

EQ 10MG BASE N20974 001  
MAR 09, 1999  
EQ 20MG BASE N20974 002  
MAR 09, 1999  
EQ 10MG BASE N20974 001  
MAR 09, 1999  
EQ 20MG BASE N20974 002  
MAR 09, 1999

FLUOCINONIDE

ointment; topical  
FLUCINONIDE  
TARO

0.05% N75008 001  
JUN 30, 1999

FOLIC ACID

tablets; oral  
FOLIC ACID  
AA VINTAGE PHARMS  
c

1MG N86296 001  
1MG N86296 001

FLUOROURACIL

injectable; injection  
FLUOROURACIL  
BIGMAR

50MG/ML N40291 001  
MAR 24, 1999  
50MG/ML N88767 001  
DEC 28, 1984  
50MG/ML N89434 001  
MAR 26, 1987  
50MG/ML N88767 001  
DEC 28, 1984  
50MG/ML N89434 001  
MAR 26, 1987

N75241 001  
MAY 28, 1999  
N70078 001  
FEB 05, 1986  
N70078 001  
FEB 05, 1986  
N70019 001  
SEP 22, 1986  
N70604 001  
JAN 02, 1987  
N70019 001  
SEP 22, 1986

10MG/ML  
10MG/ML  
10MG/ML  
10MG/ML  
10MG/ML  
10MG/ML

injectable; injection

UROSEMIDE  
ABBOTT

SMITH AND NEEHEW

STERIS

c

c

c

c

c

c



GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC  
GENTAMICIN SULFATE  
 FALCON PHARMS EQ 0.3% BASE

N62196 001

0.2MG/ML

N86947 001  
 JUN 24, 1983

GLYCOPYRROLATE

INJECTABLE; INJECTION  
GLYCOPYRROLATE  
 @ STERIS

GLIPIZIDE

TABLET; ORAL  
 GLUCOTROL  
 PFIZER

2.5MG

N17783 003

N12827 001

@

2.5MG

MAY 11, 1993  
 N17783 003  
 MAY 11, 1993

N12827 002  
 N12827 002

TABLET, EXTENDED RELEASE; ORAL  
 GLUCOTROL XL  
 + PFIZER

2.5MG

N20329 003

AUG 10, 1999

GLYBURIDE

TABLET; ORAL  
GLYBURIDE (MICRONIZED)  
 MOVA

4.5MG

N74591 003

DEC 22, 1997

4.5MG

N74591 003

DEC 22, 1997

6MG

N74792 003

AUG 17, 1999

1.5MG

N74686 001

APR 20, 1999

3MG

N74686 002

APR 20, 1999

4.5MG

N74686 003

APR 20, 1999

6MG

N74686 004

APR 20, 1999

GLYCOPYRROLATE

INJECTABLE; INJECTION  
GLYCOPYRROLATE  
 @ STERIS

0.2MG/ML

N86947 001

JUN 24, 1983

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC  
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN  
 @ STERIS

0.025MG/ML; EQ 1.75MG BASE/ML;  
 10,000 UNITS/ML

N62788 001

JUN 11, 1987

@

0.025MG/ML; EQ 1.75MG BASE/ML;  
 10,000 UNITS/ML

N62788 001

JUN 11, 1987

HALOPERIDOL

TABLET; ORAL  
HALOPERIDOL  
 SCS

0.5MG

N70720 001

JUN 10, 1986

1MG

N70721 001

JUN 10, 1986

2MG

N70722 001

JUN 10, 1986

5MG

N70723 001

JUN 10, 1986

10MG

N70724 001

JUN 10, 1986

20MG

N70725 001

SEP 24, 1986

0.5MG

N70720 001

JUN 10, 1986

1MG

N70721 001

JUN 10, 1986

HALOPERIDOL

TABLET; ORAL  
HALOPERIDOL

@ SCS

2MG

N70722 001  
JUN 10, 1986

5MG

N70723 001  
JUN 10, 1986

10MG

N70724 001  
JUN 10, 1986

20MG

N70725 001  
SEP 24, 1986

EQ 5MG BASE/ML

N70744 001  
MAY 17, 1988

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE  
GENSIA SICOR PHARMS

AO

EQ 50MG BASE/ML

N75393 001  
MAY 11, 1999

AO

EQ 100MG BASE/ML

N75393 002  
MAY 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

SCS

AA

EQ 2MG BASE/ML

N70726 001  
JUN 10, 1986

EQ 2MG BASE/ML

N70726 001  
JUN 10, 1986

INJECTABLE; INJECTION

HALOPERIDOL

SOLOPAK

AP

EQ 5MG BASE/ML

N70801 001  
DEC 14, 1987

EQ 5MG BASE/ML

N70864 001  
DEC 14, 1987

EQ 5MG BASE/ML

N70713 001  
MAY 17, 1988

EQ 5MG BASE/ML

N70744 001  
MAY 17, 1988

STRIS

AP

EQ 5MG BASE/ML

N70713 001  
MAY 17, 1988

AP

EQ 5MG BASE/ML

N70713 001  
MAY 17, 1988

EQ 5MG BASE/ML

N70713 001  
MAY 17, 1988

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

@ STERIS

EQ 5MG BASE/ML

N70744 001  
MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH  
SMITH AND NEPHEW

AP

10 UNITS/ML

N88458 001  
JUL 26, 1984

AP

10 UNITS/ML

N88580 001  
OCT 25, 1984

AP

100 UNITS/ML

N88460 001  
JUL 26, 1984

AP

100 UNITS/ML

N88581 001  
OCT 25, 1984

@

10 UNITS/ML

N88458 001  
JUL 26, 1984

@

10 UNITS/ML

N88580 001  
OCT 25, 1984

@

100 UNITS/ML

N88460 001  
JUL 26, 1984

@

100 UNITS/ML

N88581 001  
OCT 25, 1984

AP SOLOPAK

100 UNITS/ML

N88459 001  
JUL 26, 1984

@

100 UNITS/ML

N88459 001  
JUL 26, 1984

HEPARIN SODIUM  
SMITH AND NEPHEW

AP

1,000 UNITS/ML

N88239 001  
JUL 26, 1984

@

1,000 UNITS/ML

N88239 001  
JUL 26, 1984

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE  
HALSEY

AA

1.5MG/5ML; 5MG/5ML

N40285 001  
JUL 19, 1999

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HCL

AP \* WITTFOID

20MG/ML

N40136 001

20MG/ML

JUN 30, 1997

+ AP SOLOPAK

20MG/ML

JUN 30, 1997

20MG/ML

AUG 22, 1985

@

20MG/ML

AUG 22, 1985

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

AB SOLVAY

25MG;25MG

N87608 001

@ AB

50MG;50MG

FEB 08, 1982

@ AB

25MG;25MG

FEB 08, 1982

@ AB

50MG;50MG

FEB 08, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

BP SOLVAY

25MG;15MG;0.1MG

N88376 001

@ AB

25MG;15MG;0.1MG

OCT 28, 1983

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB MAST MM

25MG

N86192 001

25MG

N86192 002

50MG

N86192 001

50MG

N86192 002

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

@ SANOFI SYNTHELABO

12.5MG;75MG

N20758 001

12.5MG;150MG

SEP 30, 1997

+ 12.5MG;300MG

N20758 002

12.5MG;75MG

N20758 003

AVAPRO HCT

@ SANOFI

12.5MG;150MG

N20758 001

\* 12.5MG;150MG

SEP 30, 1997

N20758 002

SEP 30, 1997

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

PARKE DAVIS

12.5MG;EQ 10MG BASE

N20125 001

+ 12.5MG;EQ 20MG BASE

DEC 28, 1999

25MG;EQ 20MG BASE

N20125 002

+ 25MG;EQ 20MG BASE

DEC 28, 1999

25MG;EQ 20MG BASE

DEC 28, 1999

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB DURAMED

25MG;37.5MG

N75052 001

JUN 18, 1999

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

@ G. AND W. LABS

AT

1%

N84059 001

N84059 001

ENEMA; RECTAL

COLOCORT

PADDOCK

100MG/60ML

N75172 001

DEC 03, 1999

+ CORTENEMA

SOLVAY

100MG/60ML

N16199 001

HYDROCORTISONE

ENEMA; RECTAL

BR \* CORTENEMA  
SOLVAY  
 AB HYDROCORTISONE  
COPLY PHARM  
 BR

LOTION; TOPICAL

AT DERMACORT  
SOLVAY  
 AT

@  
 @  
 AT HYDROCORTISONE  
THAMES

SOLUTION; TOPICAL

AT + TEXACORT  
BIOGLAN PHAR  
 \* GENDERM  
 AT \* MEDICIS

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

AT NEO-OTOSOL-HC  
ALCON

AT STERIS

HYDROCORTISONE ACETATE

CREAM; TOPICAL  
 HYDROCORTISONE ACETATE  
 + FERNDAL LABS

2.5%

N40259 001  
 JUL 29, 1999

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

AP HYDROCORTISONE SODIUM SUCCINATE  
STERIS  
 AP EQ 100MG BASE/VIAL  
 AP EQ 100MG BASE/VIAL  
 AP EQ 250MG BASE/VIAL  
 AP EQ 500MG BASE/VIAL  
 AP EQ 1GM BASE/VIAL  
 @ EQ 100MG BASE/VIAL  
 @ EQ 100MG BASE/VIAL  
 @ EQ 250MG BASE/VIAL  
 @ EQ 500MG BASE/VIAL  
 @ EQ 1GM BASE/VIAL

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE  
 + AKORN 1%  
 \* PHARMICS 1%

HYDROXYUREA

CAPSULE; ORAL  
 HYDROXYUREA  
 PAR PHARM

N75340 001  
 FEB 24, 1999

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP HYDROXYZINE HCL  
SOLOPAK  
 AP  
 AP

1%; EQ 3.5MG BASE/ML;  
 10,000 UNITS/ML

N87531 001  
 N87593 001  
 N87595 001  
 N87591 001  
 N87593 001  
 N87595 001

IBUPROFEN

SUSPENSION; ORAL

AB \* MOTRIN  
 \* MCNEIL

100MG/5ML

N19842 001  
 SEP 19, 1989

IBUPROFEN

SUSPENSION; ORAL  
MOTRIN  
AB + MCNEIL CONS

100MG/5ML  
N19842 001  
SEP 19, 1989

TABLET; ORAL  
IBUPROFEN  
AB NORTON HN

400MG N71145 001  
SEP 23, 1986  
600MG N71146 001  
SEP 23, 1986  
800MG N71769 001  
MAY 08, 1987  
400MG N71145 001  
SEP 23, 1986  
600MG N71146 001  
SEP 23, 1986  
800MG N71769 001  
MAY 08, 1987

ZENITH GOLDLINE

MOTRIN  
MCNEIL

300MG N17463 003  
400MG N17463 002  
600MG N17463 004  
800MG N17463 005  
100MG N20418 001  
NOV 16, 1994  
300MG N17463 003  
400MG N17463 002  
600MG N17463 004  
800MG N17463 005  
100MG N20418 001  
NOV 16, 1994

MCNEIL CONS

TABLET, CHEWABLE; ORAL  
MOTRIN  
MCNEIL

50MG N20135 001  
NOV 16, 1994  
100MG N20135 002  
NOV 16, 1994  
50MG N20135 001  
NOV 16, 1994  
100MG N20135 002  
NOV 16, 1994

IMIGLUCERASE

INJECTABLE; INJECTION  
CEREZYME  
\* GENZYME

200 UNITS/VIAL N20367 001  
MAY 23, 1994  
200 UNITS/VIAL N20367 001  
MAY 23, 1994  
400 UNITS/VIAL N20367 002  
SEP 22, 1999

IMIPRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
TOPRANIL  
\* NOVARTIS  
@

12.5MG/ML N11838 002  
12.5MG/ML N11838 002

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL  
INDOCIN SR

AB EON 75MG N74464 001  
MAY 28, 1998  
AB + 75MG N74464 001  
MAY 28, 1998  
AB + MERCK 75MG N18185 001  
FEB 23, 1982  
@ 75MG N18185 001  
FEB 23, 1982

INSULIN HUMAN

INJECTABLE; INJECTION  
VELOSULIN BR  
+ NOVO NORDISK

100 UNITS/ML N21028 001  
JUL 19, 1999

INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION  
HUMALOG MIX 50/50  
+ LILLY

100 UNITS/ML N21018 001  
DEC 22, 1999



ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL  
ISOSORBIDE MONONITRATE  
 BRIGHTSTONE 60MG  
 AB

N75166 001  
 OCT 07, 1999

KANAMYCIN SULFATE

INJECTABLE; INJECTION  
KANAMYCIN SULFATE  
 @ SOLOPAK  
 EQ 1GM BASE/3ML

N62605 002  
 FEB 26, 1986

ISOTRETINOIN

CAPSULE; ORAL  
 ACCUTANE  
 HLR

10MG  
 20MG  
 40MG  
10MG  
20MG  
40MG

+

ROCHE

N18662 002  
 MAY 07, 1982  
 N18662 004  
 MAR 28, 1983  
 N18662 003  
 MAY 07, 1982  
 N18662 002  
 MAY 07, 1982  
 N18662 004  
 MAR 28, 1983  
 N18662 003  
 MAY 07, 1982

> ADD >  
 > ADD >

\*

ITRACONAZOLE

INJECTABLE; INJECTION  
 SPORANOX  
 + JANSSEN

10MG/ML

N20966 001  
 MAR 30, 1999

AB  
 NIZORAL  
 + JANSSEN  
 \*

200MG  
~~200MG~~

N18533 001  
~~N18533 001~~

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL  
KETOPROFEN  
 ANDRX PHARMS

100MG

N75270 002

150MG

N75270 003

200MG

N75270 001

100MG

N19816 003

150MG

N19816 002

100MG

N19816 003

KANAMYCIN SULFATE

INJECTABLE; INJECTION  
KANAMYCIN SULFATE  
 SOLOPAK

EQ 75MG BASE/2ML

N62605 003

EQ 500MG BASE/2ML

N62605 001

EQ 1GM BASE/3ML

N62605 002

EQ 75MG BASE/2ML

N62605 003

EQ 500MG BASE/2ML

N62605 001

AP

AP

AP

@

@

MAR 24, 1999

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL  
WYETH AYERST 150MG

N19816 002  
 FEB 08, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE  
ABBOTT 15MG/ML

N74993 001  
 JAN 27, 1999

N74993 002  
 JAN 27, 1999

N75299 001  
 NOV 03, 1999

N75299 002  
 NOV 03, 1999

N75222 001  
 APR 26, 1999

N75230 002  
 OCT 25, 1999

N75222 002  
 APR 26, 1999

N75228 001  
 APR 26, 1999

N75230 001  
 OCT 25, 1999

SOLUTION/DROPS; OPHTHALMIC

ACULAR  
 + ALLERGAN 0.5%

\* SYNTEX 0.5%

N19700 001  
 NOV 09, 1992

N19700 001  
 NOV 09, 1992

TABLET; ORAL

KETOROLAC TROMETHAMINE  
SIDMAK LABS CA 10MG

N75284 001  
 JUN 23, 1999

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR  
 + CIBA EQ 0.025% BASE

N21066 001  
 JUL 02, 1999

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL  
ABBOTT 5MG/ML

N75239 001  
 NOV 29, 1999

N75240 001  
 NOV 29, 1999

N75355 001  
 NOV 29, 1999

N75303 001  
 MAY 28, 1999

N75242 001  
 SEP 30, 1999

N75431 001  
 NOV 29, 1999

N75524 001  
 NOV 29, 1999

5MG/ML

5MG/ML

5MG/ML

5MG/ML

5MG/ML

5MG/ML

TABLET; ORAL

LABETALOL HCL  
MUTUAL PHARM 100MG

N75215 001  
 JUL 29, 1999

N75215 002  
 JUL 29, 1999

N75215 003  
 JUL 29, 1999

N18716 001  
 MAY 24, 1985

N18716 002  
 AUG 01, 1984

N18716 003  
 AUG 01, 1984

N18716 004  
 AUG 01, 1984

N18716 001  
 MAY 24, 1985

N18716 002  
 AUG 01, 1984

N18716 003  
 AUG 01, 1984

N18716 004  
 AUG 01, 1984

100MG

200MG

300MG

100MG

200MG

300MG

400MG

100MG

200MG

300MG

400MG

TRANDATE

FARO PHARMS

®

GLAXO WELLCOME

®

LACTULOSE

SOLUTION; ORAL  
LACTULOSE  
FRACO

10GM/15ML  
10GM/15ML

N73160 001  
AUG 25, 1992  
N73160 001  
AUG 25, 1992

SOLUTION; ORAL, RECTAL

LACTULOSE  
FRACO

10GM/15ML  
10GM/15ML

N72029 001  
AUG 25, 1992  
N72029 001  
AUG 25, 1992

LAMIVUDINE

SOLUTION; ORAL  
EPIVIR-HBV  
GLAXO WELLCOME

5MG/ML  
5MG/ML  
5MG/ML

N20596 002  
DEC 08, 1998  
N20596 002  
DEC 08, 1998  
N21004 001  
DEC 08, 1998

TABLET; ORAL  
EPIVIR-HBV  
GLAXO WELLCOME

100MG  
100MG  
100MG

N20564 002  
DEC 08, 1998  
N20564 002  
DEC 08, 1998  
N21003 001  
DEC 08, 1998

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION  
LEUCOVORIN CALCIUM  
ABBOTT

EQ 10MG BASE/ML

N40147 001  
JUN 25, 1997  
N40056 001  
MAY 23, 1995  
N40262 001  
DEC 15, 1999

AP + BEDFORD

EQ 200MG BASE/VIAL

AP PHARMACHEMIE

EQ 350MG BASE/VIAL

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION  
LEUCOVORIN CALCIUM PRESERVATIVE FREE  
ABBOTT

AP + BEDFORD

N40147 001  
JUN 25, 1997  
N40056 001  
MAY 23, 1995  
N40266 001  
FEB 28, 1999  
N40258 001  
FEB 26, 1999  
N40286 001  
FEB 26, 1999  
N40332 001  
JUN 28, 1999

AP BIGMAR

EQ 10MG BASE/ML

AP

EQ 200MG BASE/VIAL

+

EQ 500MG BASE/VIAL

AP GENSLA SICOR PHARMS

EQ 10MG BASE/ML

TABLET; ORAL  
LEUCOVORIN CALCIUM  
INVAMED

EQ 15MG BASE

N75327 001  
MAR 24, 1999

AB WELLCOVORIN  
GLAXO WELLCOME

EQ 5MG BASE

N18342 001  
JUL 08, 1983  
N18342 002  
JUL 08, 1983

AB +

EQ 25MG BASE

@

EQ 5MG BASE

N18342 001  
JUL 08, 1983  
N18342 002  
JUL 08, 1983

@

EQ 25MG BASE

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION  
XOPENEX  
SEPRACOR

EQ 0.021% BASE

N20837 001  
MAR 25, 1999  
N20837 002  
MAR 25, 1999

+

EQ 0.042% BASE

LEVETIRACETAM

TABLET; ORAL  
KEPPRA  
UCB

250MG

N21035 001  
NOV 30, 1999

LEVETIRACETAM

TABLET; ORAL  
KEPPRA  
UCB

500MG  
750MG

N21035 002  
NOV 30, 1999  
N21035 003  
NOV 30, 1999

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL  
EMLA  
\* ASTRA PHARMS

2.5%; 2.5%

N20962 001  
FEB 04, 1998

DISC; TOPICAL  
EMLA  
+ ASTRAZENECA

2.5%; 2.5%

N20962 001  
FEB 04, 1998

LEVOPUIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
CHIROCAINE  
DARWIN DISCOVERY

EQ 2.5MG BASE/ML  
EQ 5MG BASE/ML  
EQ 7.5MG BASE/ML

N20997 001  
AUG 05, 1999  
N20997 002  
AUG 05, 1999  
N20997 003  
AUG 05, 1999

LINDANE

CREAM; TOPICAL  
KWELL  
\* REED AND CARNRICK  
®

1%  
1%

N84218 001  
N84218 001

LOTION; TOPICAL  
KWELL

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL  
ORLAAM  
\* BIODEVELOPMENT

10MG/ML  
10MG/ML

N20315 001  
JUL 09, 1993  
N20315 001  
JUL 09, 1993

AT \* REED AND CARNRICK  
KWELL

1%  
1%

N84218 002  
N84218 002

AT LINDANE  
AT ALPHARMA  
AT \*

1%  
1%

N87313 001  
N87313 001

SHAMPOO; TOPICAL  
KWELL

1%  
1%

N84219 001  
N84219 001

LEVONORGESTREL

TABLET; ORAL  
PLAN B  
+ WOMENS CAPITAL

0.75MG

N21045 001  
JUL 28, 1999

AT \* REED AND CARNRICK  
KWELL

1%  
1%

N84219 001  
N84219 001

AT LINDANE  
AT ALPHARMA  
AT \*

1%  
1%

N87266 001  
N87266 001

LISINAPRIL

TABLET; ORAL  
ZESTRIL  
ZENECA

30MG

N19777 006  
JAN 20, 1999

LIDOCAINE

FILM, EXTENDED RELEASE; TOPICAL  
LIDODERM  
+ TEIKOKU PHARMA USA

700MG/12HR

N20612 001  
MAR 19, 1999

FILM, EXTENDED RELEASE; TRANSFERMAL  
LIDODERM  
\* HIND HLTHCARE

700MG/12HR

N28612 001  
MAR 19, 1999

LITHIUM CARBONATE

CAPSULE; ORAL  
LITHONATE  
SOLVAY

300MG

N16782 001

LITHIUM CARBONATE

capsule; oral  
LITHONATE  
@ SOLVAY

300MG N16782 001

TABLET; ORAL

LITHIUM CARBONATE

AB + EFIZER

N16834 001

300MG

AB + LITHOTABS

N16834 001

300MG

AB + SOLVAY

N16980 001

300MG

LOPERAMIDE HYDROCHLORIDE

capsule; oral

IMODIUM

AB + JANSSEN

N17694 001

2MG

AB + MCNEIL CONS

N17694 001

2MG

AB + MCNEIL CONS

N17694 001

2MG

LORACARBEEF

capsule; oral

LORABID

KING PHARMS

200MG

N50668 001

+

400MG

N50668 002

LILLY

200MG

N50668 001

\*

400MG

N50668 002

POWDER FOR RECONSTITUTION; ORAL

LORABID

KING PHARMS

100MG/5ML

N50667 001

+

200MG/5ML

N50667 002

LILLY

100MG/5ML

N50667 001

\*

200MG/5ML

N50667 002

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

0.5%

N20841 001

MAR 09, 1998

N20841 001

MAR 09, 1998

0.5%

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE;  
MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE;  
SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML;

370MG/100ML; 530MG/100ML; 500MG/100ML;

12MG/100ML N19006 001

APR 04, 1984

30MG/100ML; 37MG/100ML; 0.82MG/100ML;

370MG/100ML; 530MG/100ML; 500MG/100ML;

12MG/100ML N19006 001

APR 04, 1984

MALATHION

LOTION; TOPICAL

OVIDE

@ MEDICIS

0.5%

N18613 001

AUG 02, 1982

N18613 001

AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

STERIS

12.5GM/50ML

N87460 001

JUN 27, 1983

N87460 001

JUN 27, 1983

12.5GM/50ML

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX  
\* JANSSEN 100MG  
\* MCNEIL CONS 100MG

N17481 001  
N17481 001

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLEN  
\* JOHNSON AND JOHNSON 1%  
\* 1%

N50518 001  
N50518 001

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

CYCRIN  
ESI

2.5MG  
5MG  
10MG

N81239 001  
OCT 30, 1992  
N81240 001  
OCT 30, 1992  
N89386 001  
SEP 09, 1987

2.5MG  
5MG  
10MG

N81239 001  
OCT 30, 1992  
N81240 001  
OCT 30, 1992  
N89386 001  
SEP 09, 1987

MEDROXYPROGESTERONE ACETATE  
DURAMED

2.5MG  
5MG  
10MG

N40311 001  
DEC 01, 1999  
N40311 002  
DEC 01, 1999  
N40311 003  
DEC 01, 1999

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

REPRONEX  
FERRING

75 IU/VIAL; 75 IU/VIAL  
AUG 27, 1999  
150 IU/VIAL; 150 IU/VIAL  
AUG 27, 1999

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL  
\* ABBOTT 25MG/ML  
\* 50MG/ML  
\* 75MG/ML  
\* 100MG/ML  
\* SANOFI SYNTHELABO 25MG/ML  
\* 50MG/ML  
\* 75MG/ML  
\* 100MG/ML  
\* MEPERIDINE HCL 10MG/ML  
\* ABBOTT 10MG/ML  
\* ASTRA PHARMS 10MG/ML  
\* INTL MEDICATION 10MG/ML  
\* MALLINCKRODT 10MG/ML  
\* STERIS 10MG/ML

N88432 001  
AUG 16, 1984  
N81002 001  
JUL 30, 1993  
N81309 001  
AUG 30, 1993  
N40163 001  
MAY 12, 1997  
N73443 001  
MAR 17, 1992

MEPERIDINE HCL PRESERVATIVE FREE  
\* ABBOTT 10MG/ML  
\* ASTRA PHARMS 10MG/ML  
\* FAULDING 10MG/ML  
\* INTL MEDICATION 10MG/ML  
\* MALLINCKRODT 10MG/ML  
\* STERIS 10MG/ML

N88432 001  
AUG 16, 1984  
N81002 001  
JUL 30, 1993  
N40305 001  
MAR 10, 1999  
N81309 001  
AUG 30, 1993  
N40163 001  
MAY 12, 1997  
N73443 001  
MAR 17, 1992

SYRUP; ORAL  
DEMEROL  
\* ABBOTT 50MG/5ML  
\* SANOFI SYNTHELABO 50MG/5ML

N05010 005  
N05010 005

TABLET; ORAL

DEMEROL  
\* ABBOTT 50MG  
\* SANOFI SYNTHELABO 100MG  
\* 50MG  
\* 100MG

N05010 001  
N05010 004  
N05010 001  
N05010 004

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL  
MEPERIDINE HCL  
 AMIDE PHARM  
AA 50MG N40331 001  
 MAY 28, 1999  
AA 100MG N40331 002  
 MAY 28, 1999  
AA 50MG N40318 001  
 OCT 05, 1999  
AA 100MG N40318 002  
 OCT 05, 1999

MEPROBAMATE

TABLET; ORAL  
MEPROBAMATE  
 PHARMAVITE  
AA 400MG N84438 001  
 400MG N84438 001

MEQUINOL; TRETINOIN

> ADD >  
 > ADD >  
 > ADD >  
 > ADD >  
 > ADD >

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION  
MERSALYL-THEOPHYLLINE  
 \* STERIS  
 @  
 100MG/ML; 50MG/ML N84875 001  
 100MG/ML; 50MG/ML N84875 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL  
 GLUCOPHAGE  
 \* BRISTOL MYERS SQUIBB 500MG N20357 001  
 625MG MAR 03, 1995  
 750MG N20357 003  
 NOV 05, 1998  
 N20357 004  
 NOV 05, 1998

METFORMIN HYDROCHLORIDE

TABLET; ORAL  
 GLUCOPHAGE  
 BRISTOL MYERS SQUIBB 500MG N20357 001  
 MAR 03, 1995  
 @ N20357 003  
 NOV 05, 1998  
 @ N20357 004  
 NOV 05, 1998

METHOTREXATE SODIUM

INJECTABLE; INJECTION  
METHOTREXATE  
 BIGMAR EQ 25MG BASE/ML N40263 001  
 FEB 26, 1999  
AP EQ 25MG BASE/ML N40265 001  
 FEB 26, 1999  
AP EQ 25MG BASE/ML N40266 001  
 FEB 26, 1999  
AP EQ 1GM BASE/VIAL N11719 009  
 APR 07, 1988  
AP + LEDERLE EQ 1GM BASE/VIAL N11719 009  
 APR 07, 1988

TABLET; ORAL  
METHOTREXATE SODIUM  
 DURAMED EQ 2.5MG BASE N40233 001  
 JUN 17, 1999

METHOTRIMEPAZINE

INJECTABLE; INJECTION  
 LEVOPROME 20MG/ML N15865 001  
 \* IMMUNEX 20MG/ML N15865 001  
 @

METHOXSALEN

INJECTABLE; INJECTION  
 UVADEX 0.02MG/ML N20969 001  
 + THERAKOS FEB 25, 1999

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION  
METHYLDOPATE HCL  
SMITH AND NEPHEW

AP 50MG/ML  
50MG/ML

N70841 001  
JAN 02, 1987  
N70841 001  
JAN 02, 1987

N88524 001  
JUL 24, 1984

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
METADATE ER  
MEDEVA

10MG  
10MG

N40306 001  
OCT 20, 1999  
N40306 001  
OCT 20, 1999

AB METHYLPHENIDATE HCL  
NEDEVA PHARMS CA

20MG  
20MG  
20MG  
20MG

N89601 001  
JUN 01, 1988  
N89601 001  
JUN 01, 1988  
N18029 001  
MAR 30, 1982  
N18029 001  
MAR 30, 1982

AB RITALIN-SR  
\* NOVARTIS

20MG  
20MG

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION  
METHYLPREDNISOLONE SODIUM SUCCINATE  
STERIS

AP EQ 40MG BASE/VIAL  
AP EQ 125MG BASE/VIAL  
AP EQ 500MG BASE/VIAL  
AP EQ 1GM BASE/VIAL  
EQ 40MG BASE/VIAL  
EQ 125MG BASE/VIAL  
EQ 500MG BASE/VIAL

N86953 001  
JUL 22, 1982  
N87030 001  
JUL 22, 1982  
N88523 001  
JUL 24, 1984  
N88524 001  
JUL 24, 1984  
N86953 001  
JUL 22, 1982  
N87030 001  
JUL 22, 1982  
N88523 001  
JUL 24, 1984

EQ 40MG BASE/VIAL  
EQ 125MG BASE/VIAL  
EQ 500MG BASE/VIAL

N86953 001  
JUL 22, 1982  
N87030 001  
JUL 22, 1982  
N88523 001  
JUL 24, 1984

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION  
METHYLPREDNISOLONE SODIUM SUCCINATE  
STERIS

EQ 1GM BASE/VIAL

N88524 001  
JUL 24, 1984

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION  
METOCLOPRAMIDE HCL  
SMITH AND NEPHEW

AP EQ 5MG BASE/ML  
EQ 5MG BASE/ML

N70623 001  
MAR 02, 1987  
N70623 001  
MAR 02, 1987

METOLAZONE

TABLET; ORAL  
ZAROXOLYN  
MEDEVA

2.5MG  
2.5MG

N17386 001  
N17386 001

METOPROLOL TARTRATE

TABLET; ORAL  
METOPROLOL TARTRATE  
PUREPAC PHARM

AB 50MG  
AB 100MG  
50MG  
100MG

N74380 001  
JUL 29, 1994  
N74380 002  
JUL 29, 1994  
N74380 001  
JUL 29, 1994  
N74380 002  
JUL 29, 1994

METRIZAMIDE

INJECTABLE; INJECTION  
AMIPAQUE  
NYCOMED

3.75GM/VIAL  
6.75GM/VIAL  
3.75GM/VIAL  
6.75GM/VIAL

N17982 001  
N17982 002  
N17982 001  
N17982 002

> DLT >  
> DLT >  
> DLT >  
> DLT >  
> ADD >  
> ADD >

> DLT >  
> DLT >  
> ADD >  
> ADD >  
> DLT >  
> DLT >  
> ADD >  
> ADD >  
> DLT >  
> DLT >  
> ADD >  
> ADD >

METRONIDAZOLE

INJECTABLE; INJECTION  
 FLAGYL I.V. RTU IN PLASTIC CONTAINER  
 AP + BAXTER HLHCARE 500MG/100ML  
 AP \* SCS 500MG/100ML  
 METRONIDAZOLE 500MG/100ML  
 AP STERIS  
 500MG/100ML  
 @

N18657 001  
 N18657 001  
 N70170 001  
 APR 01, 1986  
 N70170 001  
 APR 01, 1986

N20682 003  
 DEC 18, 1996

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL  
 MONISTAT DUAL-PAK  
 + ADVANCED CARE PRODS 1.2GM, 2%

N63065 002  
 JUN 10, 1999  
 N65005 001  
 MAR 23, 1999  
 N65005 002  
 MAR 23, 1999  
 N63066 001  
 AUG 14, 1990  
 N63067 001  
 JUL 31, 1990

EQ 75MG BASE  
 EQ 50MG BASE  
 EQ 100MG BASE  
 EQ 50MG BASE  
 EQ 100MG BASE

SUPPOSITORY; VAGINAL  
 MICONAZOLE NITRATE  
 ALPHAERMA US PHARM

N73508 001  
 NOV 19, 1993  
 N73508 001  
 NOV 19, 1993

200MG  
 200MG

N63066 001  
 AUG 14, 1990  
 N63067 002  
 SEP 15, 1999  
 N63067 001  
 JUL 31, 1990  
 N63067 002  
 SEP 15, 1999

EQ 50MG BASE  
 EQ 75MG BASE  
 EQ 100MG BASE  
 EQ 75MG BASE

TAMPON; VAGINAL  
 MONISTAT 5  
 + ADVANCED CARE PRODS

100MG  
 100MG  
 @

N18592 001  
 OCT 27, 1989  
 N18592 001  
 OCT 27, 1989

MITOMYCIN

MIGLITOL

TABLET; ORAL  
 GLYSET  
 BAYER

N64180 001  
 DEC 23, 1999  
 N64180 002  
 DEC 23, 1999

5MG/VIAL  
 20MG/VIAL

\*

PHARMACIA AND UPJOHN 25MG  
 50MG

N20098 001  
 JAN 22, 1992

EQ 2MG BASE/ML

INJECTABLE; INJECTION

MITOMYCIN

ESI LEDERLE

AP  
 > ADD >  
 > ADD >  
 AP  
 > ADD >  
 > ADD >

N20682 001  
 DEC 18, 1996  
 N20682 002  
 DEC 18, 1996  
 N20682 003  
 DEC 18, 1996  
 N20682 001  
 DEC 18, 1996  
 N20682 002  
 DEC 18, 1996

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION  
 MIVACRON  
 + ABBOTT

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION  
 MIVACON  
 \* GLAXO WELLCOME EQ 2MG BASE/ML N20098 001  
 MIVACON IN DEXTROSE 5% IN PLASTIC CONTAINER JAN 22, 1992  
 + ABBOTT EQ 0.5MG BASE/ML N20098 002  
 + EQ 50MG BASE/100ML JAN 22, 1992  
 \* GLAXO WELLCOME EQ 0.5MG BASE/ML N20098 002  
 \* EQ 50MG BASE/100ML JAN 22, 1992  
 \* EQ 50MG BASE/100ML JAN 22, 1992

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION  
 NALOXONE HCL  
 SMITH AND NEPHEW 0.4MG/ML N71681 001  
 @ NOV 17, 1987  
 @ 0.02MG/ML N71671 001  
 @ NOV 17, 1987  
 @ 0.4MG/ML N71681 001  
 @ STERIS 0.4MG/ML N71339 001  
 @ NOV 17, 1987  
 @ 0.4MG/ML N71339 001  
 @ NOV 18, 1987  
 @ 0.4MG/ML N71339 001  
 @ NOV 18, 1987

MOXIFLOXACIN HYDROCHLORIDE

> ADD >  
 > ADD >  
 > ADD >  
 > ADD >  
 > ADD >

TABLET; ORAL  
 AVELOX  
 + BAYER EQ 400MG BASE N21085 001  
 DEC 10, 1999

NALTREXONE HYDROCHLORIDE

TABLET; ORAL  
 NALTREXONE HCL  
 AMIDE PHARM 50MG N75274 001  
 @ MAY 26, 1999

NADOLOL

TABLET; ORAL  
 CORGARD  
 APOTHECON 20MG N18063 005  
 AB OCT 28, 1986  
 AB 40MG N18063 001  
 AB 80MG N18063 002  
 AB 120MG N18063 003  
 AB 160MG N18063 004  
 AB + BRISTOL MYERS SQUIBB 20MG N18063 005  
 AB OCT 28, 1986  
 AB 40MG N18063 001  
 AB 80MG N18063 002  
 AB 120MG N18063 003  
 AB 160MG N18063 004  
 AB \*

NANDROLONE DECANOATE

INJECTABLE; INJECTION  
 NANDROLONE DECANOATE  
 STERIS 50MG/ML N88554 001  
 @ FEB 10, 1986  
 @ 50MG/ML N88554 001  
 @ FEB 10, 1986

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION  
 DURABOLIN  
 \* ORGANON 25MG/ML N11891 001  
 \* 50MG/ML N11891 002  
 \* 25MG/ML N11891 001  
 \* 50MG/ML N11891 002  
 + NANDROLONE PHENPROPIONATE  
 STERIS 25MG/ML N86386 001  
 @ JUN 17, 1983  
 @ 50MG/ML N87488 001  
 @ JUN 17, 1983  
 @ 25MG/ML N86386 001  
 @ JUN 17, 1983

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION  
 NALOXONE HCL  
 SMITH AND NEPHEW 0.02MG/ML N71671 001  
 @ NOV 17, 1987

NANDROLONE PHENPROPIONATE

INJECTABLE, INJECTION  
NANDROLONE PHENPROPIONATE 50MG/ML  
 @ STERIS

> ADD >  
 > ADD >  
 > ADD >  
 > ADD >

N87488 001  
 JUN 17, 1983

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC  
 ALOCRIL  
 + ALLERGAN 2%

N21009 001  
 DEC 08, 1999

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
NAPHAZOLINE HCL  
 AKORN 0.1%  
 TAYLOR 0.1%

N83590 001  
 N83590 001

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL  
 TPN SUSPENSION  
 \* INTL MINERALS  
 @  
 15MG/5ML; 3.75MG/5ML;  
 600MG/5ML  
 15MG/5ML; 3.75MG/5ML;  
 600MG/5ML

N08378 003  
 N08378 003

NAPROXEN

TABLET, DELAYED RELEASE; ORAL  
NAPROXEN  
 SIDMAK LABS CA 375MG  
 500MG

N75337 001  
 MAY 26, 1999  
 N75337 002  
 MAY 26, 1999

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL  
 PROSTEP  
 \* ELAN PHARM 11MG/24HR  
 \* 22MG/24HR  
 @ 11MG/24HR  
 @ 22MG/24HR

N19883 001  
 JAN 28, 1992  
 N19883 002  
 JAN 28, 1992  
 N19883 001  
 JAN 28, 1992  
 N19883 002  
 JAN 28, 1992

NAPROXEN SODIUM

TABLET; ORAL  
NAPROXEN SODIUM  
 PUREPAC PHARM EQ 250MG BASE  
 EQ 500MG BASE  
 @ EQ 250MG BASE  
 @ EQ 500MG BASE

N74319 001  
 MAR 20, 1995  
 N74319 002  
 MAR 20, 1995  
 N74319 001  
 MAR 20, 1995  
 N74319 002  
 MAR 20, 1995

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL  
 NIFEDIPINE  
 @ MYLAN 30MG

N75108 001  
 DEC 17, 1999

NEDOCROMIL SODIUM

SOLUTION, INHALATION  
 TILADE  
 \* RHONE POULENC FORER 0.5%  
 @ 0.5%

> ADD >  
 > ADD >  
 > ADD >  
 > ADD >  
 > ADD >

N20750 001  
 OCT 01, 1997  
 N20750 001  
 OCT 01, 1997

NITRIC OXIDE

GAS; INHALATION  
 INOMAX  
 INO  
 +  
 100PPM  
 800PPM

N20845 002  
 DEC 23, 1999  
 N20845 003  
 DEC 23, 1999

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'99 - DEC'99

<u>NITROGLYCERIN</u>					
FILM, EXTENDED RELEASE; TRANSDERMAL					
<u>NITROGLYCERIN</u>					
MYLAN TECHNOLOGIES	0.1MG/HR	N75076 001	CAPSULE, DELAYED REL PELLETS; ORAL		N19810 003
AB1		NOV 12, 1999	PRIOLOSEC		OCT 05, 1995
AB1	0.2MG/HR	N75073 001	ASTRAZENECA	10MG	
AB1	0.4MG/HR	NOV 12, 1999			
AB1	0.6MG/HR	N75075 001			
		NOV 12, 1999			
		N74992 001			
		NOV 12, 1999			
INJECTABLE; INJECTION					
<u>NITROGLYCERIN</u>					
SMITH AND NEPHEW	5MG/ML	N70633 001	TABLET, ORALLY DISINTEGRATING; ORAL		N20781 001
AE		JUN 19, 1986	ZOFRAN ODT		JAN 27, 1999
@		N70633 001	GLAXO WELLCOME	EQ 4MG BASE	N20781 002
		JUN 19, 1986		EQ 8MG BASE	JAN 27, 1999
OINTMENT; TRANSDERMAL					
<u>NITROGLYCERIN</u>					
ALTANA	2%	N87355 001	TABLET; ORAL		
+		JUL 08, 1988	ZOFRAN		
		N87355 001	* GLAXO WELLCOME	EQ 8MG BASE	N20103 002
		JUL 08, 1988		EQ 8MG BASE	DEC 31, 1992
				EQ 24MG BASE	DEC 31, 1992
SPRAY, METERED; SUBLINGUAL					N20103 003
NITROLINGUAL PUMPSPRAY	0.4MG/SPRAY	N18705 002			AUG 27, 1999
+ POHL BOSKAMP		JAN 10, 1997			
<u>OLANZAPINE</u>					
TABLET; ORAL					
ZYPREXA					
* Lilly	2.5MG	N20592 001	CAPSULE; ORAL		N20766 001
		SEP 30, 1996	XENICAL		APR 23, 1999
	2.5MG	N20592 001	+ ROCHE	120MG	
		SEP 30, 1996			
<u>OMEPRAZOLE</u>					
CAPSULE, DELAYED REL PELLETS; ORAL					
PRIOLOSEC					
* ASTRA PHARMS	10MG	N19810 003	ORPHENADRINE CITRATE		N40249 001
		OCT 05, 1995	ORPHENADRINE CITRATE	100MG	JAN 29, 1999
			AB KIEL		

OSELTAMIVIR PHOSPHATE

capsule; oral  
TAMIFLU  
+ ROCHE

EQ 75MG BASE  
N21087 001  
OCT 27, 1999

EQ 250MG BASE/VIAL  
EQ 500MG BASE/VIAL  
EQ 250MG BASE/VIAL  
EQ 500MG BASE/VIAL  
N60586 001  
N60586 002  
N60586 001  
N60586 002

OXAZEPAM

capsule; oral  
SERAX

10MG  
15MG  
30MG  
10MG  
15MG  
30MG  
N15539 002  
N15539 004  
N15539 006  
N15539 002  
N15539 004  
N15539 006

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

ointment; otic

TERRAMYCIN w/ POLYMYXIN  
\* PFIZER  
EQ 5MG BASE/GM;  
10,000 UNITS/GM  
EQ 5MG BASE/GM;  
10,000 UNITS/GM  
N61841 001  
N61841 001

tablet; oral

SERAX  
+ FAULDING  
\* WYETH AYERST  
15MG  
15MG  
N15539 008  
N15539 008

tablet; vaginal  
TERRAMYCIN-POLYMYXIN  
\* PFIZER  
EQ 100MG BASE;  
100,000 UNITS  
EQ 100MG BASE;  
100,000 UNITS  
N61009 001  
N61009 001

OXYBUTYRIN CHLORIDE

SYRUP; ORAL  
OXYBUTYRIN CHLORIDE  
AA MIKART

5MG/5ML  
N75039 001  
JAN 29, 1999

PAROMOMYCIN SULFATE

capsule; oral

HUMATIN  
\* PARKE-DALE  
AA \*  
AA \*  
AA \*  
EQ 250MG BASE  
EQ 250MG BASE  
EQ 250MG BASE  
N60521 001  
N62310 001  
N62310 001  
N60521 001

tablet, extended release; oral  
DITROPAN XL  
+ ALZA  
15MG  
N20897 003  
JUN 22, 1999

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL  
TERRAMYCIN  
\* PFIZER  
@

EQ 125MG BASE/5ML  
EQ 125MG BASE/5ML  
N60595 001  
N60595 001

PAROXETINE HYDROCHLORIDE

capsule; oral  
PAXIL

SMITHKLINE-BEECHAM  
EQ 10MG BASE  
EQ 20MG BASE  
EQ 30MG BASE  
EQ 40MG BASE  
N20885 001  
OCT 09, 1998  
N20885 002  
OCT 09, 1998  
N20885 003  
OCT 09, 1998  
N20885 004  
OCT 09, 1998

PAROXETINE HYDROCHLORIDE

capsule, oral  
Paxil

@ SMITHKLINE BEECHAM EQ 10MG BASE  
 @ EQ 20MG BASE  
 @ EQ 30MG BASE  
 @ EQ 40MG BASE

N20885 001  
 OCT 09, 1998  
 N20885 002  
 OCT 09, 1998  
 N20885 003  
 OCT 09, 1998  
 N20885 004  
 OCT 09, 1998

N75286 003  
 JUN 30, 1999

TABLET, EXTENDED RELEASE; ORAL  
 PAXIL CR

+ SMITHKLINE BEECHAM EQ 12.5MG BASE  
 + EQ 25MG BASE

N20936 001  
 FEB 16, 1999  
 N20936 002  
 FEB 16, 1999

EQ 50MG BASE  
 EQ 50MG BASE

N16732 001  
 N16732 001

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC

ALAMAST  
 + SANTEN 0.1%

N21079 001  
 SEP 24, 1999

N75093 001  
 AUG 10, 1999  
 N74874 001  
 MAY 25, 1999  
 N75199 001  
 SEP 03, 1999  
 N75191 001  
 JUN 09, 1999

PEMOLINE

TABLET; ORAL

CYLERT  
 + ABBOTT

> ADD > AB 18.75MG  
 AB 37.5MG  
 > DLT > AB 18.75MG  
 AB 37.5MG  
 AB 75MG

N16832 001  
 N16832 002  
 N16832 003  
 N16832 001  
 N16832 002  
 N16832 003

PEMOLINE  
 COPLEY PHARM

AB 37.5MG  
 AB 75MG  
 > ADD > AB 18.75MG  
 > ADD > AB 37.5MG

N75030 001  
 JAN 29, 1999  
 N75030 002  
 JAN 29, 1999  
 N75286 001  
 DEC 27, 1999  
 N75286 002  
 JUN 30, 1999

N20184 001  
 DEC 30, 1993  
 N20184 002  
 DEC 30, 1993  
 N20184 003  
 DEC 30, 1993  
 N20184 001  
 DEC 30, 1993  
 N20184 002  
 DEC 30, 1993  
 N20184 003  
 DEC 30, 1993

PEMOLINE

TABLET; ORAL

PEMOLINE  
 INVAMED

AB 75MG

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50  
 @ SANOFI SYNTHELABO  
 @ STERLING WINTHROP

EQ 50MG BASE  
 EQ 50MG BASE

N16732 001  
 N16732 001

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE  
 IMPAX PHARM

AB 400MG  
 AB 400MG  
 AB 400MG  
 AB 400MG  
 AB 400MG

N75093 001  
 AUG 10, 1999  
 N74874 001  
 MAY 25, 1999  
 N75199 001  
 SEP 03, 1999  
 N75191 001  
 JUN 09, 1999

PENTOXIL  
 UPSHER SMITH

N74962 001  
 MAR 31, 1999

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON  
 @ HUESCHEN

2MG  
 4MG  
 8MG  
 2MG  
 4MG  
 8MG

N20184 001  
 DEC 30, 1993  
 N20184 002  
 DEC 30, 1993  
 N20184 003  
 DEC 30, 1993  
 N20184 001  
 DEC 30, 1993  
 N20184 002  
 DEC 30, 1993  
 N20184 003  
 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

PHENDIMETRAZINE TARTRATE

AA FASTIN 35MG  
AA \* SMITHKLINE BEECHAM 35MG  
AA FASTIN 35MG  
AA FASTIN 35MG  
AA FASTIN 35MG  
AA FASTIN 35MG

TABLET; ORAL

AA PHENAZINE 35MG  
AA MAST MM 35MG  
AA PHENDIMETRAZINE TARTRATE 35MG  
AA MFG CHEMISTS 35MG  
AA PVT FORM 35MG

PHENOXYBENZAMINE HYDROCHLORIDE

PHENOXYBENZAMINE HYDROCHLORIDE

AA DIBENZYLIN 10MG  
AA \* SMITHKLINE BEECHAM 10MG  
AA WELLSPRING PHARM 10MG

PENTERMINE HYDROCHLORIDE

PENTERMINE HYDROCHLORIDE

AA FASTIN 30MG  
AA \* SMITHKLINE BEECHAM 30MG  
AA PENTERMINE HCL 30MG  
AA EON 30MG  
AA + 30MG

PHENYTOIN SODIUM

PHENYTOIN SODIUM

AA PHENYTOIN SODIUM 50MG/ML  
AA STERIS 50MG/ML

PIOGLITAZONE HYDROCHLORIDE

PIOGLITAZONE HYDROCHLORIDE

AA ACTOS EQ 15MG BASE  
AA TAKEDA EQ 30MG BASE  
AA + EQ 45MG BASE  
AA ACTOS EQ 15MG BASE  
AA TAKEDA EQ 30MG BASE  
AA + EQ 45MG BASE

POLYETHYLENE GLYCOL 3350

POLYETHYLENE GLYCOL 3350

AA MIRALAX 17GM/SCOOPFUL  
AA + BRAINTREE 17GM/SCOOPFUL

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

AA ALCON 10,000 UNITS/ML;  
AA FALCON PHARMS 10,000 UNITS/ML;  
AA ALCON EQ 1MG BASE/ML  
AA FALCON PHARMS EQ 1MG BASE/ML

FORACTANT ALPHA

FORACTANT ALPHA

AA CUROSURF 80MG/ML  
AA + DEY 80MG/ML  
AA POTASSIUM CHLORIDE  
AA MICRO-K CAPSULE, EXTENDED RELEASE; ORAL  
AA KV PHARM 8MEQ  
AA ROBINS AH 8MEQ  
AA MICRO-K 10 10MEQ  
AA + KV PHARM 10MEQ

POTASSIUM CHLORIDE

POTASSIUM CHLORIDE

AA MICRO-K CAPSULE, EXTENDED RELEASE; ORAL  
AA KV PHARM 8MEQ  
AA ROBINS AH 8MEQ  
AA MICRO-K 10 10MEQ  
AA + KV PHARM 10MEQ

> DLT >  
> ADD >

N21073 001  
JUL 15, 1999  
N21073 002  
JUL 15, 1999  
N21073 003  
JUL 15, 1999

N20698 001  
FEB 18, 1999

N64211 001  
APR 13, 1998  
N64211 001  
APR 13, 1998

N20744 001  
NOV 18, 1999

N18238 001  
N18238 001  
N18238 002  
MAY 14, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K 10

AB \* ROBINS AH

10MEQ

N18238 002  
MAY 14, 1984

GRANULE, FOR RECONSTITUTION ER; ORAL

MICRO-K LS

@ KV PHARM

@ ROBINS AH

20MEQ/PACKET

N19561 003

AUG 26, 1988

20MEQ/PACKET

N19561 003  
AUG 26, 1988

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AM PHARM PARTNERS

3MEQ/ML

3MEQ/ML

4MEQ/ML

4MEQ/ML

2MEQ/ML

2MEQ/ML

2MEQ/ML

2MEQ/ML

2MEQ/ML

3MEQ/ML

2MEQ/ML

2MEQ/ML

2MEQ/ML

2MEQ/ML

3MEQ/ML

3MEQ/ML

3MEQ/ML

3MEQ/ML

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

\* ABBOTT

@

370MG/VIAL; 1.75GM/VIAL

36GM/VIAL

370MG/VIAL; 1.75GM/VIAL

36GM/VIAL

36GM/VIAL

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL

POTASSIUM CITRATE

@ MISSION PHARMA

10MEQ/PACKET

N19647 002

OCT 13, 1988

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL

POTASSIUM CITRATE

@ MISSION PHARMA

20MEQ/PACKET

N19647 001

OCT 13, 1988

N19647 002

OCT 13, 1988

N19647 001

OCT 13, 1988

@ UNIV TX

10MEQ/PACKET

20MEQ/PACKET

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

BETADINE

+ ALCON

5%

N18634 001

DEC 17, 1986

N18634 001

DEC 17, 1986

\* PURDUE FREDERICK

5%

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HCL

ZENITH GOLDLINE

EQ 2MG BASE

N71995 001

MAY 16, 1989

N71995 001

SEP 12, 1988

N71745 001

MAY 16, 1989

N71745 001

SEP 12, 1988

EQ 2MG BASE

EQ 2MG BASE

EQ 5MG BASE

EQ 5MG BASE

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

HALSEY

15MG/5ML

N40287 001

MAY 28, 1999

N40323 001

MAY 13, 1999

AA

AA

UDL

UDL

N13025 001

N13025 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION  
PREDNISOLONE ACETATE  
\* STERIS

40MG/ML  
40MG/ML

N83767 001  
N83767 001

SUSPENSION/DROPS; OPHTHALMIC  
ECONOPRED PLUS

AB ALCON  
AB FALCON PHARMS

N17469 001  
N17469 001

AB AB +

500MG  
500MG  
500MG

N07898 004  
N84211 002  
N84211 002

PROBENECID

TABLET; ORAL  
BENEMID

@ MERCK  
PROBENECID  
NYLAN

500MG  
500MG  
500MG

N07898 004  
N84211 002  
N84211 002

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL  
SMITH AND NEPHEW

100MG/ML  
500MG/ML  
100MG/ML

N88530 001  
MAR 04, 1985  
N88531 001  
MAR 04, 1985  
N88530 001  
MAR 04, 1985  
N88531 001  
MAR 04, 1985  
N87079 001  
N87080 001  
N87079 001  
N87080 001

AP AP

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION  
HYDELTRA-TBA

BP \* MERCK  
+

20MG/ML  
20MG/ML

N10562 001  
N10562 001

AP AP

100MG/ML  
500MG/ML  
100MG/ML  
500MG/ML

PREDNISOLONE TEBUTATE  
STERIS

20MG/ML  
20MG/ML

N83362 001  
FEB 17, 1984  
N83362 001  
FEB 17, 1984

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION  
PROCHLORPERAZINE EDISYLATE

EQ 5MG BASE/ML  
EQ 5MG BASE/ML

N89251 001  
DEC 04, 1986  
N89251 001  
DEC 04, 1986  
N89606 001  
JUL 08, 1987  
N89606 001  
JUL 08, 1987

AP @

PREDNISON

TABLET; ORAL  
ORASON

AB SOLVAY  
@

50MG  
50MG

N85999 001  
N85999 001

AP STERIS

EQ 5MG BASE/ML  
EQ 5MG BASE/ML

BX PREDNISON  
PHARMAVITE

5MG  
5MG

N84662 002  
N84662 002

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL  
COMPAZINE

SMITHKLINE BEECHAM EQ 10MG BASE

N21019 001  
OCT 06, 1999

PROBENECID

TABLET; ORAL  
BENEMID

AB \* MERCK

500MG

N07898 004

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL  
COMPAZINE  
SMITHKLINE BEECHAM EQ 15MG BASE

N21019 002  
OCT 06, 1999

PROGESTERONE

CAPSULE; ORAL  
PROMETRIUM  
\* SCHERING PLOUGH

100MG  
100MG  
200MG  
300MG  
N19781 001  
MAY 14, 1998  
N19781 001  
MAY 14, 1998  
N19781 002  
OCT 15, 1999  
N19781 003  
OCT 15, 1999

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION  
PROMAZINE HCL  
STERIS

AP 50MG/ML  
25MG/ML  
25MG/ML  
50MG/ML  
@  
@  
SPARINE  
AP \* WYETH AYERST  
+  
50MG/ML  
50MG/ML

PROPOFOL

INJECTABLE; INJECTION  
DIPRIVAN  
ZENECA

AB + 10MG/ML  
\* 10MG/ML  
PROPOFOL  
GENSIA SICOR PHARMS  
AB N75102 001  
JAN 04, 1999

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
INDERAL LA  
AB \* WYETH AYERST

AB 60MG  
AB 80MG  
AB 120MG  
AB 160MG  
+ 60MG  
+ 80MG  
+ 120MG  
+ 160MG  
PROPRANOLOL HCL  
INWOOD LABS  
AB 60MG  
AB 80MG  
AB 120MG  
AB 160MG  
@ 60MG  
@ 80MG  
@ 120MG  
@ 160MG  
INJECTABLE; INJECTION  
INDERAL  
AB \* WYETH AYERST  
+  
PROPRANOLOL HCL  
SMITH AND NEPHEW  
AP 1MG/ML  
1MG/ML  
1MG/ML  
1MG/ML  
N18553 004  
MAR 18, 1987  
N18553 002  
APR 19, 1983  
N18553 003  
APR 19, 1983  
N18553 001  
APR 19, 1983  
N18553 004  
MAR 18, 1987  
N18553 002  
APR 19, 1983  
N18553 003  
APR 19, 1983  
N18553 001  
APR 19, 1983  
N72499 001  
APR 11, 1989  
N72500 001  
APR 11, 1989  
N72501 001  
APR 11, 1989  
N72502 001  
APR 11, 1989  
N72499 001  
APR 11, 1989  
N72500 001  
APR 11, 1989  
N72501 001  
APR 11, 1989  
N72502 001  
APR 11, 1989  
N16419 001  
N70137 001  
APR 15, 1986  
N70137 001  
APR 15, 1986

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'99 - DEC'99

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL  
ACIPHEX  
+ EISAI 20MG

N20973 002  
AUG 19, 1999

RANITIDINE BISMUTH CITRATE

TABLET, ORAL  
TRITEC  
\* GLAXO WELLCOME

N20559 001  
AUG 08, 1996  
N20559 001  
AUG 08, 1996

400MG  
400MG

RANITIDINE HYDROCHLORIDE

TABLET; ORAL  
RANITIDINE HCL  
GRANULEC PHARMS

N74488 001  
JUL 31, 1997  
N74488 002  
JUL 31, 1997  
N74488 001  
JUL 31, 1997  
N74488 002  
JUL 31, 1997  
N75180 001  
JAN 28, 1999  
N75180 002  
JAN 28, 1999

EQ 150MG BASE  
EQ 300MG BASE  
EQ 150MG BASE  
EQ 300MG BASE  
EQ 150MG BASE  
EQ 300MG BASE

AB  
AB  
AB  
AB  
AB  
AB

N74488 001  
JUL 31, 1997  
N74488 002  
JUL 31, 1997  
N74488 001  
JUL 31, 1997  
N74488 002  
JUL 31, 1997  
N75180 001  
JAN 28, 1999  
N75180 002  
JAN 28, 1999

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION  
ULTIVA  
ABBOTT

N20630 001  
JUL 12, 1996  
N20630 002  
JUL 12, 1996  
N20630 003  
JUL 12, 1996  
N20630 001  
JUL 12, 1996  
N20630 002  
JUL 12, 1996  
N20630 003  
JUL 12, 1996

EQ 1MG BASE/VIAL  
EQ 2MG BASE/VIAL  
EQ 5MG BASE/VIAL  
EQ 1MG BASE/VIAL  
EQ 2MG BASE/VIAL  
EQ 5MG BASE/VIAL

+

GLAXO WELLCOME

\*

RIFAMPIN

INJECTABLE; INJECTION  
RIFADIN

N50627 001  
MAY 25, 1989  
N50627 001  
MAY 25, 1989  
N64217 001  
OCT 29, 1999

AP + HOECHST MARION RSSL 600MG/VIAL  
600MG/VIAL  
600MG/VIAL

AP  
RIFAMPIN  
BEDFORD

RISPERIDONE

TABLET; ORAL  
RISPERDAL  
JANSSEN

N20272 008  
MAY 10, 1999  
N20272 007  
JAN 27, 1999

0.25MG  
0.5MG

RITONAVIR

CAPSULE; ORAL  
NORVIR  
ABBOTT

N20945 001  
JUN 29, 1999

100MG

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION  
RAPLON  
ORGANON

N20984 001  
AUG 18, 1999  
N20984 002  
AUG 18, 1999

100MG/VIAL  
200MG/VIAL

+

RITONAVIR

SOLUTION; ORAL  
NORVIR  
ABBOTT

80MG/ML  
80MG/ML

N20659 001  
MAR 01, 1996  
N20659 001  
MAR 01, 1996

SAQUINAVIR

CAPSULE; ORAL  
FORTOVASE  
+ HLR

200MG  
200MG

N20828 001  
NOV 07, 1997  
N20828 001  
NOV 07, 1997

ROFECOXIB

SUSPENSION; ORAL  
VIOXX  
MERCCK

12.5MG/5ML  
25MG/5ML

N21052 001  
MAY 20, 1999  
N21052 002  
MAY 20, 1999

SAQUINAVIR MESYLATE

CAPSULE; ORAL  
INVIRASE  
+ HLR

EQ 200MG BASE  
EQ 200MG BASE

N20628 001  
DEC 06, 1995  
N20628 001  
DEC 06, 1995

TABLET; ORAL  
VIOXX  
MERCCK

12.5MG  
25MG

N21042 001  
MAY 20, 1999  
N21042 002  
MAY 20, 1999

SELEGILINE HYDROCHLORIDE

TABLET; ORAL  
ELDEPRYL  
SOMERSET

5MG

N19334 001  
JUN 05, 1989

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL  
REQUIP  
SMITHKLINE BEECHAM

EQ 3MG BASE  
EQ 4MG BASE

N20658 006  
JAN 27, 1999  
N20658 007  
JAN 27, 1999

AB + SELEGILINE HCL  
+ SOMERSET

5MG

N19334 001  
JUN 05, 1989

> ADD >  
> ADD >  
> ADD >  
> ADD >

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL  
ZOLOFT  
+ PFIZER

EQ 20MG BASE/ML

N20990 001  
DEC 07, 1999

ROSIGLITAZONE MALEATE

TABLET; ORAL  
AVANDIA  
SMITHKLINE BEECHAM

EQ 2MG BASE  
EQ 4MG BASE  
EQ 8MG BASE

N21071 002  
MAY 25, 1999  
N21071 003  
MAY 25, 1999  
N21071 004  
MAY 25, 1999

SILVER SULFADIAZINE

CREAM; TOPICAL  
THERMAZENE  
KENDALL LP

1%

N18810 001  
DEC 23, 1985

AB SHERWOOD MEDICAL

1%

N18810 001  
DEC 23, 1985

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'99 - DEC'99

SIROLIMUS  
 SOLUTION; ORAL  
 RAPAMUNE  
 + WYETH AYERST  
 1MG/ML  
 N21083 001  
 SEP 15, 1999  
 N20280 012  
 JAN 27, 1998  
 N20280 013  
 JAN 27, 1998

SODIUM PHENYL BUTYRATE  
 POWDER; ORAL  
 BUPHENYL  
 + MEDICIS  
 3GM/TEASPOONFUL  
 N19640 005  
 FEB 04, 1999  
 N19640 006  
 FEB 04, 1999  
 N19640 007  
 FEB 04, 1999

\* UCYCLIXD  
 3GM/TEASPOONFUL  
 N20573 001  
 APR 30, 1996  
 N20573 001  
 APR 30, 1996

TABLET; ORAL  
 BUPHENYL  
 + MEDICIS  
 500MG  
 N20572 001  
 MAY 13, 1996  
 500MG  
 N20572 001  
 MAY 13, 1996

\* UCYCLIXD  
 500MG  
 N21075 001  
 DEC 22, 1999  
 N21075 002  
 DEC 22, 1999  
 N21075 003  
 DEC 22, 1999

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION  
 GENOTROPIN PRESERVATIVE FREE  
 PHARMACIA AND UPJOHN  
 2MG/VIAL  
 N20280 012  
 JAN 27, 1998  
 N20280 013  
 JAN 27, 1998

+  
 HUMATROPE  
 LILLY  
 6MG/VIAL  
 N19640 005  
 FEB 04, 1999  
 12MG/VIAL  
 N19640 006  
 FEB 04, 1999  
 24MG/VIAL  
 N19640 007  
 FEB 04, 1999

+  
 NUTROPIN DEPOT  
 GENENTECH  
 13.5MG/VIAL  
 N21075 001  
 DEC 22, 1999  
 18MG/VIAL  
 N21075 002  
 DEC 22, 1999  
 22.5MG/VIAL  
 N21075 003  
 DEC 22, 1999

SOYBEAN OIL

INJECTABLE; INJECTION  
 INTRALIPID 10%  
 FRESENIUS KABI  
 10%  
 N17643 001  
 N17643 001  
 N18449 001  
 N20248 001  
 AUG 07, 1996  
 N18449 001  
 N20248 001  
 N20248 001  
 AUG 07, 1996

+  
 INTRALIPID 20%  
 FRESENIUS KABI  
 20%  
 N18449 001  
 N20248 001  
 N20248 001  
 AUG 07, 1996

+  
 PHARMACIA AND UPJOHN  
 20%  
 N18449 001  
 N20248 001  
 N20248 001  
 AUG 07, 1996

+  
 INTRALIPID 30%  
 FRESENIUS KABI  
 30%  
 N19942 001  
 DEC 30, 1993  
 N19942 001  
 DEC 30, 1993

+  
 PHARMACIA AND UPJOHN  
 30%  
 N19942 001  
 DEC 30, 1993  
 N19942 001  
 DEC 30, 1993

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION  
 GENOTROPIN PRESERVATIVE FREE  
 PHARMACIA AND UPJOHN  
 1.5MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

0.2MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

0.4MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

0.6MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

0.8MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

1MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

1.2MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

1.4MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

1.5MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

1.6MG/VIAL  
 N20280 004  
 AUG 24, 1995  
 N20280 001  
 JAN 27, 1998  
 N20280 002  
 JAN 27, 1998  
 N20280 003  
 JAN 27, 1998  
 N20280 005  
 JAN 27, 1998  
 N20280 008  
 JAN 27, 1998  
 N20280 009  
 JAN 27, 1998  
 N20280 010  
 JAN 27, 1998  
 N20280 004  
 AUG 24, 1995  
 N20280 011  
 JAN 27, 1998

SPIRONOLACTONE

TABLET; ORAL  
 ALDACTONE  
 SEARLE  
 50MG  
 N12151 008  
 DEC 30, 1982

SPIRONOLACTONE

TABLET; ORAL  
ALDACTONE  
AB + SEARLE

100MG  
50MG  
100MG  
50MG  
100MG  
25MG  
50MG  
100MG  
25MG

N12151 010  
DEC 30, 1983  
N12151 008  
DEC 30, 1982  
N12151 010  
DEC 30, 1983  
N89424 002  
AUG 11, 1999  
N89424 003  
AUG 11, 1999  
N87998 001  
OCT 14, 1983  
N40353 001  
JUL 29, 1999  
N40353 002  
JUL 29, 1999  
N87998 001  
OCT 14, 1983

AB  
MUTUAL PHARM

AB  
PUREPAC PHARM

AB  
@

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC  
SODIUM SULFACETAMIDE  
AKORN

10%  
15%  
30%  
10%  
15%  
30%  
10%  
30%

N83021 001  
N83021 002  
N83021 003  
N83021 001  
N83021 002  
N83021 003

AT  
AKORN

AT  
AKORN

SULFADIAZINE

TABLET; ORAL  
SULFADIAZINE  
AB + EON

500MG

N40091 001  
JUL 29, 1994

SULFADIAZINE

TABLET; ORAL  
SULFADIAZINE  
+ EON

500MG  
500MG  
500MG  
500MG

N40091 001  
JUL 29, 1994  
N80081 001  
N80081 001  
N80084 001  
N80084 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION  
SULFAMETHOXAZOLE AND TRIMETHOPRIM  
STERIS

80MG/ML; 16MG/ML  
80MG/ML; 16MG/ML

N71556 001  
DEC 29, 1987  
N71556 001  
DEC 29, 1987

TACROLIMUS

CAPSULE; ORAL  
PROGRAF

\* FUJISAWA HEALTHCARE  
EQ 1MG BASE  
EQ 0.5MG BASE  
EQ 1MG BASE

N50708 001  
APR 08, 1994  
N50708 003  
AUG 24, 1998  
N50708 001  
APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION  
A-N STANNOUS AGGREGATED ALBUMIN  
NORTH AM CHEMS  
@ SYNCOR PHARMS  
PULMOLITE

BS  
BS  
CIS  
DUPONT PHARMS  
N/A  
N/A

N17916 001  
N17916 001  
N17776 001  
N17776 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION  
MICROLITE  
CIS N/A  
DUPONT PHARMS N/A

N18263 001  
MAR 25, 1983  
N18263 001  
MAR 25, 1983

N17684 001  
N17684 001

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION  
NEO TECT KIT N/A  
+ DIATIDE

N21012 001  
AUG 03, 1999

N21029 001  
AUG 11, 1999  
N21029 002  
AUG 11, 1999  
N21029 003  
AUG 11, 1999  
N21029 004  
AUG 11, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION  
HEPATOLITE N/A  
CIS N/A  
DUPONT PHARMS N/A

N18467 001  
MAR 16, 1982  
N18467 001  
MAR 16, 1982

N18571 001  
N18571 001  
N17466 001  
N17466 001

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION  
TECHNESCAN HIDA N/A  
DRAXIMAGE N/A  
®

N18489 001  
OCT 31, 1986  
N18489 001  
OCT 31, 1986

N17849 001  
N17849 002  
N17849 001  
N17849 002

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION  
OSTEOLITE N/A  
CIS N/A  
DUPONT PHARMS N/A  
AP  
AP

N17972 001  
N17972 001

N17618 001  
N17618 002  
N17618 001  
N17618 002

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION  
PYROLITE  
CIS N/A  
DUPONT PHARMS N/A

TEMOZOLOMIDE

CAPSULE; ORAL  
TEMODAR 5MG  
SCHERING 20MG  
100MG  
250MG  
+

TERBUTALINE SULFATE

INJECTABLE; INJECTION  
BRETHINE  
AP \* NOVARTIS 1MG/ML  
+ 1MG/ML  
BRICANYL  
AP \* HOECHST MARION RSSL 1MG/ML  
® 1MG/ML

N18489 001  
OCT 31, 1986  
N18489 001  
OCT 31, 1986

N17849 001  
N17849 002  
N17849 001  
N17849 002

BP  
BP \*  
+  
BRICANYL  
BP HOECHST MARION RSSL 2.5MG  
BP 5MG  
® 2.5MG  
® 5MG

N17972 001  
N17972 001

N17618 001  
N17618 002  
N17618 001  
N17618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION  
PARATHAR

\* RHONE-POULENC RORER 200 UNITS/VIAL  
@ 200 UNITS/VIAL

N19498 001  
DEC 23, 1987  
N19498 001  
DEC 23, 1987

BC \* THEOCLEAR L.A.-260 260MG  
@ SCHWARZ PHARMA 260MG

N86569 002  
MAY 27, 1982  
N86569 002  
MAY 27, 1982

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION  
TESTOSTERONE ENANTHATE  
STERIS

@ 100MG/ML  
100MG/ML

N85599 001  
N85599 001

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER  
@ B BRAUN 40MG/100ML  
@ MCGAW 40MG/100ML  
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER  
@ B BRAUN 80MG/100ML  
@ MCGAW 80MG/100ML  
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER  
@ B BRAUN 160MG/100ML  
@ MCGAW 160MG/100ML

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL  
PUREPAC PHARM

AB 250MG  
AB 500MG  
@ 250MG  
@ 500MG  
TETRACYN  
PEIPHARMECS  
@ 250MG  
@ 500MG  
@ 250MG  
@ 500MG

N60290 001  
N60290 002  
N60290 001  
N60290 002  
N60082 003  
N60082 004  
N60082 003  
N60082 004

SYRUP; ORAL  
AQUAPHYLLIN  
FERNDAL LABS

AA 80MG/15ML  
@ 80MG/15ML

N87917 001  
JAN 18, 1983  
N87917 001  
JAN 18, 1983

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL  
@ SANOFI SYNTHELABO

100MG  
200MG  
@ STERLING WINTHROP 100MG  
@ 200MG

N85264 001  
N85264 002  
N85264 001  
N85264 002

TABLET, EXTENDED RELEASE; ORAL

SUSTAIRE  
ROERIG

BC 100MG  
BC 300MG  
@ 100MG  
@ 300MG

N85665 001  
N85665 002  
N85665 001  
N85665 002

CAPSULE, EXTENDED RELEASE; ORAL

THEOCLEAR L.A.-130

BC \* CENT PHARMS 130MG  
@ SCHWARZ PHARMA 130MG

N86569 001  
MAY 27, 1982  
N86569 001  
MAY 27, 1982

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

THIOTHIXENE HCL  
ALPHARMA

AA EQ 5MG BASE/ML  
@ EQ 5MG BASE/ML

N70969 001  
OCT 16, 1987  
N70969 001  
OCT 16, 1987

TIAGABINE HYDROCHLORIDE

TABLET; ORAL  
GABITRIL  
+ ABBOTT

2MG  
N20646 005  
APR 16, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL  
TICLID  
@ ROCHE

125MG  
N19979 001  
MAR 24, 1993  
250MG  
N19979 002  
OCT 31, 1991  
125MG  
N19979 001  
MAR 24, 1993  
250MG  
N19979 002  
OCT 31, 1991

AB + SYNTEX

@

\* SYNTEX USA

TICLOPIDINE HCL

AB EON  
AB GENPHARM  
AB INVAMED  
AB MYLAN  
AB PUREPAC PHARM  
AB TEVA  
AB TORPHARM

N75326 001  
AUG 20, 1999  
N75161 001  
SEP 13, 1999  
N75318 001  
AUG 20, 1999  
N75316 001  
NOV 02, 1999  
N75253 001  
AUG 20, 1999  
N75149 001  
AUG 20, 1999  
N75089 001  
JUL 01, 1999

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC  
TIMOLOL MALEATE  
ADV REMEDIES

AT EQ 0.5% BASE  
AT EQ 0.5% BASE  
AT EQ 0.25% BASE  
AT EQ 0.5% BASE  
EQ 0.25% BASE  
EQ 0.5% BASE

N74466 001  
MAR 25, 1997  
N74466 001  
MAR 25, 1997  
N74261 001  
APR 28, 1995  
N74262 001  
APR 28, 1995  
N74261 001  
APR 28, 1995  
N74262 001  
APR 28, 1995

@ FALCON PHARMS  
@

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

AT TOBEX  
AT \* ALCON  
AT + FALCON PHARMS

N50541 001  
N50541 001

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION  
TOBRAMYCIN SULFATE  
APOTHECON

AP EQ 40MG BASE/ML  
EQ 40MG BASE/ML

N64026 001  
MAY 31, 1994  
N64026 001  
MAY 31, 1994

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC  
TIMOLOL MALEATE  
ALCON

AB EQ 0.25% BASE  
AB EQ 0.5% BASE  
AB EQ 0.25% BASE  
AB EQ 0.5% BASE

N20963 001  
OCT 21, 1998  
N20963 002  
OCT 21, 1998  
N20963 001  
OCT 21, 1998  
N20963 002  
OCT 21, 1998

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION  
HYCAMTIN  
+ SMITHKLINE

EQ 4MG BASE/VIAL  
EQ 4MG BASE/VIAL

N20671 001  
MAY 28, 1996  
N20671 001  
MAY 28, 1996

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

\* APOTHECON

> DLT >  
> ADD >  
> ADD >  
> ADD >  
> DLT >  
> DLT >

100MG  
100MG  
300MG  
300MG

N18207 002  
N18207 002  
N18207 004  
NOV 07, 1988  
N18207 004  
NOV 07, 1988

TRAZODONE HCL

BARR

> ADD >  
> ADD >  
> ADD >

150MG  
300MG

N71196 002  
APR 26, 1999  
N71196 003  
APR 26, 1999

TRETINOIN

GEL; TOPICAL

RETIN-A MICRO

\* ADY POLYMER

+

JOHNSON AND JOHNSON

0.1%

SOLUTION; TOPICAL

TRETINOIN

MORTON GROVE

AT

0.05%

N20475 001  
FEB 07, 1997  
N20475 001  
FEB 07, 1997  
N75260 001  
JAN 25, 1999

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

FUJISAWA HLTHCARE

BP

BP

4MG  
8MG

LEDERLE

BP

BP

BP

2MG  
2MG  
4MG  
8MG  
1MG

TRIAMCINOLONE

ROXANE

BP

BP

BP

2MG  
4MG  
8MG  
2MG

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

@ ROXANE

@

TEVA

@

4MG  
8MG  
4MG  
4MG

N84709 001  
N84707 001  
N84775 001  
N84775 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

ARISTOCORT

FUJISAWA HLTHCARE

AT

AT

AT

AT

AT

AT

AT

AT

0.025%  
0.1%  
0.5%  
0.025%  
0.1%  
0.5%

N83017 003  
N83016 004  
N83015 002  
N83017 003  
N83016 004  
N83015 002

ARISTOCORT A

FUJISAWA HLTHCARE

AT

AT

AT

AT

AT

AT

AT

AT

0.025%  
0.025%  
0.1%  
0.1%  
0.5%  
0.5%

N83017 004  
N88818 001  
OCT 16, 1984  
N83016 005  
N88819 001  
OCT 16, 1984  
N83015 003  
N88820 001  
OCT 16, 1984

LEDERLE

AT

AT

AT

AT

AT

AT

AT

0.025%  
0.025%  
0.1%  
0.1%  
0.5%  
0.5%

N83017 004  
N88818 001  
OCT 16, 1984  
N83016 005  
N88819 001  
OCT 16, 1984  
N83015 003  
N88820 001  
OCT 16, 1984

GEL; TOPICAL

ARISTOGEL

@ FUJISAWA HLTHCARE

@ LEDERLE

0.1%  
0.1%

N83380 001  
N83380 001

LOTION; TOPICAL

KENALOG

@ APOTHECON

@

0.025%  
0.1%

N11602 003  
N11602 001

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'99 - DEC'99

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL  
KENALOG  
© BRISTOL MYERS SQUIBB 0.025%  
0.1%  
©

N11602 003  
N11602 001

TRIAMCINOLONE ACETONIDE

© OINTMENT; TOPICAL  
ARISTOCORT  
FUJISAWA HLTHCARE 0.1%  
0.5%  
LEDERLE 0.1%  
0.5%  
ARISTOCORT A 0.1%  
FUJISAWA HLTHCARE 0.1%  
0.5%  
0.5%  
©  
LEDERLE 0.1%  
0.1%  
0.5%  
0.5%  
©

N80750 004  
N80745 002  
N80750 004  
N80745 002  
N80750 003  
N88780 001  
N88781 001  
OCT 01, 1984  
OCT 05, 1984  
N80750 003  
N88780 001  
OCT 01, 1984  
N80745 003  
N88781 001  
OCT 05, 1984

TRIAMCINOLONE ACETONIDE

ALPHARMA 0.5%  
0.5%

N89913 001  
DEC 23, 1988  
N89913 001  
DEC 23, 1988

TRIAMCINOLONE DIACETATE

SYRUP; ORAL  
ARISTOCORT  
FUJISAWA HLTHCARE 2MG/5ML  
LEDERLE 2MG/5ML

N11960 004  
N11960 004

TRIAMTERENE

© CAPSULE; ORAL  
DYRENUM  
SMITHKLINE BEECHAM 50MG  
100MG  
\* WELLSPRING PHARM 50MG  
100MG  
+

N13174 001  
N13174 002  
N13174 001  
N13174 002

TRICHLORMETHIAZIDE

TABLET; ORAL  
TRICHLORMAS  
MAST MM 4MG  
4MG  
©

N86259 001  
N86259 001

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC  
TRIFLURIDINE 1%  
ALCON 1%  
STERIS 1%

N74311 001  
OCT 05, 1995  
N74311 001  
OCT 05, 1995

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL  
TRIHEXYPHENIDYL HCL 2MG/5ML  
MIKART

N40251 001  
SEP 27, 1999

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION  
TIGAN 100MG/ML  
+ KING PHARMS 100MG/ML  
AP \* ROBERTS LABS 100MG/ML  
AP \* TRIMETHOBENZAMIDE HCL 100MG/ML  
SMITH AND NEPHEW 100MG/ML  
© 100MG/ML

N17530 001  
N17530 001

N88960 001  
APR 04, 1986  
N88960 001  
APR 04, 1986

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL  
SULFA-TRIPLE #2 167MG;167MG;167MG  
\* GLOBAL PHARM 167MG;167MG;167MG  
©  
TRIPLE SULFOLD 167MG;167MG;167MG  
PAL PAK 167MG;167MG;167MG  
+

N80079 001  
N80079 001

N80094 001  
N80094 001

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC  
TROPICAMIDE

AT STERIS 0.5% 0.5%  
N89171 001  
DEC 28, 1990  
N89171 001  
DEC 28, 1990

TYROPANCOATE SODIUM

> DLT >  
> DLT >  
> DLT >  
> ADD >  
CAPSULE; ORAL  
BILOPAQUE  
\* NYCOMED  
750MG  
750MG

UREA, C-13

> ADD >  
> ADD >  
> ADD >  
POWDER FOR RECONSTITUTION; ORAL  
HELICOSOL  
BX + METABOLIC SOLUTIONS 125MG/VIAL  
PYLORI-CHEK BREATH TEST  
+ ALIMENTERICIS 100MG/VIAL

VALRUBICIN

SOLUTION;  
VALSTAR PRESERVATIVE FREE  
+ ANTHRA 40MG/ML  
SOLUTION; INTRAVESICAL  
VALSTAR PRESERVATIVE FREE  
+ ANTHRA 40MG/ML

VECURONIUM BROMIDE

INJECTABLE; INJECTION  
VECURONIUM BROMIDE  
ABBOTT 10MG/VIAL  
N75164 001  
OCT 21, 1999

VECURONIUM BROMIDE

INJECTABLE; INJECTION  
VECURONIUM BROMIDE

AP ABBOTT 20MG/VIAL  
N75164 002  
OCT 21, 1999  
AP ESI LEDELERLE 10MG/VIAL  
N75218 001  
AUG 23, 1999  
AP 20MG/VIAL  
N75218 002  
AUG 23, 1999  
AP GENSIA 10MG/VIAL  
N74688 001  
AUG 25, 1999  
AP 20MG/VIAL  
N74688 002  
AUG 25, 1999

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
VERAPAMIL HCL

AB MYLAN 120MG  
N75138 001  
APR 20, 1999  
AB 180MG  
N75138 002  
APR 20, 1999  
AB 240MG  
N75138 003  
APR 20, 1999

VERELAN  
+ ELAN

\* 120MG  
N19614 001  
MAY 29, 1990  
\* 180MG  
N19614 003  
JAN 09, 1992  
\* 240MG  
N19614 002  
MAY 29, 1990  
AB + ELAN PHARM 120MG  
N19614 001  
MAY 29, 1990  
AB + 180MG  
N19614 003  
JAN 09, 1992  
AB + 240MG  
N19614 002  
MAY 29, 1990

INJECTABLE; INJECTION

AP VERAPAMIL HCL 2.5MG/ML  
SMITH AND NEPHEW 2.5MG/ML  
N70696 001  
JUL 31, 1987  
N70696 001  
JUL 31, 1987

TABLET, EXTENDED RELEASE; ORAL  
VERAPAMIL HCL

AB DURAMED 120MG  
N75072 001  
MAY 25, 1999

VERAPAMIL HYDROCHLORIDE

AB TABLET, EXTENDED RELEASE; ORAL  
VERAPAMIL HCL  
 DURAMED 240MG

N75072 003  
 MAY 25, 1999

WARFARIN SODIUM

AB TABLET; ORAL  
WARFARIN SODIUM  
 TARO 7.5MG

N40301 009  
 JUL 15, 1999  
 N40301 001  
 JUL 15, 1999

10MG

VINCRIStINE SULFATE

AP INJECTABLE; INJECTION  
VINCRIStINE SULFATE PFS  
 GENsIA SICOR PHARMS 1MG/ML

N75493 001  
 SEP 01, 1999

XYLOSE

AA POWDER; ORAL  
XYLO-PFAN  
 SAVAGE LABS 25GM/BOT

N17605 001  
 N17605 001

25GM/BOT

VITAMIN A PALMITATE

AA CAPSULE; ORAL  
DEL-VI-A  
 DEL RAY LABS EQ 50,000 UNITS BASE

N80830 001  
 N80830 001

EQ 50,000 UNITS BASE  
EQ 50,000 UNITS BASE

AA XYLOSE  
 LYNE 25GM/BOT

N18856 001  
 MAR 26, 1987  
 N18856 001  
 MAR 26, 1987

25GM/BOT

25GM/BOT

WARFARIN SODIUM

AB TABLET; ORAL  
COUMADIN  
 DUPONT MERCK 2MG

N09218 013  
 N09218 013  
 N09218 018  
 N09218 018  
 N09218 007  
 N09218 007

2MG  
2MG  
2.5MG  
2.5MG  
5MG  
5MG

AA CAPSULE; ORAL  
 SONATA 5MG

N20859 001  
 AUG 13, 1999  
 N20859 002  
 AUG 13, 1999

5MG  
10MG

ZANAMIVIR

AB CAPSULE; INHALATION  
 RELENZA 5MG

N21036 001  
 JUL 26, 1999

5MG

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN  
\* G AND W LABS

120MG  
325MG

N18060 001  
N18060 003  
DEC 18, 1986

SUSPENSION; ORAL  
TAGAMET HB 200  
+ SMITHKLINE BEECHAM 200MG/20ML

N20951 001  
JUL 09, 1999

\*

650MG  
120MG  
325MG

N18060 002  
N18060 001  
N18060 003  
DEC 18, 1986

TABLET; ORAL  
CIMETIDINE  
DANBURY PHARMA 200MG

N75425 001  
JUL 29, 1999  
N75345 001  
JUN 16, 1999

ACETAMINOPHEN  
ASCENT PEDS

120MG  
325MG  
650MG  
120MG

N18337 003  
SEP 12, 1983

ZENITH GOLDDLINE 200MG

+

UPSHER SMITH

650MG  
325MG  
650MG

N18337 001  
N18337 003  
SEP 12, 1983  
N18337 002  
N18337 001

CREAM; TOPICAL  
LOTRIMIN AF  
SCHERING PLOUGH 1\*

N17619 002  
OCT 27, 1989

INFANTS' FEVERALL  
ASCENT PEDS

80MG  
80MG

N18337 004  
AUG 26, 1992

LOTION; TOPICAL  
LOTRIMIN AF  
SCHERING 1\*

N18813 002  
OCT 27, 1989

UPSHER SMITH

CHLORPHENIRAMINE MALEATE, PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC

\* SMITHKLINE

8MG; 75MG  
8MG; 75MG

N18099 001  
N18099 001

PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE

8MG; 75MG

N18809 001  
MAY 07, 1984  
N18809 001  
MAY 07, 1984

EPINEPHRINE BITARTRATE  
AEROSOL, METERED; INHALATION  
MEDIHALER-EPI  
\* 3M  
® 0.3MG/INH  
0.3MG/INH

N10374 003  
N10374 003

+

TRIAMINIC-12  
NOVARTIS

12MG; 75MG  
12MG; 75MG

N19613 001  
JUN 13, 1986  
N19613 001  
JUN 13, 1986

TABLET, EXTENDED RELEASE; ORAL  
CONTAC  
NOVARTIS  
+  
1.0MG

N20902 001  
AUG 05, 1999

\* TRIAMINIC-12  
NOVARTIS

12MG; 75MG  
12MG; 75MG

N18115 001  
N18115 001

FAMOTIDINE  
TABLET; ORAL  
PEPCID AC  
MERCK

IBUPROFEN

SUSPENSION; ORAL  
IBUPROFEN  
ALPHARMA

100MG/5ML

N74916 001  
APR 30, 1999

TABLET; ORAL  
IBUPROFEN  
LNK

200MG

N75010 001  
MAR 01, 1999

200MG

N75139 001  
MAR 01, 1999

NORTON HN

200MG

N71144 001  
JAN 20, 1987

200MG

N72901 001  
DEC 19, 1991

200MG

N72903 001  
DEC 19, 1991

ZENITH GOLDLINE

200MG

N71144 001  
JAN 20, 1987

200MG

N72901 001  
DEC 19, 1991

200MG

N72903 001  
DEC 19, 1991

JUNIOR STRENGTH IBUPROFEN  
PERRIGO

100MG

N75367 001  
APR 22, 1999

IBUPROFEN POTASSIUM

CAPSULE; ORAL  
PROVEL

200MG

N20402 001  
APR 20, 1995

\* NOVARTIS

200MG

N20402 001  
APR 20, 1995

+ WHITEHALL ROBINS

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL  
M-ZOLE 3 COMBINATION PACK  
ALPHARMA US PHARM

2%, 200MG

N74926 001  
APR 16, 1999

MICONAZOLE NITRATE COMBINATION PACK  
PERRIGO

2%, 200MG

N75329 001  
APR 20, 1999

SUPPOSITORY; VAGINAL  
MICONAZOLE NITRATE  
ALPHARMA US PHARM

100MG

N73507 001  
NOV 19, 1993

100MG

N73507 001  
NOV 19, 1993

MINOXIDIL

SOLUTION; TOPICAL  
MINOXIDIL (FOR MEN)  
PERRIGO

2%

N75357 001  
JUL 30, 1999

MINOXIDIL (FOR WOMEN)  
PERRIGO

2%

N75357 002  
JUL 30, 1999

NAPROXEN SODIUM

TABLET; ORAL  
NAPROXEN SODIUM  
GRANDTEC

EQ 200MG BASE

N74635 001  
JAN 13, 1997

NOVOPHARM NC

EQ 200MG BASE

N74635 001  
JAN 13, 1997

NAPROXEN SODIUM, PSEUDOEPHEDRINE HYDROCHLORIDE

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION  
LENTIS Iletin II  
\* LILLY

100 UNITS/ML  
100 UNITS/ML

TABLET, EXTENDED RELEASE; ORAL  
ALEVE COLD AND SINUS  
+ BAYER

EQ 200MG BASE, 120MG

N21076 001  
NOV 29, 1999

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL  
HABITROL

> ADD >  
+ NOVARTIS 7MG/24HR N20076 004 NOV 12, 1999  
+ 14MG/24HR N20076 005 NOV 12, 1999  
+ 21MG/24HR N20076 006 NOV 12, 1999  
PROSTEP  
+ ELAN PHARM 11MG/24HR N19983 003 DEC 23, 1998  
+ 22MG/24HR N19983 004 DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL  
NICOTINE POLACRILEX  
WATSON LAB

EQ 2MG BASE N74507 001 MAR 15, 1999  
EQ 4MG BASE N74707 001 MAR 19, 1999

NONOXYNOL-9

SPONGE; VAGINAL

TODAY  
@ ALLENDALE PHARMS 1GM N18683 001 APR 01, 1983  
@ WHITEHALL ROBINS 1GM N18683 001 APR 01, 1983

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
PSEUDOEPHEDRINE HCL  
PERRIGO 120MG

N75153 001  
FEB 26, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL  
RANITIDINE HCL  
NOVOPHARM

EQ 75MG BASE N75094 001 JUN 21, 1999  
EQ 75MG BASE N75132 001  
\* GLAXO WELLCOME N20520 001 DEC 19, 1995  
+ WARNER LAMBERT N20520 001 DEC 19, 1995

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL  
LAMISIL  
+ NOVARTIS

EQ 1% N20980 001 MAR 09, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE  
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 12 DEC '99

NO DECEMBER 1999 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

### Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
111Indium pentetreotide TN= SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Seattle, WA 98119 DD=02/10/1999
506U78 TN=	Treatment of chronic lymphocytic leukemia.	Glaxo Wellcome, Inc. Five Moore Dr. P.O. Box 13398 Durham, NC 27709 DD=09/02/1999
6-hydroxymethyla cylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=04/06/1999
6-hydroxymethyla cylfulvene TN=	Treatment of ovarian cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/06/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
6-hydroxymethyla cylfulvene TN=	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/27/1999
AP1903 TN=	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Ariad Gene Therapeutics, Inc. 26 Landsdowne St. Cambridge, MA 02139 DD=11/24/1999
Adenovirus-based vector Factor VIII complementary DNA to somatic cells TN= MiniAdFVIII	Treatment of hemophilia A.	GenStar Therapeutics Corporation 10835 Altman Row Suite 150 San Diego, CA 92121 DD=12/15/1999
Alitretinoin TN= Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998 MA=02/02/1999
Alpha1-proteinase inhibitor (human) TN=	For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.	Centeon LLC 1020 First Ave. King of Prussia, PA 19406 DD=11/24/1999
Amifostine TN= Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998 MA=06/24/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Amifostine TN= Ethyol	Treatment of myelodysplastic syndromes.	US Bioscience, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken, PA 19428 DD=10/04/1999
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized TN= Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Centeon Pharma GmbH Emil-von-Behring-Strasse 76 35041 Marburg Germany, DE DD=10/16/1992 MA=04/01/1999
Artesunate TN=	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tropical Diseases Via Appia , Geneva 27 Switzerland, CH DD=07/19/1999
Atovaquone TN= Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm <sup>3</sup> .	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709 DD=08/14/1991 MA=01/05/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Autologous DNP-conjugated tumor vaccine TN= M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City, MO 64111 DD=02/23/1999
Azathioprine TN= Imuran	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc. 787 Seventh Ave., 48th Floor New York, NY 10019 DD=09/14/1999
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park, NC 27709 DD=04/29/1999
Bexarotene TN= Targretin	Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego, CA 92121 DD=06/18/1999 MA=12/29/1999
Bleomycin TN= Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego, CA 92121 DD=02/09/1999
Botulinum toxin type A TN= Dysport	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited 1 Bath Rd., Maidenhead Berkshire SL6 4UH England, GB DD=10/20/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Busulfan TN= Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka, MN 55305 DD=07/28/1994 MA=02/04/1999
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle, WA 98119 DD=04/16/1999
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle, WA 98119 DD=04/16/1999
Caffeine TN= Cafcit	Treatment of apnea of prematurity.	O.P.R. Development, L.P. 1501 Wakarusa Drive Lawrence, KS 66047 DD=09/20/1988 MA=09/21/1999
Coagulation factor VIIa (recombinant) TN= NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center Suite 200 Princeton, NJ 08540 DD=06/06/1988 MA=03/25/1999
Cytarabine liposomal TN= DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego, CA 92121 DD=06/02/1993 MA=04/01/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Decitabine TN=	Treatment of myelodysplastic syndromes.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem The Netherlands, NL DD=03/08/1999
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem The Netherlands, NL DD=03/08/1999
Denileukin diftitox TN= Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/1996 MA=02/05/1999
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View, CA 94039 DD=11/04/1998 MA=06/28/1999
Epirubicin TN= Ellence	Treatment of breast cancer.	Pharmacia & Upjohn Company 0634-298-113 7000 Portage Rd. Kalamazoo, MI 49001 DD=09/14/1999 MA=09/15/1999
Epoprostenol TN= Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park, NC 27709 DD=03/22/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Etanercept TN= Enbrel	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998 MA=05/27/1999
Etanercept TN= Enbrel	Treatment of Wegener's granulomatosis.	Immunex Corporation 51 University Street Seattle, WA 98101 DD=04/06/1999
Exemestane TN= Aromasin	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn 7000 Portage Road Mail Stop: 0636-298-113 Kalamazoo, MI 49001 DD=09/19/1991 MA=10/21/1999
Fluoxetine TN= Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy Place New York, NY 10029 DD=04/30/1999
Gemtuzumab zogamicin TN=	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories PO Box 8299 Philadelphia, PA 19101 DD=11/24/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Guanfacine TN= Tenex	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona, CA 91718 DD=08/05/1999
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex TN= Allovectin-7	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated 9373 Towne Centre Dr., Suite 100 San Diego, CA 92121 DD=09/30/1999
Histamine TN= Maxamine	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane Suite 400 San Diego, CA 92122 DD=12/15/1999
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego, CA 92121 DD=02/09/1999
Interferon beta-1a (recombinant human) TN= Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=01/07/1999
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) TN= 131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave Tustin, CA 92780 DD=02/12/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Japanese encephalitis vaccine (live, attenuated) TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul 121-010 South Korea, KR DD=05/19/1999
L-5-hydroxytrypt ophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories Inc. 311 Bonnie Circle P.O. Box 1900 Corona, CA 91718 DD=01/20/1999
L-glutamyl-L-try ptophan TN=	Treatment of AIDS-related Kaposi's sarcoma.	Cytran Incorporated 10230 N.E. Points Dr. Suite 530 Kirkland, WA 98033 DD=10/20/1999
Lactic acid TN= Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale, NY 11735 DD=06/29/1999
Levocarnitine TN= Carnitor	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=09/06/1988 MA=12/15/1999
Lidocaine patch 5% TN= Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Hind Health Care, Inc. 3707 Williams Rd., Suite 101 San Jose, CA 95117 DD=10/24/1995 MA=03/19/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal-cis-bis-n s-neodecanoato-t rans-R,R-1,2-dia minocyclohexane- Pt (II) TN=	Treatment of malignant mesothelioma.	Aronex Pharmaceuticals, Inc. 8707 Technolgo Forest Place The Woodlands, TX 77381 DD=09/01/1999
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle, WA 98119 DD=06/10/1999
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont, MA 02478 DD=05/25/1999
Mitoxantrone TN= Novantrone	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Mitoxantrone TN= Novantrone	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 TN= Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma West Africa House Hanger Lane London W5 3QR, GB DD=03/22/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
N-acetylgalactosamine-4-sulfatase, recombinant human TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato, CA 94949 DD=02/17/1999
Nitric oxide TN= INOmax	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc. 54 Old Highway 22 Clinton, NJ 08809 DD=06/22/1993 MA=12/23/1999
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine TN= MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=05/07/1999
Peginterferon alfa-2a TN= PEGASYS	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=09/30/1999
Pegylated arginine deiminase TN= Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=03/26/1999
Pegylated arginine deiminase TN= Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=04/12/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Pentostatin TN= Nipent	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon, CA 94583 DD=11/24/1999
Polyethylene glycol-modified uricase TN= Zurase	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=09/14/1999
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel Belgium, BE DD=02/23/1999
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel Belgium, BE DD=02/23/1999
Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3 TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Dr. Santa Clara, CA 95054 DD=06/15/1999
Recombinant human keratinocyte growth factor TN=	Reducing the incidence and severity of radiation-induced xerostomia.	Amgen Inc. One Amgen Center Dr. Thousand Oaks, CA 91320 DD=12/20/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=04/16/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=04/13/1999
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=04/12/1999
Silver sulfadiazine and cerium nitrate TN= Flammacerium	Prevention of mortality in severely burned patients.	Synthes (USA) 1690 Russell Road PO Box 1766 Paoli, PA 19301 DD=11/17/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sodium 1,3-propanedisul fonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1, CA DD=04/06/1999
Sodium dichloroacetate TN= Ceresine	Treatment of severe head injury.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=06/14/1999
Somatropin (rDNA origin) TN= Nutropin Depot	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=10/28/1999 MA=12/22/1999
Somatropin [rDNA] TN= Genotropin	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 0633-298-113 Kalamazoo, MI 49001 DD=07/06/1999
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Temoporfin TN= Foscan	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Scotia Pharmaceuticals Ltd. Scotia House, Castle Business Park Stirling Scotland FK9 4TZ, GB DD=10/28/1999
Temozolomide TN= Temodar	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998 MA=08/11/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Teriparatide TN= Parathar	Treatment of idiopathic osteoporosis.	Henri Beaufour Institute USA, Inc. 27 Maple St. Milford, MA 01757 DD=10/28/1999
Thalidomide TN= Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=04/06/1999
Tobramycin TN= Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=06/18/1999
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland, GB DD=05/19/1999
Trastuzumab TN= Herceptin	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=12/14/1999
Ubiquinone TN= Ubiqgel	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp. 30 New York Ave. PO Box 331 Westbury, NY 11590 DD=12/14/1999

## Orphan Product Designations and Approvals List December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembr oyonic antigen IgG antibody TN= Cea-Cide	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=08/03/1999
pVGI.1 (VEGF2) TN=	Treatment of thromboangiitis obliterans.	Vascular Genetics, Inc. 200 Westpark Corporate Center 4364 South Alston Ave. Durham, NC 27713 DD=11/09/1999

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY  
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

---

NO DECEMBER 1999 ADDITIONS

## PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 19TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

### ABBREVIATIONS

NP\* NEW PRODUCT ( MINT FLAVORED)

### REFERENCES

#### *NEW DOSING SCHEDULE*

- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 TO BE DEFINED IN SUPPLEMENT
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE

#### *NEW INDICATION*

- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
- I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
- I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

## PATENT AND EXCLUSIVITY TERMS

### NEW INDICATION

- I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
- I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
- I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
- I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
- I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
- I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
- I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
- I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
- I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
- I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER
- I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON-FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIa and IIb)
- I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- I-283 TO BE DEFINED IN SUPPLEMENT
- I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AND ADJUNCT TO USUAL CARE
- I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER

### REFERENCES

#### MISCELLANEOUS EXCLUSIVITY CODES

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION

### PATENT USE CODE

- U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
- U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
- U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
- U-257 TREATMENT OF HIV INFECTION
- U-258 TREATMENT OF NEURODEGENERATIVE DISEASES

## PATENT AND EXCLUSIVITY TERMS

### PATENT USE CODE

U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	OSTEOARTHRITIS
U-267	METHOD FOR PREVENTING HEARTBURN
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA, NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES

**PATENT AND EXCLUSIVITY TERMS***PATENT USE CODE*

- U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
- U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
- U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
- U-305 METHODS FOR USING THE DRUG PRODUCT
- U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
- U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
- U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020482 004	ACARBOSE; PRECOSE	5972916	JUL 14, 2017	U-296	I-252	SEP 29, 2001
>ADD>	ACETAMINOPHEN; EXCEDRIN (MIGRAINE)	4943565	JUL 24, 2007		I-253	SEP 29, 2001
>ADD>	ADAPALENE; DIFFERIN	4717720	MAY 31, 2010	U-134		
020338 001	ADAPALENE; DIFFERIN	RE34440	MAR 31, 2010	U-275		
020380 001	ADAPALENE; DIFFERIN	4717720	MAY 31, 2010	U-134		
020059 001	ADENOSINE; ADENOSCAN	RE34440	MAY 31, 2010	U-275		
020760 001	ALATROFLOXACIN MESYLATE; TROVAN PRESERVATIVE FREE	5070877	MAY 18, 2009	U-116		
020760 002	ALATROFLOXACIN MESYLATE; TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
		5763454	JUN 15, 2015	U-282		
020503 001	ALBUTEROL SULFATE; PROVENTIL-HFA	4594359	JUN 10, 2003		I-262	JUN 02, 2002
019621 001	ALBUTEROL SULFATE; VENTOLIN	6008207	JUN 06, 2015	U-303	I-272	JUN 16, 2002
>ADD>	ALENDRONATE SODIUM; FOSAMAX	6008207	JUN 06, 2015	U-303	I-272	JUN 16, 2002
>ADD>	ALENDRONATE SODIUM; FOSAMAX	6008207	JUN 06, 2015	U-303	I-272	JUN 16, 2002
>ADD>	ALITRETINOIN; PANRETIN	5741523	APR 21, 2015		NCE	FEB 02, 2004
>ADD>	ALPROSTADIL; CAVERJECT	5741523	APR 21, 2015		NCE	FEB 02, 2004
>ADD>	ALPROSTADIL; CAVERJECT	5741523	APR 21, 2015		NCE	FEB 02, 2004
>ADD>	ALPROSTADIL; CAVERJECT	5741523	APR 21, 2015		NCE	FEB 02, 2004
>ADD>	AMIFOSTINE; ETHYOL	5994409	DEC 08, 2017	U-305	ODE	JUN 24, 2006
>ADD>	AMIFOSTINE; ETHYOL	5591731	JUL 31, 2012		NCE	DEC 08, 2000
>ADD>	AMIFOSTINE; ETHYOL	5591731	JUL 31, 2012		ODE	JUN 24, 2006
>ADD>	AMIFOSTINE; ETHYOL	5994409	DEC 08, 2017	U-305	ODE	DEC 08, 2002
>ADD>	AMIFOSTINE; ETHYOL	5994409	DEC 08, 2017	U-305	ODE	DEC 08, 2002
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE; LEVULAN	5211938	MAY 18, 2010	U-289		
		5422093	JUL 28, 2009	U-289		
020364 002	AMLODIPINE BESYLATE; LOTREL	4572909	JUL 31, 2006			
020364 003	AMLODIPINE BESYLATE; LOTREL	4572909	JUL 31, 2006			
020364 004	AMLODIPINE BESYLATE; LOTREL	4572909	JUL 31, 2006			
020508 001	AMMONIUM LACTATE; LAC-HYDRIN	4572909	JUL 31, 2006			
021007 001	AMPRENAVIR; AGENERASE	4572909	JUL 31, 2006			
021007 002	AMPRENAVIR; AGENERASE	4572909	JUL 31, 2006			
021039 001	AMPRENAVIR; AGENERASE	4572909	JUL 31, 2006			
020884 001	ASPIRIN; AGGRENOL	5585397	DEC 17, 2013		PED	FEB 29, 2000
>ADD>	ATORVASTATIN CALCIUM; LIPITOR	6015577	JAN 18, 2017		NCE	APR 15, 2004
>ADD>	ATORVASTATIN CALCIUM; LIPITOR	5969156	JUL 08, 2016		NCE	APR 15, 2004
>ADD>	ATORVASTATIN CALCIUM; LIPITOR	5969156	JUL 08, 2016		NCE	APR 15, 2004
>ADD>	ATORVASTATIN CALCIUM; LIPITOR	5969156	JUL 08, 2016		NCE	APR 15, 2004
020702 002	ATORVASTATIN CALCIUM; LIPITOR	5969156	JUL 08, 2016		NCE	APR 15, 2004
020702 003	ATORVASTATIN CALCIUM; LIPITOR	5969156	JUL 08, 2016		NCE	APR 15, 2004
020500 001	ATOVAQUONE; MEPRON	5780676	JUL 14, 2015		I-255	JAN 05, 2002
>ADD>	BEXAROTENE; TARGRETIN	5466861	NOV 14, 2012		NCE	DEC 29, 2004
>ADD>	BEXAROTENE; TARGRETIN	5466861	NOV 14, 2012		NCE	DEC 29, 2004
020746 001	BUDESONIDE; RHINOCORT	5763493	AUG 12, 2013		NDF	OCT 01, 2002
020746 002	BUDESONIDE; RHINOCORT	5763493	AUG 12, 2013		NDF	OCT 01, 2002
020711 002	BUPROPION HYDROCHLORIDE; ZYBAN	5763493	AUG 12, 2013		NDF	OCT 01, 2002

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020711 003	BUPROPION HYDROCHLORIDE; ZYBAN	5763493	AUG 12, 2013			
020954 001	BUSULFAN; BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
		5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
		4526892	DEC 29, 2005		NE	SEP 21, 2002
>ADD>						
020664 001	CABERGOLINE; DOSTINEX	5759565	JUN 02, 2015			
020793 001	CAFFEINE CITRATE; CAFKIT	5472949	DEC 14, 2013	U-271		
020313 002	CALCITONIN, SALMON; MICALCIN	4966891	NOV 08, 2008	U-272		
020896 001	CAPECITABINE; XELODA	5472949	DEC 14, 2013	U-271		
		4966891	NOV 08, 2008	U-272		
020896 002	CAPECITABINE; XELODA	5912013	JUN 15, 2016	U-277		
020712 001	CARBAMAZEPINE; CARBATROL	5912013	JUN 15, 2016	U-277		
020712 002	CARBAMAZEPINE; CARBATROL	5760068	JUN 15, 2016	U-19	I-284	DEC 23, 2002
020998 001	CELECOXIB; CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
>ADD>		5972986	OCT 14, 2017	U-299		
>ADD>		5760068	JUN 02, 2015	U-299		
>ADD>		5466823	NOV 30, 2013	U-299		
		5563165	NOV 30, 2013			
020998 002	CELECOXIB; CELEBREX	5760068	NOV 30, 2013	U-19	I-284	DEC 23, 2002
>ADD>		5760068	JUN 02, 2015	U-299		
>ADD>		5972986	OCT 14, 2017	U-299		
>ADD>		5563165	NOV 30, 2013			
		5066530	JAN 17, 2009	NS		MAY 24, 2002
020740 005	CERIVASTATIN SODIUM; BAYCOL	5177080	NOV 26, 2011			
>ADD>		5142051	JUN 26, 2010	NDF		DEC 17, 2002
021022 001	CICLOPIROX; PENLAC	4277479	AUG 29, 2000	NCE		JAN 15, 2004
020638 001	CIDOFOVIR; VISTIDE	4277479	AUG 29, 2000	NCE		JAN 15, 2004
020863 001	CILOSTAZOL; PLETAL	4277479	AUG 29, 2000			
020863 002	CILOSTAZOL; PLETAL	4670444	DEC 09, 2003	U-36		
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	FEB 15, 2011			
020767 001	CISAPRIDE MONOHYDRATE; PROPULSID QUICKSOLV	5286754	FEB 15, 2011			
>ADD>		5648093	JUL 15, 2014	PC		MAY 15, 2000
074735 001	CISPLATIN; CISPLATIN			PED		JUL 03, 2000
020463 001	CROMOLYN SODIUM; NASALCROM			ODE		APR 01, 2006
021041 001	CYTARABINE; DEPOCYT			NP		APR 01, 2002
020287 001	DALTEPARIN SODIUM; FRAGMIN			I-263		MAY 25, 2002
020287 003	DALTEPARIN SODIUM; FRAGMIN			I-259		MAR 30, 2002
020287 004	DALTEPARIN SODIUM; FRAGMIN			I-263		MAY 25, 2002
				I-259		MAR 30, 2002
				I-263		MAY 25, 2002
				I-259		MAR 30, 2002
				I-263		MAY 25, 2002
				I-259		MAR 30, 2002
017922 001	DESMOPRESSIN ACETATE; DDAVP	5763407	JUN 29, 2013			
017922 002	DESMOPRESSIN ACETATE; DDAVP	5763407	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE; DDAVP	5763407	JUN 29, 2013			
018938 002	DESMOPRESSIN ACETATE; DDAVP	5763407	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE; DDAVP	5763407	JUN 29, 2013			
019955 002	DESMOPRESSIN ACETATE; DDAVP	5763407	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE; DDAVP	5763407	JUN 29, 2013			
020713 001	DESOGESTREL; MIRCETTE	4921843	OCT 20, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
021038 001	DEXMEDETOMIDINE; PRECEDEX			NCE	DEC 17, 2004
074752 001	DILTIAZEM HYDROCHLORIDE; CARTIA XT			PC	DEC 20, 1999
074752 003	DILTIAZEM HYDROCHLORIDE; CARTIA XT			PC	DEC 20, 1999
074752 004	DILTIAZEM HYDROCHLORIDE; CARTIA XT			PC	DEC 20, 1999
020449 001	DOCETAXEL; TAXOTERE	4814470	MAY 14, 2010	I-282	DEC 23, 2002
		5438072	NOV 22, 2013		
		5698582	JUL 03, 2012		
		5714512	JUL 03, 2012		
020931 001	DOFETILIDE; TIKOSYN	4797413	APR 28, 2008	NCE	OCT 01, 2004
020931 002	DOFETILIDE; TIKOSYN	4619339	OCT 28, 2003	NCE	OCT 01, 2004
020931 003	DOFETILIDE; TIKOSYN	5602116	APR 03, 2115	NCE	OCT 01, 2004
020869 001	DORZOLAMIDE HYDROCHLORIDE; COSOPT	5707980	FEB 11, 2117		
020862 001	DOXERCALCIFEROL; HECTOROL				
050718 001	DOXORUBICIN HYDROCHLORIDE; DOXIL	5811423	AUG 07, 2012	ODE	JUN 28, 2006
020972 001	EFAVIRENZ; SUSTIVA	5519021	MAY 21, 2013		
		5663169	SEP 02, 2014		
		5811423	AUG 07, 2012		
020972 002	EFAVIRENZ; SUSTIVA	5519021	MAY 21, 2013		
		5663169	SEP 02, 2014		
020972 003	EFAVIRENZ; SUSTIVA	5519021	MAY 21, 2013		
		5663169	SEP 02, 2014		
		5811423	AUG 07, 2012		
020796 001	ENTACAPONE; COMTAN			NCE	OCT 19, 2004
050778 001	EPIRUBICIN HYDROCHLORIDE; ELLENCE			ODE	SEP 15, 2006
020375 001	ESTRADIOL; CLIMARA			I-254	MAR 05, 2002
020375 002	ESTRADIOL; CLIMARA			I-254	MAR 05, 2002
020375 003	ESTRADIOL; CLIMARA			I-254	MAR 05, 2002
020375 004	ESTRADIOL; CLIMARA			I-254	MAR 05, 2002
020472 001	ESTRADIOL; ESTRING			I-254	MAR 05, 2002
020908 001	ESTRADIOL; VAGIFEM				
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN	5223261	JUN 29, 2010		
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN	4871543	JUN 12, 2007	U-306	
010971 005	ESTROGENS, CONJUGATED; PMB 200	5188835	JUN 12, 2007	U-306	
010971 003	ESTROGENS, CONJUGATED; PMB 400				
004782 001	ESTROGENS, CONJUGATED; PREMARIN	5210081	FEB 26, 2012		
004782 002	ESTROGENS, CONJUGATED; PREMARIN	5210081	FEB 26, 2012		
004782 003	ESTROGENS, CONJUGATED; PREMARIN	5210081	FEB 26, 2012		
004782 004	ESTROGENS, CONJUGATED; PREMARIN	5210081	FEB 26, 2012		
004782 005	ESTROGENS, CONJUGATED; PREMARIN	5210081	FEB 26, 2012		
010402 001	ESTROGENS, CONJUGATED; PREMARIN	5210081	FEB 26, 2012		
020216 001	ESTROGENS, CONJUGATED; PREMARIN	5210081	FEB 26, 2012		
020303 002	ESTROGENS, CONJUGATED; PREMPHASE (PREMARIN; CYCRIN 14/14)	5210081	FEB 26, 2012		
020527 002	ESTROGENS, CONJUGATED; PREMPHASE 14/14	5210081	FEB 26, 2012		
020303 001	ESTROGENS, CONJUGATED; PREMPRO (PREMARIN; CYCRIN 14/14)	RE36247	MAY 02, 2006	U-284	

>ADD>  
 >ADD>

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
\*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020527 001	ESTROGENS, CONJUGATED; PREMPRO 14/14	RE36247	MAY 02, 2006			
020527 003	ESTROGENS, CONJUGATED; PREMPRO 14/14	5210081	FEB 26, 2012			
		4826831	MAY 02, 2006			
		5547948	JAN 17, 2015			
		RE36247	MAY 02, 2006			
		5210081	FEB 26, 2012			
021065 001	ETHINYL ESTRADIOL; FEMHRT	5208225	MAY 04, 2010	U-283 NP		OCT 15, 2002
021065 002	ETHINYL ESTRADIOL; FEMHRT	5208225	MAY 04, 2010	U-283 NP		OCT 15, 2002
021065 003	ETHINYL ESTRADIOL; FEMHRT	5208225	MAY 04, 2010	U-283 NP		OCT 15, 2002
020584 001	ETODOLAC; LODINE XL	4966768	OCT 30, 2007	PED		APR 25, 2000
020584 002	ETODOLAC; LODINE XL	4966768	APR 30, 2007	PED		OCT 25, 1999
020584 003	ETODOLAC; LODINE XL	4966768	OCT 30, 2007	PED		APR 25, 2000
		4966768	APR 30, 2007	NDF		OCT 25, 1999
020753 001	EXEMESTANE; AROMASIN	4966768	OCT 30, 2007	PED		OCT 25, 1999
020363 001	FAMCICLOVIR; FAMVIR	4966768	OCT 30, 2007			
020363 003	FAMCICLOVIR; FAMVIR	4966768	OCT 30, 2007			
020325 001	FAMOTIDINE; PEPCID AC	4808616	JUL 07, 2006			
020801 001	FAMOTIDINE; PEPCID AC	4904650	JUL 07, 2006			
		5246937	SEP 21, 2010	U-96		OCT 21, 2006
		5246937	SEP 21, 2010	U-96		OCT 21, 2006
		5854267	DEC 29, 2015	U-267		
		5667794	MAY 02, 2015			
		5854267	DEC 29, 2015	U-267		
		5075114	DEC 24, 2008			
		4895726	JAN 19, 2009			
		4895726	JAN 19, 2009			
		4895726	JAN 19, 2009			
		4895726	JAN 19, 2009			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2012			
		4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		4377584	MAR 22, 2000	U-261		
		5942519	OCT 23, 2018	U-280		
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4314981	FEB 02, 2001			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003			
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5855912	FEB 28, 2015			
		5571817	NOV 05, 2013	U-259		
		5886184	NOV 19, 2			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84	I-267	JUN 17, 2002
				U-154	I-258	DEC 11, 2001
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84	PED	JUN 05, 2000
		4626549	DEC 02, 2003	U-154	NCE	DEC 05, 1999
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001	U-84	NCE	JUN 05, 2000
		4626549	DEC 02, 2003	U-154	NCE	DEC 05, 1999
		4314081	FEB 02, 2001		NCE	DEC 05, 2000
019958 001	FLUTICASON PROPIONATE;CUTIVATE				NCE	DEC 05, 1999
020121 001	FLUTICASON PROPIONATE;FLONASE				NCE	DEC 05, 1999
020243 001	FLUOXAMINE MALEATE;LUVOX				NCE	DEC 05, 1999
020243 002	FLUOXAMINE MALEATE;LUVOX				NCE	DEC 05, 1999
020243 003	FLUOXAMINE MALEATE;LUVOX				NCE	DEC 05, 1999
020243 004	FLUOXAMINE MALEATE;LUVOX				NCE	DEC 05, 1999
020582 001	FOLLITROPIN ALFA/BETA; FOLLISTIM	5767251	JUN 16, 2015		NCE	DEC 08, 2004
020582 002	FOLLITROPIN ALFA/BETA; FOLLISTIM	5767251	JUN 16, 2015		NCE	DEC 08, 2004
020882 001	GABAPENTIN; NEURONTIN	4087544	JAN 16, 2000	U-106		
		5084479	JAN 02, 2010	U-258		
		4087544	JAN 16, 2000	U-106		
020882 002	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-258		
		5130120	JUL 14, 2009		NCE	DEC 08, 2004
020937 001	GADOVERSETAMIDE; OPTIMARK	5137711	JUL 14, 2009		NCE	DEC 08, 2004
		5130120	JUL 14, 2009		NCE	DEC 08, 2004
020975 001	GADOVERSETAMIDE; OPTIMARK	5137711	JUL 14, 2009		NCE	DEC 08, 2004
		5130120	JUL 14, 2009		NCE	DEC 08, 2004
020976 001	GADOVERSETAMIDE; OPTIMARK	5137711	JUL 14, 2009		NCE	DEC 08, 2004
		5130120	JUL 14, 2009		NCE	DEC 08, 2004
020460 001	GANCICLOVIR; CVTOVENE	4507305	MAY 21, 2001	U-64		
020460 002	GANCICLOVIR; CVTOVENE	4507305	MAY 21, 2001	U-64		
021057 001	GANIRELIX ACETATE; ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
		5767082	JUN 16, 2015		NCE	JUL 29, 2004
021061 001	GATIFLOXACIN; TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
021061 002	GATIFLOXACIN; TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
021062 001	GATIFLOXACIN; TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
021062 002	GATIFLOXACIN; TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
020509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	4808614	MAY 15, 2010		NCE	DEC 17, 2004
020509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR	4808614	MAY 15, 2010		NCE	DEC 17, 2004
020496 001	GLIMEPIRIDE; AMARYL	4379785	APR 06, 2005	U-118		
020496 002	GLIMEPIRIDE; AMARYL	4379785	APR 06, 2005	U-118		
020305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4379785	APR 06, 2005	U-118		
020305 002	GRANISETRON HYDROCHLORIDE; KYTRIL	4379785	APR 06, 2005	U-118		
020125 001	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949	OCT 03, 2002	U-3	I-264	JUL 27, 2002
		4743450	FEB 24, 2007		I-264	JUL 27, 2002
020125 002	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		4344949	OCT 03, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD>	020125 003 HYDROCHLOROTHIAZIDE; ACCURETIC	4344949 4743450	OCT 03, 2002 FEB 24, 2007	U-3	
	020758 001 HYDROCHLOROTHIAZIDE; AVALIDE	5994348	JUN 07, 2015		
	020758 002 HYDROCHLOROTHIAZIDE; AVALIDE	5994348	JUN 07, 2015	NCE	SEP 30, 2002
	020758 003 HYDROCHLOROTHIAZIDE; AVALIDE	5270317 5994348	MAR 20, 2011 JUN 07, 2015	D-50	MAY 13, 2002
	020491 001 IBUTILIDE FUMARATE; CORVERT	4689338	AUG 25, 2009	U-172	
	020723 001 IMIQUIMOD; ALDARA	5413999	MAY 09, 2012	U-132	
>ADD>	020685 001 INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 09, 2012	U-132	
>ADD>	020685 003 INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 09, 2012	U-132	
>ADD>	020685 005 INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 09, 2012	NP	JUL 19, 2002
	021028 001 INSULIN HUMAN; VELOSULIN BR			NC	DEC 22, 2002
>ADD>	021017 001 INSULIN LISPRO PROTAMINE; HUMALOG MIX 75/25	5461031	JUN 26, 2014		
>ADD>	021018 001 INSULIN LISPRO PROTAMINE; HUMALOG MIX 50/50	5474978	JUN 16, 2014		
>ADD>		5514646	MAY 07, 2013		
>ADD>		5747642	JUN 16, 2014		
	020083 001 ITRACONAZOLE; SPORANOX	4791111	DEC 23, 2005		
	020657 001 ITRACONAZOLE; SPORANOX	4791111	DEC 23, 2005		
	020966 001 ITRACONAZOLE; SPORANOX	4791111	DEC 23, 2005		
	021066 001 KETOTIFEN FUMARATE; ZADITOR	4267179	JUN 23, 2000		
	020564 001 LAMIVUDINE; EPIVIR	5905082	MAY 18, 2016		
>ADD>	020596 001 LAMIVUDINE; EPIVIR	6004968	MAR 20, 2018		
	021003 001 LAMIVUDINE; EPIVIR-HBV	5047407	FEB 08, 2009	I-257	DEC 08, 2001
	021004 001 LAMIVUDINE; EPIVIR-HBV	5532246	JUL 02, 2013	U-250	
	020406 001 LANSOPRAZOLE; PREVACID	5905082	MAY 18, 2016		
	020406 002 LANSOPRAZOLE; PREVACID	6004968	MAR 20, 2018		
>ADD>	020597 001 LATANOPROST; XALATAN	5047407	FEB 08, 2009		
	020764 001 LAMOTRIGINE; LAMICTAL CD	5532246	JUL 02, 2013	U-250	
	020764 002 LAMOTRIGINE; LAMICTAL CD	5905082	MAY 18, 2016		
	020764 003 LAMOTRIGINE; LAMICTAL CD	6004968	MAR 20, 2018		
	020406 001 LANSOPRAZOLE; PREVACID	5047407	FEB 08, 2009		
	020406 002 LANSOPRAZOLE; PREVACID	5047407	FEB 08, 2009		
	020517 002 LEUPROLIDE ACETATE; LUPRON DEPOT-4	5532246	JUL 02, 2013		
	020837 001 LEVALBUTEROL HYDROCHLORIDE; XOPENEX	5296504	MAR 22, 2011		
	020837 002 LEVALBUTEROL HYDROCHLORIDE; XOPENEX	5422368	MAR 22, 2011		
	020035 001 LEVAMISOLE HYDROCHLORIDE; ERGAMISOL	4599353	JUL 28, 2006		
	021035 001 LEVETIRACETAM; KEPPRA	4652441	NOV 01, 2004		
	021035 002 LEVETIRACETAM; KEPPRA	4584305	JUN 18, 2004		
	021035 003 LEVETIRACETAM; KEPPRA	4943639	JUL 06, 2006		
	020997 001 LEVOBUPIVACAINE HYDROCHLORIDE; CHIROCAINE	4837223	JUN 06, 2006		
		4943639	JUN 06, 2006		
		4837223	JUN 06, 2006		
		4943639	JUN 06, 2006		
		4837223	JUN 06, 2006		
		4943639	JUN 06, 2006		
		4837223	JUN 06, 2006		
		5708011	OCT 13, 2014		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
\*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	LEVOPRIVACAIN HYDROCHLORIDE; CHIROCAINE	5708011	OCT 13, 2014	U-276 NP	NP	AUG 05, 2002
>ADD>	LEVOPRIVACAIN HYDROCHLORIDE; CHIROCAINE	5708011	OCT 13, 2014	U-276 NP	I-280	AUG 05, 2002
>ADD>	LEVOCARNITINE; CARNITOR				ODE	DEC 15, 2006
>ADD>	LEVONORGESTREL; PLAN B				NP	JUL 28, 2002
	LIDOCAINE; EMLA				I-260	MAR 11, 2002
	LIDOCAINE; LIDODERM				ODE	MAR 19, 2006
>ADD>	LISINAPRIL; PRINIVIL	4374829	DEC 30, 2001			
	LISINAPRIL; ZESTRIL	4374829	DEC 30, 2001		I-250	MAR 11, 2002
	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		NP	AUG 27, 2002
	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		NP	AUG 27, 2002
	LUTEINIZING HORMONE; REPRONEX				NC	DEC 10, 2004
>ADD>	LUTEINIZING HORMONE; REPRONEX	5194247	MAR 16, 2010	U-294	NC	DEC 10, 2004
	MEQUINOL; SOLAGE	5470567	MAR 19, 2010	U-294		
	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				NCE	MAR 03, 2000
	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				NCE	MAR 03, 2000
	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				NCE	MAR 03, 2000
	METHOXSALEN; UVADEX				NP	FEB 25, 2002
	MICONAZOLE NITRATE; MONISTAT DUAL- PAK				NP	JUN 30, 2002
	MIGLITOL; GLYSET	4845075	APR 11, 2009	U-273		
	MIGLITOL; GLYSET	5036102	JUL 30, 2008			
	MIGLITOL; GLYSET	4999375	MAR 12, 2008			
	MIGLITOL; GLYSET	5514698	MAR 21, 2014			
	MIGLITOL; GLYSET	4639436	JAN 27, 2009			
	MIGLITOL; GLYSET	4639436	JAN 27, 2009			
	MILRINONE LACTATE; PRIMACOR	4639436	JAN 27, 2009			
	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	MODAFINIL; PROVIGIL	4177290	MAR 09, 1999			
	MODAFINIL; PROVIGIL	5618845	OCT 06, 2014	U-255		
	MODAFINIL; PROVIGIL	4927855	MAY 22, 2007	U-255		
	MODAFINIL; PROVIGIL	4177290	MAR 09, 1999			
	MODAFINIL; PROVIGIL	5618845	OCT 06, 2014	U-255		
	MODAFINIL; PROVIGIL	4927855	MAY 22, 2007	U-255		
>ADD>	MOMETASONE FUROATE MONOHYDRATE; NASONEX	4990517	JUN 30, 2009	U-298	I-285	DEC 02, 2002
>ADD>	MOXIFLOXACIN HYDROCHLORIDE; AVELOX	5607942	MAR 04, 2014	U-298	NCE	DEC 10, 2004
>ADD>	MOMETASONE FUROATE MONOHYDRATE; NASONEX	5849752	DEC 05, 2016	U-298		
>ADD>	NAPROXEN SODIUM; ALEVE COLD AND SINUS				NC	NOV 29, 2002
>ADD>	NEDOCROMIL SODIUM; ALOCRIL	4474787	OCT 02, 2006	U-304 NP	NP	DEC 08, 2002
	NEDOCROMIL SODIUM; ALOCRIL	4760072	JUL 26, 2005			
>ADD>	NELFINAVIR MESYLATE; VIRACEPT	5952343	OCT 07, 2013	U-257 D-52	D-52	NOV 24, 2002
>ADD>	NELFINAVIR MESYLATE; VIRACEPT	5952343	OCT 07, 2013	U-257 D-52	D-52	NOV 24, 2002
	NEVIRAPINE; VIRAMUNE				NP*	DEC 23, 2001
	NICOTINE POLACRILEX; NICORETTE (MINT)	5366972	NOV 22, 2011		NP*	DEC 23, 2001
	NICOTINE POLACRILEX; NICORETTE (MINT)				NP*	DEC 23, 2001
	NICOTINE POLACRILEX; NICORETTE (MINT)					
	NICOTINE POLACRILEX; NICORETTE (MINT)					
	NICOTINE; NICOTROL	5656255	AUG 12, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PEX EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020714 001	NICOTINE; NICOTROL	5400808 4917120 4800903 4793366 5167242 5501236 5485827	JUN 08, 2010 APR 17, 2007 JAN 31, 2006 DEC 27, 2005 JUN 08, 2010 JUN 08, 2010 JAN 23, 2013	U-297 ODE NCE U-297 ODE NCE		DEC 23, 2006 DEC 23, 2004 DEC 23, 2006 DEC 23, 2004 DEC 23, 2004
>ADD> >ADD> >ADD> >ADD>	NITRIC OXIDE; INOMAX NITRIC OXIDE; INOMAX	5485827	JAN 23, 2013	U-297 ODE NCE		DEC 23, 2006 DEC 23, 2004 DEC 23, 2006 DEC 23, 2004
018705 002 021008 001	NITROGLYCERIN; NITROLINGUAL PUMPSPRAY OCTREOTIDE ACETATE; SANDOSTATIN LAR	5186925 5688530 4395403 5538739 5639480 5922338 5922682 5688530 4395403	FEB 16, 2010 NOV 18, 2014 NOV 21, 2002 JUL 23, 2013 JUN 17, 2014 JUL 13, 2016 JUL 13, 2016 NOV 18, 2014 NOV 21, 2002	U-268 NP U-269 ODE U-268 NP U-269 ODE		NOV 25, 2001 NOV 25, 2005
>ADD>	OCTREOTIDE ACETATE; SANDOSTATIN LAR	4395403	NOV 21, 2002	U-268 NP U-269 ODE		NOV 25, 2001 NOV 25, 2005
021008 003	OCTREOTIDE ACETATE; SANDOSTATIN LAR	5538739 5639480 5922338 5922682 5688530 4395403	JUL 23, 2013 JUN 17, 2014 JUL 13, 2016 JUL 13, 2016 NOV 18, 2014 NOV 21, 2002	U-268 NP U-269 ODE		NOV 25, 2001 NOV 25, 2005
>ADD> >ADD> >ADD> >ADD> >ADD>	OCTREOTIDE ACETATE; SANDOSTATIN LAR	5538739 5639480 5922338 5922682 5688530 4395403	JUL 23, 2013 JUN 17, 2014 JUL 13, 2016 JUL 13, 2016 NOV 18, 2014 NOV 21, 2002	U-268 NP U-269 ODE		NOV 25, 2001 NOV 25, 2005
020592 001 020592 002 020592 003	OLANZAPINE; ZYPREXA OLANZAPINE; ZYPREXA OLANZAPINE; ZYPREXA	5736541 5919485 5736541 5919485 5736541 5919485	MAR 24, 2015 MAR 24, 2015 MAR 24, 2015 MAR 24, 2015 MAR 24, 2015 MAR 24, 2015	U-307 U-308 U-307 U-308 U-307 U-308		
>ADD> >ADD> >ADD> >ADD> >ADD>	OLANZAPINE; ZYPREXA OLANZAPINE; ZYPREXA OLANZAPINE; ZYPREXA	5736541 5919485 5736541 5919485	MAR 24, 2015 MAR 24, 2015 MAR 24, 2015 MAR 24, 2015	U-307 U-308 U-307 U-308		
020103 001 020103 002 020766 001	ONDANSETRON HYDROCHLORIDE; ZOFTRAN ONDANSETRON HYDROCHLORIDE; ZOFTRAN ORLISTAT; XENICAL	6004996 4598089 5763483 5866601 5952375	JAN 18, 2018 JUN 18, 2004 DEC 27, 2016 FEB 02, 2016 FEB 02, 2016	I-269 I-269 NCE NCE		AUG 27, 2002 AUG 27, 2002 APR 23, 2004 OCT 27, 2004
>ADD>	SELTAMIVIR PHOSPHATE; TAMIFLU	021087 001				

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
\*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018841 004	OXAPROZIN; DAYPRO	4783337		PED	APR 29, 2000
020897 001	OXYBUTYRIN CHLORIDE;DITROPAN XL	5674895		NCE	OCT 29, 1999
		5082668		NP	DEC 16, 2001
		5840754			
		4612008			
		4519801			
		5912268			
020897 002	OXYBUTYRIN CHLORIDE;DITROPAN XL	5840754		NP	DEC 16, 2001
		5674895			
		5082668			
		4783337			
		4612008			
		4519801			
020897 003	OXYBUTYRIN CHLORIDE;DITROPAN XL	5912268		NP	DEC 16, 2001
		4612008			
		4519801			
		5840754			
		5674895			
		5082668			
020553 001	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4783337			
020553 002	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5508042			
020553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5508042			
020553 004	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5508042			
020262 001	PACLITAXEL; TAXOL	5656295			
020031 001	PAROXETINE HYDROCHLORIDE; PAXIL	5508042			
020031 002	PAROXETINE HYDROCHLORIDE; PAXIL	5872132		I-270	OCT 25, 2002
		5900423		I-261	MAY 17, 2002
020031 003	PAROXETINE HYDROCHLORIDE; PAXIL	5789449	U-285		
		5872132			
		5900423			
020031 004	PAROXETINE HYDROCHLORIDE; PAXIL	5872132			
		5900423			
020031 005	PAROXETINE HYDROCHLORIDE; PAXIL	5789449			
		5872132			
		5900423			
020710 001	PAROXETINE HYDROCHLORIDE; PAXIL	5789449	U-285		
		5872132			
		5900423			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020885 001	PAROXETINE HYDROCHLORIDE; PAXIL	5872132		I-261	MAY 17, 2002
		5900423			
		5789449	U-285		
>ADD> 020885 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	U-12		
		5872132		I-261	MAY 17, 2002
		5900423			
		5789449	U-285		
>ADD> 020885 003	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	U-12		
		5872132		I-261	MAY 17, 2002
		5900423			
		5789449	U-285		
>ADD> 020885 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	U-12		
		5872132		I-261	MAY 17, 2002
		5900423			
		5789449	U-285		
020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR	4721723	U-12		
		5872132		NDF	FEB 16, 2002
		4839177			
		5422123			
		4721723			
		5900423			
		5789449	U-286		
020936 002	PAROXETINE HYDROCHLORIDE; PAXIL CR	5872132		NDF	FEB 16, 2002
		4839177			
		5422123			
		4721723			
		5900423			
		5789449	U-286		
021079 001	PEMIROLAST POTASSIUM; ALAMAST	5034230			
021073 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS	5034230*PED			
		4444779			
021073 002	PIOGLITAZONE HYDROCHLORIDE; ACTOS	4687777			
		4444779			
021073 003	PIOGLITAZONE HYDROCHLORIDE; ACTOS	4687777			
		4444779			
020698 001	POLYETHYLENE GLYCOL 3350; MIRALAX	5710183			
020744 001	FORACTANT ALPHA; CUROSURF	4886812			
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4886812			
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4886812			
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4886812			
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4886812			
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4886812			
020667 006	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX	4886812			
019627 002	PROPOFOL; DIPRIVAN	5714520			
		5714520*PED			
		5731355			
		5731355*PED			
		5731356			
		5731356*PED			
		5908869			
		5908869*PED			
		5714520	U-217		
		5731355	U-217		
		5731356	U-218		
		5731356*PED	U-218		
		5908869	U-270		
		5908869*PED	U-270		

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
075102 001	PROPOFOL; PROPOFOL	4879288	MAR 20, 2007			
020639 004	QUETIAPINE FUMARATE; SEROQUEL	5466810	JUN 10, 2014		PC	OCT 17, 1999
020973 002	RABEPRAZOLE SODIUM; ACIPHEX	5514826	JUN 07, 2015		NCE	SEP 26, 2002
020815 001	RALOXIFENE HYDROCHLORIDE; EVISTA	569772	JUN 07, 2015		NCE	AUG 19, 2004
		5629425	SEP 19, 2014		I-271	SEP 30, 2002
		5659087	JUN 07, 2015			
		5710285	MAR 31, 2015			
		5731327	MAR 24, 2015			
		5731342	JAN 27, 2017			
		5747510	MAR 02, 2014			
		5808061	MAR 31, 2014			
		5811120	MAR 02, 2014			
		5843984	APR 14, 2017			
		5972383	MAR 02, 2014			
075094 001	RANITIDINE HYDROCHLORIDE; RANITIDINE HCL			U-287		
>ADD>					PC	JAN 14, 2000
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					D-53	OCT 29, 2002
>ADD>					NCE	AUG 18, 2004
>ADD>					NCE	AUG 18, 2004
020984 001	RAPACURONIUM BROMIDE; RAPLON			U-90		
020984 002	RAPACURONIUM BROMIDE; RAPLON			U-90		
020903 001	RIBAVIRIN; REBETOL			U-90		
020272 007	RISPERIDONE; RISPERDAL			U-90		
020272 008	RISPERIDONE; RISPERDAL			U-90		
020680 001	RITONAVIR; NORVIR			U-266		
020865 001	RIZATRIPTAN BENZOATE; MAXALT-MLT			U-266		
020865 002	RIZATRIPTAN BENZOATE; MAXALT-MLT			U-266		
021042 001	ROFECOXIB; VIOXX			U-266		
021042 002	ROFECOXIB; VIOXX			U-266		
021052 001	ROFECOXIB; VIOXX			U-266		
021052 002	ROFECOXIB; VIOXX			U-266		
021071 002	ROSIGLITAZONE MALEATE; AVANDIA					
021071 003	ROSIGLITAZONE MALEATE; AVANDIA					
021071 004	ROSIGLITAZONE MALEATE; AVANDIA					
019839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT			U-152	I-279	
>ADD>						

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
019839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002
>ADD>						
019839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002
>ADD>						
019839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002
>ADD>						
019839 005	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002
>ADD>						
020990 001	SERTRALINE HYDROCHLORIDE; ZOLOFT					
>ADD>						
020478 001	SEVOFLURANE; ULTANE	5990176	JAN 27, 2017		I-208	OCT 10, 2000
>ADD>						
019766 001	SIMVASTATIN; ZOCOR	RE36481 RE36520	JUL 10, 2007 MAY 26, 2009	U-300 U-300	I-277 I-278	NOV 22, 2002 NOV 22, 2002
>ADD>						
019766 002	SIMVASTATIN; ZOCOR	RE36481 RE36520	JUL 10, 2007 MAY 26, 2009	U-300 U-300	I-277 I-278	NOV 22, 2002 NOV 22, 2002
>ADD>						
019766 003	SIMVASTATIN; ZOCOR	RE36481 RE36520	JUL 10, 2007 MAY 26, 2009	U-300 U-300	I-277 I-278	NOV 22, 2002 NOV 22, 2002
>ADD>						
019766 004	SIMVASTATIN; ZOCOR	RE36481 RE36520	JUL 10, 2007 MAY 26, 2009	U-300 U-300	I-277 I-278	NOV 22, 2002 NOV 22, 2002
>ADD>						
019766 005	SIMVASTATIN; ZOCOR	RE36481 RE36520	JUL 10, 2007 MAY 26, 2009	U-300 U-300	I-277 I-278	NOV 22, 2002 NOV 22, 2002
>ADD>						
021083 001	SIROLIMUS; RAPAMUNE					
>ADD>						
019640 005	SOMATROPIN, BIOSYNTHETIC; HUMATROPE	5100899 5212155 5308847 5403833 5536729	JUN 06, 2009 MAY 18, 2010 MAY 03, 2011 APR 04, 2012 SEP 30, 2013	U-290 NCE U-291 U-292 U-293		SEP 15, 2004
>ADD>						
019640 006	SOMATROPIN, BIOSYNTHETIC; HUMATROPE					
>ADD>						
019640 007	SOMATROPIN, BIOSYNTHETIC; HUMATROPE					
>ADD>						
021075 001	SOMATROPIN, BIOSYNTHETIC; NUTROPIN DEPOT					
>ADD>						
021075 002	SOMATROPIN, BIOSYNTHETIC; NUTROPIN DEPOT					
>ADD>						
021075 003	SOMATROPIN, BIOSYNTHETIC; NUTROPIN DEPOT					
>ADD>						
019865 001	SOTALOL HYDROCHLORIDE; BETAPACE	5656297 5654010 5656297 5654010 5656297 5654010	JUL 25, 2014 AUG 05, 2014 JUL 25, 2014 AUG 05, 2014 JUL 25, 2014 AUG 05, 2014			
>ADD>						
019865 002	SOTALOL HYDROCHLORIDE; BETAPACE					
>ADD>						
019865 003	SOTALOL HYDROCHLORIDE; BETAPACE					
>ADD>						
019865 004	SOTALOL HYDROCHLORIDE; BETAPACE					
>ADD>						
019865 005	SOTALOL HYDROCHLORIDE; BETAPACE					
>ADD>						

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020412 001	STAVUDINE; ZERIT	4978655	JUN 24, 2008	U-94	
020412 002	STAVUDINE; ZERIT	4978655	JUN 24, 2008	U-94	
020412 003	STAVUDINE; ZERIT	4978655	JUN 24, 2008	U-94	
020412 004	STAVUDINE; ZERIT	4978655	JUN 24, 2008	U-94	
020412 005	STAVUDINE; ZERIT	4978655	JUN 24, 2008	U-94	
020413 001	TAMULOSIN HYDROCHLORIDE; FLOWMAX	4978655	JUN 24, 2008	U-94	
020579 001	TECHNETIUM TC-99m DEPREOTIDE; NEO TECT KIT	4703063	OCT 27, 2009		
021012 001	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		NCE AUG 03, 2004
021029 001	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		NCE AUG 11, 2004
021029 002	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		ODE AUG 11, 2006
021029 003	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		NCE AUG 11, 2004
021029 004	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		ODE AUG 11, 2006
074823 001	TERAZOSIN HYDROCHLORIDE; TERAZOSIN HCL	4680291	JUL 14, 2004	U-281	NCE AUG 11, 2004
074823 002	TERAZOSIN HYDROCHLORIDE; TERAZOSIN HCL	4680291	JUL 14, 2004	U-73	ODE AUG 11, 2006
074823 003	TERAZOSIN HYDROCHLORIDE; TERAZOSIN HCL	4755534	DEC 30, 2006	U-73	NCE DEC 30, 1999
074823 004	TERAZOSIN HYDROCHLORIDE; TERAZOSIN HCL	4755534	DEC 30, 2006	U-73	NCE DEC 30, 1999
020539 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	5840327	AUG 15, 2016		PC FEB 09, 2000
020749 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	5840327	AUG 15, 2016		PC FEB 09, 2000
020980 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	5010090	OCT 07, 2008		PC FEB 09, 2000
020846 001	TERBINAFINE; LAMISIL	5354760	MAR 24, 2012		PC FEB 09, 2000
019762 001	TESTOSTERONE; TESTODERM	4876248	JAN 30, 2010		PC FEB 09, 2000
019762 002	TESTOSTERONE; TESTODERM	4876248	JAN 30, 2010		PC FEB 09, 2000
020646 005	TIAGABINE HYDROCHLORIDE; GABITRIL	5978698	OCT 08, 2017		PC FEB 09, 2000
020707 001	TILUDRONATE DISODIUM; SKELID	5292756	MAY 14, 2012		PC FEB 09, 2000
020912 001	TIROFIBAN HYDROCHLORIDE; AGGRASTAT	5880136	SEP 27, 2010	U-230	PC FEB 09, 2000
>ADD>		5965581	OCT 23, 2016	U-254	
>ADD>		5972967	OCT 23, 2016		
020913 001	TIROFIBAN HYDROCHLORIDE; AGGRASTAT	5972967	OCT 23, 2016		
020505 001	TOPIRAMATE; TOPAMAX	5292756	MAY 14, 2012	U-230	
020505 002	TOPIRAMATE; TOPAMAX	5880136	SEP 27, 2010	U-254	
020505 003	TOPIRAMATE; TOPAMAX	5965581	OCT 23, 2016		
020505 004	TOPIRAMATE; TOPAMAX	5972967	OCT 23, 2016		
I-266					JUL 23, 2002
I-274					OCT 01, 2002
I-266					JUL 23, 2002
I-274					OCT 01, 2002
I-266					JUL 23, 2002
I-274					OCT 01, 2002
I-266					JUL 23, 2002
I-274					OCT 01, 2002
I-266					JUL 23, 2002
I-274					OCT 01, 2002





ST. LOUIS COLLEGE OF PHARMACY



3 2201 90037 0640

RM301.45 .A66 1999 Dec Suppl

Approved drug products with  
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

LIBRARY  
ST. LOUIS COLLEGE OF PHARMACY  
4588 PARKVIEW PL.  
ST. LOUIS, 63110

